


**CUMULATIVE
SUPPLEMENT 6
June 2025**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

45th EDITION

**Cumulative Supplement 6
June 2025**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

45th EDITION

CUMULATIVE SUPPLEMENT 6
June 2025

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPA) of any changes or corrections. The DOBPA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
DR REDDYS LABORATORIES INC (DR REDDYS LABS INC)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES LTD (DR REDDYS)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES LTD (DR REDDYS LABS LTD)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
ICU MEDICAL INC (ICU MEDICAL INC)	OTSUKA ICU MEDICAL LLC (OTSUKA ICU MEDCL)
MYLAN INSTITUTIONAL LLC (MYLAN INSTITUTIONAL)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)

MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)	PHARMBEDIENT CONSULTING LLC (PHARMBEDIENT)
STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)	ONESOURCE SPECIALTY PTE LTE (ONESOURCE SPECIALTY)
STRIDES SOFTGELS PTE LTD (STRIDES SOFTGELS)	ONESOURCE SPECIALTY PTE LTD (ONESOURCE SPECIALTY)
WOCKHARDT LTD (WOCKHARDT)	WOCKHARDT BIO AG (WOCKHARDT BIO AG)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2024</u>	<u>MAR</u> <u>2025</u>	<u>JUN</u> <u>2025</u>	<u>SEP</u> <u>2025</u>	<u>DEC</u> <u>2025</u>
DRUG PRODUCTS	23856	23679	23798		
LISTED SINGLE	2772	2740	2744		
SOURCE	(11.8%)	(11.6%)	(11.5%)		

MULTISOURCE	20814 (88.2%)	20939 (88.4%)	21054 (88.5%)
THERAPEUTICALLY EQUIVALENT	20741 (87.9%)	20826 (88%)	20952 (88%)
NOT THERAPEUTICALLY EQUIVALENT	73 (0.3%)	113 (0.5%)	102 (0.4%)
EXCEPTIONS ⁴	47 (0.2%)	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	43	13	7
NUMBER OF APPLICANTS	1197	1209	1226

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration

CFTG Change. A TE Code is added when a first time generic for an innovator is approved.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMKT Change. RX to OTC marketing status switch.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug

CHRS Change. Reference Standard

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		HETERO LABS LTD V	EQ 600MG BASE;300MG	A205412	001	Apr 16, 2025	Apr NEWA
>D>	AB	MACLEODS PHARMS LTD	EQ 600MG BASE;300MG	A212663	001	Dec 19, 2024	Jun DISC
>A>	@		EQ 600MG BASE;300MG	A212663	001	Dec 19, 2024	Jun DISC

ABIRATERONE ACETATE

TABLET; ORAL

ABIRATERONE ACETATE

@	TEVA PHARMS USA	250MG	A208432	001	Oct 31, 2018	Mar DISC
@		500MG	A210726	001	Jan 26, 2023	Mar DISC

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUM

AB		GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Mar CMFD
----	--	---------------------	-------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION; INTRAVENOUS

ACETAMINOPHEN

AP1		ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Mar CTEC
AP	+	B BRAUN MEDICAL	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Mar CFTG
AP2	+		1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Mar CFTG
	!	BAXTER HLTHCARE CORP	650MG/65ML (10MG/ML)	A214331	002	May 21, 2025	May NEWA
AP1			1GM/100ML (10MG/ML)	A214331	001	Sep 17, 2021	Mar CTEC
AP1		EUGIA PHARMA	1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020	Mar CTEC
AP		GLAND	500MG/50ML (10MG/ML)	A219215	001	Apr 02, 2025	Mar NFTG
AP2			1GM/100ML (10MG/ML)	A219215	002	Apr 02, 2025	Mar NFTG
AP1		HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Mar CTEC
AP1		INFORLIFE	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Mar CTEC
AP1		MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Mar CTEC
AP1	!	SANDOZ	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar CTEC
AP1		WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Mar CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

@	AVIV PHARMA	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May CAHN
---	-------------	----------------------	---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Feb DISC
!	GENUS LIFESCIENCES	120MG/5ML;12MG/5ML	A087508	001		Feb CTEC
@	XTTRIUM LABS INC	120MG/5ML;12MG/5ML	A087006	001		Feb CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	ANI PHARMS	300MG;15MG	A088629	002	Mar 06, 1985	May CAHN
@		300MG;30MG	A088629	003	Mar 06, 1985	May CAHN
@ +		300MG;60MG	A088629	001	Mar 06, 1985	May CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Feb DISC	
AA	!	WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb CHRS

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006	Feb DISC	
@		300MG;7.5MG	A040658	002	Mar 24, 2006	Feb DISC	
@		300MG;10MG	A040658	003	Jun 23, 2004	Feb DISC	
@		325MG;7.5MG	A040432	001	Jan 22, 2003	Feb DISC	
@	RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018	Jan DISC	
@		300MG;7.5MG	A207808	002	Mar 30, 2018	Jan DISC	
@		300MG;10MG	A207808	003	Mar 30, 2018	Jan DISC	
AA	!	SPECGX LLC	300MG;5MG	A206718	001	Mar 31, 2017	Feb CHRS
AA	!		300MG;7.5MG	A206718	002	Mar 31, 2017	Feb CHRS
AA	!		300MG;10MG	A206718	003	Mar 31, 2017	Feb CHRS

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	SANKALP LIFECARE	325MG/5ML; 5MG/5ML	A201448	001	Aug 26, 2021	Apr	CAHN
	TABLET; ORAL						
	OXYCODONE AND ACETAMINOPHEN						
	@ CHARTWELL	325MG; 5MG	A207834	001	Aug 15, 2019	Feb	DISC
	@	325MG; 7.5MG	A207834	002	Aug 15, 2019	Feb	DISC
	@	325MG; 10MG	A207834	003	Aug 15, 2019	Feb	DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A>	@ MPP PHARMA	325MG; 37.5MG	A078778	001	Apr 07, 2014	Jun	CAHN
>D>	@ NOSTRUM LABS INC	325MG; 37.5MG	A078778	001	Apr 07, 2014	Jun	CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB	MPP PHARMA	500MG	A204691	001	Mar 29, 2016	May	CAHN
	TABLET; ORAL						
	ACETAZOLAMIDE						
AB	AUROBINDO PHARMA LTD	125MG	A212089	001	May 30, 2025	May	NEWA
AB		250MG	A212089	002	May 30, 2025	May	NEWA
	DIAMOX						
	@ + TEVA BRANDED PHARM	125MG	N008943	001		Feb	CAHN
	@ +	250MG	N008943	002		Feb	CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

>A>	AP GLAND	EQ 500MG BASE/VIAL	A219775	001	Jun 17, 2025	Jun	NEWA
-----	----------	--------------------	---------	-----	--------------	-----	------

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	CONBA USA	10%	A214177	001	Mar 14, 2025	Mar	NEWA
AN		20%	A214177	002	Mar 14, 2025	Mar	NEWA
AN	SOMERSET THERAPS LLC	10%	A219194	001	Feb 12, 2025	Jan	NEWA
AN		20%	A219194	002	Feb 12, 2025	Jan	NEWA

ACETYLCYSTEINE LYSINE

FOR SOLUTION; ORAL

LEGUBETI

>D>	@ + GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun	CMFD
>A>	+!	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun	CMFD
>D>	@ +	EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun	CMFD
>A>	+!	EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun	CMFD

ACITRETIN

CAPSULE; ORAL

ACITRETIN

	@ MYLAN	17.5MG	A203707	001	Sep 10, 2015	Apr	CAHN
	@	22.5MG	A203707	002	Sep 10, 2015	Apr	CAHN

ACOLTREMOM

SOLUTION/DROPS; OPHTHALMIC

TRYPTYR

	+! ALCON LABS INC	0.003%	N217370	001	May 28, 2025	May	NEWA
--	-------------------	--------	---------	-----	--------------	-----	------

ACYCLOVIR

CREAM; TOPICAL

ACYCLOVIR

	@ CIPLA	5%	A212981	001	May 02, 2025	May	DISC
AB		5%	A212981	001	May 02, 2025	Apr	NEWA
BX	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Mar	CTEC

OINTMENT; TOPICAL

ACYCLOVIR

	@ APOTEX	5%	A210774	001	Sep 06, 2019	Jan	DISC
	@ CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017	Feb	CAHN
	@ CIPLA	5%	A211794	001	Jan 18, 2019	May	DISC

	OINTMENT; TOPICAL							
	ACYCLOVIR							
BX		5%		A211794	001	Jan 18, 2019	Mar	CTEC
	TABLET; BUCCAL							
	SITAVIG							
>A>	+	LIGAND PHARMS	50MG	N203791	001	Apr 12, 2013	Jun	CAHN
>D>	+	LNHC	50MG	N203791	001	Apr 12, 2013	Jun	CAHN
	<u>ACYCLOVIR SODIUM</u>							
	INJECTABLE; INJECTION							
	ACYCLOVIR SODIUM							
AP	FRESENIUS KABI USA	EQ 50MG BASE/ML		A215404	001	Jun 25, 2024	May	CMFD
	@	EQ 50MG BASE/ML		A215404	001	Jun 25, 2024	Feb	DISC
	<u>ALBUTEROL SULFATE</u>							
	AEROSOL, METERED; INHALATION							
	ALBUTEROL SULFATE							
AB2	PADAGIS US	EQ 0.09MG BASE/INH		A203760	001	Feb 24, 2020	Mar	CMFD
	POWDER, METERED; INHALATION							
	PROAIR DIGIHALER							
	@ +	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Feb	CAHN
	PROAIR RESPICLICK							
	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Feb	CAHN
	SOLUTION; INHALATION							
	ALBUTEROL SULFATE							
AN	RITEDOSE CORP	EQ 0.5% BASE		A218386	001	Mar 12, 2025	Feb	NEWA
	SYRUP; ORAL							
	ALBUTEROL SULFATE							
	@	COSETTE	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Jan	DISC
	TABLET; ORAL							
	ALBUTEROL SULFATE							
AB	ACERTIS PHARMS	EQ 2MG BASE		A211397	001	Oct 26, 2018	May	CAHN
AB		EQ 4MG BASE		A211397	002	Oct 26, 2018	May	CAHN
	<u>ALCOHOL</u>							
	SOLUTION; INTRA-ARTERIAL							
	ABLYSINOL							
>D>	+	BPI LABS	99% (5ML)	N207987	002	Jun 21, 2018	Jun	CFTG
>A>	AP	+	99% (5ML)	N207987	002	Jun 21, 2018	Jun	CFTG
>A>	DEHYDRATED ALCOHOL							
>A>	AP	ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jun	NFTG
>A>	AP	BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jun	NFTG
>A>	AP	INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jun	NEWA
>A>	AP	XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jun	NFTG
	<u>ALENDRONATE SODIUM</u>							
	TABLET; ORAL							
	ALENDRONATE SODIUM							
	@	APOTEX	EQ 5MG BASE	A077982	001	Aug 04, 2008	Mar	DISC
	@		EQ 10MG BASE	A077982	002	Aug 04, 2008	Mar	DISC
	@		EQ 35MG BASE	A077982	003	Aug 04, 2008	Mar	DISC
	@		EQ 70MG BASE	A077982	004	Aug 04, 2008	Mar	DISC
	<u>ALLOPURINOL</u>							
	TABLET; ORAL							
	ALLOPURINOL							
AB	AUROBINDO PHARMA LTD	100MG		A215091	001	Apr 14, 2025	Apr	NEWA
AB		300MG		A215091	002	Apr 14, 2025	Apr	NEWA
AB	INDOCO	200MG		A204467	003	May 22, 2025	May	NEWA
>A>	AB	ZYDUS PHARMS	200MG	A210117	003	Jun 13, 2025	Jun	NEWA
	<u>ALPRAZOLAM</u>							
	TABLET; ORAL							
	ALPRAZOLAM							
	@	APOTEX INC	0.25MG	A077741	001	Jan 19, 2007	Mar	DISC
	@		0.5MG	A077741	002	Jan 19, 2007	Mar	DISC
	@		1MG	A077741	003	Jan 19, 2007	Mar	DISC
	@		2MG	A077741	004	Jan 19, 2007	Mar	DISC
	TABLET, EXTENDED RELEASE; ORAL							
	ALPRAZOLAM							
	@	APOTEX INC	0.5MG	A078449	001	Nov 12, 2008	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

@		1MG	A078449	004	Dec 23, 2015	Mar	DISC
@		2MG	A078449	002	Nov 12, 2008	Mar	DISC
@		3MG	A078449	003	Nov 12, 2008	Mar	DISC

ALPROSTADIL

SUPPOSITORY;URETHRAL
MUSE

@ +	VIATRIS	0.125MG	N020700	001	Nov 19, 1996	Feb	CAHN
@ +		0.25MG	N020700	002	Nov 19, 1996	Feb	CAHN
@ +		0.5MG	N020700	003	Nov 19, 1996	Feb	CAHN
@ +		1MG	N020700	004	Nov 19, 1996	Feb	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
AMANTADINE HYDROCHLORIDE

@	ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024	May	DISC
	GOCOVRI						
+	SUPERMUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	May	CTEC

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@	BAJAJ	50MG/5ML	A075819	001	Sep 11, 2002	Mar	CAHN
---	-------	----------	---------	-----	--------------	-----	------

AMCINONIDE

LOTION;TOPICAL

AMCINONIDE

!	SOLUBIOMIX	0.1%	A076329	001	Nov 06, 2002	Feb	CAHN
---	------------	------	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SOLUTION;ORAL

AMINOCAPROIC ACID

AA	AJENAT PHARMS	0.25GM/ML	A213825	001	Apr 08, 2021	Jan	CAHN
AA	APOZEAL PHARMS	0.25GM/ML	A213216	001	May 19, 2025	May	NEWA

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

>D>	!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Jun	CRLD
>A>	+	!	25MG/ML	A087242	001	Oct 26, 1983	Jun	CRLD

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

BX	RUBICON	10MG	A215376	001	May 01, 2023	Mar	CTEC	
BX		25MG	A215376	002	May 01, 2023	Mar	CTEC	
BX		50MG	A215376	003	May 01, 2023	Mar	CTEC	
BX		75MG	A215376	004	May 01, 2023	Mar	CTEC	
BX		100MG	A215376	005	May 01, 2023	Mar	CTEC	
BX		150MG	A215376	006	May 01, 2023	Mar	CTEC	
>A>	AB	UNIQUE PHARM	10MG	A218389	001	Jun 23, 2025	Jun	NEWA
>A>	AB		25MG	A218389	002	Jun 23, 2025	Jun	NEWA
>A>	AB		50MG	A218389	003	Jun 23, 2025	Jun	NEWA
>A>	AB		75MG	A218389	004	Jun 23, 2025	Jun	NEWA
>A>	AB		100MG	A218389	005	Jun 23, 2025	Jun	NEWA
>A>	AB		150MG	A218389	006	Jun 23, 2025	Jun	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Apr	DISC
@		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Apr	DISC
	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Apr	CTEC
!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Apr	CTEC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

>A>	@	CHARTWELL RX	50MG;4MG	A071863	001	Dec 21, 1987	Jun	CAHN
>D>	@	FOSUN PHARMA	50MG;4MG	A071863	001	Dec 21, 1987	Jun	CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	ALEMBIC	EQ 2.5MG BASE;EQ 10MG BASE	A217279	001	May 22, 2025	May	NEWA
AB		EQ 2.5MG BASE;EQ 20MG BASE	A217279	002	May 22, 2025	May	NEWA
AB		EQ 2.5MG BASE;EQ 40MG BASE	A217279	003	May 22, 2025	May	NEWA
AB		EQ 5MG BASE;EQ 10MG BASE	A217279	004	May 22, 2025	May	NEWA
AB		EQ 5MG BASE;EQ 20MG BASE	A217279	005	May 22, 2025	May	NEWA
AB		EQ 5MG BASE;EQ 40MG BASE	A217279	006	May 22, 2025	May	NEWA
AB		EQ 5MG BASE;EQ 80MG BASE	A217279	007	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 10MG BASE	A217279	008	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 20MG BASE	A217279	009	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 40MG BASE	A217279	010	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 80MG BASE	A217279	011	May 22, 2025	May	NEWA
AB	APDM PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb	CAHN
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb	CAHN
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	CHARTWELL RX	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	Apr	CAHN
@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	Apr	CAHN
@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	Apr	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	PIRAMAL	EQ 5MG BASE;12.5MG;20MG	A210718	001	May 14, 2025	May	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A210718	002	May 14, 2025	May	NEWA
AB		EQ 5MG BASE;25MG;40MG	A210718	003	May 14, 2025	May	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A210718	004	May 14, 2025	May	NEWA
AB		EQ 10MG BASE;25MG;40MG	A210718	005	May 14, 2025	May	NEWA
>D>	TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Jun	DISC
>A>	@	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Jun	DISC
>D>	AB	EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Jun	DISC
>A>	@	EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Jun	DISC
>D>	AB	EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Jun	DISC
>A>	@	EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Jun	DISC

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

>A> TABLET;ORAL

>A> WIDAPLIK

>A>	+	GEORGE MEDICINES	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun	NEWA
>A>	@ +		EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun	DISC
>A>	+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun	NEWA
>A>	@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun	DISC
>A>	+		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun	NEWA
>A>	@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun	DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	HETERO LABS LTD V	EQ 5MG BASE;20MG	A209591	001	Feb 14, 2025	Feb	NEWA
AB		EQ 5MG BASE;40MG	A209591	002	Feb 14, 2025	Feb	NEWA
AB		EQ 10MG BASE;20MG	A209591	003	Feb 14, 2025	Feb	NEWA
AB		EQ 10MG BASE;40MG	A209591	004	Feb 14, 2025	Feb	NEWA

AMMONIA N-13INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP	SOFIE	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar	CAHN
----	-------	------------------------------------	---------	-----	--------------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE
TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jan	CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jan	CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jan	CMFD
AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jan	CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jan	CMFD

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

@ RHODES PHARMS

@

5MG

10MG

A213852 001 Sep 07, 2021 Jan DISC

A213852 002 Sep 07, 2021 Jan DISC

AMPHOTERICIN B

INJECTABLE, LIPOSOMAL; INJECTION

AMPHOTERICIN B

AB	AVET LIFESCIENCES	50MG/VIAL	A215354	001	Jun 02, 2025	May	NEWA
>A>	MYLAN LABS LTD	50MG/VIAL	A212967	001	Jun 30, 2025	Jun	NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

@ HIKMA

@

EQ 1GM BASE/VIAL;EQ 500MG
BASE/VIALEQ 2GM BASE/VIAL;EQ 1GM
BASE/VIAL

A065074 001 Mar 19, 2002 Mar DISC

A065074 002 Mar 19, 2002 Mar DISC

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

@ BARR LABS

@

EQ 0.5MG BASE

EQ 1MG BASE

A076530 001 Apr 18, 2005 Mar CAHN

A076530 002 Apr 18, 2005 Mar CAHN

ANGIOTENSIN II ACETATE

SOLUTION; INTRAVENOUS

ANGIOTENSIN II ACETATE

AP	GLAND	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	A216966	001	Jun 03, 2025	May	NFTG
----	-------	--	---------	-----	--------------	-----	------

AP	GIAPREZA +! LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	May	CFTG
----	--------------------------------	--	---------	-----	--------------	-----	------

APALUTAMIDE

TABLET; ORAL

APALUTAMIDE

AB	ZYDUS	60MG	A217113	001	Mar 17, 2025	Mar	NFTG
----	-------	------	---------	-----	--------------	-----	------

AB	ERLEADA + JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Mar	CFTG
----	------------------------------	------	---------	-----	--------------	-----	------

APIXABAN

FOR SUSPENSION; ORAL

ELIQUIS SPRINKLE

+! BRISTOL

0.15MG

N220073 001 Apr 17, 2025 Apr NEWA

TABLET; ORAL

APIXABAN

@ HETERO LABS LTD V

@

2.5MG

5MG

A210066 001 Nov 21, 2023 Apr DISC

A210066 002 Nov 21, 2023 Apr DISC

AB	IMPAX	2.5MG	A209810	001	Feb 14, 2025	Feb	NEWA
----	-------	-------	---------	-----	--------------	-----	------

AB		5MG	A209810	002	Feb 14, 2025	Feb	NEWA
----	--	-----	---------	-----	--------------	-----	------

>D>	AB	MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025	Jun	DISC
-----	----	---------------------	-------	---------	-----	--------------	-----	------

>A>	@		2.5MG	A210067	001	Feb 27, 2025	Jun	DISC
-----	---	--	-------	---------	-----	--------------	-----	------

AB		2.5MG	A210067	001	Feb 27, 2025	Feb	NEWA
----	--	-------	---------	-----	--------------	-----	------

>D>	AB		5MG	A210067	002	Feb 27, 2025	Jun	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	@		5MG	A210067	002	Feb 27, 2025	Jun	DISC
-----	---	--	-----	---------	-----	--------------	-----	------

TABLET;ORAL

APIXABAN

AB		5MG	A210067	002	Feb 27, 2025	Feb	NEWA	
>D>	AB	TORRENT	2.5MG	A210156	001	Dec 17, 2024	Jun	DISC
>A>	@		2.5MG	A210156	001	Dec 17, 2024	Jun	DISC
>D>	AB		5MG	A210156	002	Dec 17, 2024	Jun	DISC
>A>	@		5MG	A210156	002	Dec 17, 2024	Jun	DISC

TABLET, FOR SUSPENSION;ORAL

ELIQUIS

+	!	BRISTOL MYERS SQUIBB	0.5MG	N202155	003	Apr 17, 2025	Apr	NEWA
---	---	----------------------	-------	---------	-----	--------------	-----	------

APOMORPHINE HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

ONAPGO

+	!	MDD US	98MG/20ML (4.9MG/ML)	N214056	001	Feb 03, 2025	Feb	NEWA
---	---	--------	----------------------	---------	-----	--------------	-----	------

APREMILAST

TABLET;ORAL

APREMILAST

>D>	AB	GLENMARK PHARMS LTD	10MG	A211674	001	Oct 16, 2023	Jun	DISC
>A>	@		10MG	A211674	001	Oct 16, 2023	Jun	DISC
>D>	AB		20MG	A211674	002	Oct 16, 2023	Jun	DISC
>A>	@		20MG	A211674	002	Oct 16, 2023	Jun	DISC
>D>	AB		30MG	A211674	003	Oct 16, 2023	Jun	DISC
>A>	@		30MG	A211674	003	Oct 16, 2023	Jun	DISC
>D>	AB	MACLEODS PHARMS LTD	10MG	A211788	001	Nov 25, 2024	Jun	DISC
>A>	@		10MG	A211788	001	Nov 25, 2024	Jun	DISC
>D>	AB		20MG	A211788	002	Nov 25, 2024	Jun	DISC
>A>	@		20MG	A211788	002	Nov 25, 2024	Jun	DISC
>D>	AB		30MG	A211788	003	Nov 25, 2024	Jun	DISC
>A>	@		30MG	A211788	003	Nov 25, 2024	Jun	DISC
>A>	AB	TORRENT	10MG	A211834	001	Jun 20, 2025	Jun	NEWA
>A>	AB		20MG	A211834	002	Jun 20, 2025	Jun	NEWA
>A>	AB		30MG	A211834	003	Jun 20, 2025	Jun	NEWA

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN		AUCTA	EQ 0.015MG BASE/2ML	A218380	001	Feb 03, 2025	Jan	NEWA
AN		MICRO LABS	EQ 0.015MG BASE/2ML	A218555	001	Mar 07, 2025	Feb	NEWA
AN		SABA ILAC SANAYI	EQ 0.015MG BASE/2ML	A218429	001	Apr 25, 2025	Apr	NEWA

ARGATROBAN

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AP	+	!	PLANO PHARMS	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Mar	CAHN
----	---	---	--------------	----------------------	---------	-----	--------------	-----	------

ARIPIPIRAZOLE

FILM;ORAL

MEZOFY

+		CMG PHARM CO LTD	5MG	N211448	001	Apr 15, 2025	Apr	NEWA
+	!		10MG	N211448	002	Apr 15, 2025	Apr	NEWA
+			15MG	N211448	003	Apr 15, 2025	Apr	NEWA

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY MAINTENA KIT

+		OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Jan	CTEC
+	!		400MG/VIAL	N202971	002	Feb 28, 2013	Jan	CTEC

ARIPIPIRAZOLE

@		MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Jan	DISC
@			400MG/VIAL	A216608	002	Dec 03, 2024	Jan	DISC

SOLUTION;ORAL

ARIPIPIRAZOLE

AA		VISTAPHARM LLC	1MG/ML	A212870	001	Dec 26, 2019	Jan	CAHN
----	--	----------------	--------	---------	-----	--------------	-----	------

ARMODAFINIL

TABLET;ORAL

NUVIGIL

AB	+	NUVO PHARMS	50MG	N021875	001	Jun 15, 2007	Jan	CAHN
	@	+	100MG	N021875	002	Mar 26, 2009	Jan	CAHN
AB	+		150MG	N021875	003	Jun 15, 2007	Jan	CAHN
AB	+		200MG	N021875	005	Mar 26, 2009	Jan	CAHN
AB	+	!	250MG	N021875	004	Jun 15, 2007	Jan	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	MPP PHARMA	325MG;50MG;40MG	A 078149	001	Jun 13, 2007	May	CAHN
----	------------	-----------------	----------	-----	--------------	-----	------

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

>D>	AB	AGNITIO	EQ 10MG BASE	A 214969	001	Sep 02, 2021	Jun	CAHN
>D>	AB		EQ 20MG BASE	A 214969	002	Sep 02, 2021	Jun	CAHN
>D>	AB		EQ 40MG BASE	A 214969	003	Sep 02, 2021	Jun	CAHN
>D>	AB		EQ 80MG BASE	A 214969	004	Sep 02, 2021	Jun	CAHN
>A>	AB	APOTEX	EQ 10MG BASE	A 214969	001	Sep 02, 2021	Jun	CAHN
>A>	AB		EQ 20MG BASE	A 214969	002	Sep 02, 2021	Jun	CAHN
>A>	AB		EQ 40MG BASE	A 214969	003	Sep 02, 2021	Jun	CAHN
>A>	AB		EQ 80MG BASE	A 214969	004	Sep 02, 2021	Jun	CAHN
	@	SUN PHARM INDS LTD	EQ 10MG BASE	A 076477	001	Nov 30, 2011	Mar	DISC
	@		EQ 20MG BASE	A 076477	002	Nov 30, 2011	Apr	DISC
	@		EQ 40MG BASE	A 076477	003	Nov 30, 2011	Apr	DISC
	@		EQ 80MG BASE	A 076477	004	Nov 30, 2011	Apr	DISC

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

>D>	AB	ABON PHARMS LLC	750MG/5ML	A 214272	001	Oct 25, 2021	Jun	CAHN
	@	APOTEX	750MG/5ML	A 209750	001	Oct 11, 2017	Mar	DISC
>A>	AB	PAI HOLDINGS	750MG/5ML	A 214272	001	Oct 25, 2021	Jun	CAHN

ATRASENTAN HYDROCHLORIDE

TABLET;ORAL

VANRAFIA

+! NOVARTIS

EQ 0.75MG BASE

N 219208 001 Apr 02, 2025 Apr NEWA

AVIBACTAM SODIUM; AZTREONAM

POWDER;INTRAVENOUS

EMBLAVEO

+! ABBVIE

EQ 0.5GM BASE/VIAL;1.5GM/VIAL

N 217906 001 Feb 07, 2025 Feb NEWA

AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE

CAPSULE, TABLET;ORAL

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

+! VERASTEM INC

EQ 0.8MG BASE;EQ 200MG BASE

N 219616 001 May 08, 2025 May NEWA

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	RELIANCE LIFE	100MG/VIAL	A 217453	001	May 20, 2025	May	NEWA
----	---------------	------------	----------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

ASTEPRO

@ + NORVIUM BIOSCIENCE

0.137MG/SPRAY

N 022203 001 Oct 15, 2008 Jan CAHN

@

0.2055MG/SPRAY

N 022203 002 Aug 31, 2009 Jan CAHN

@ + VIATRIS

0.137MG/SPRAY

N 022203 001 Oct 15, 2008 Apr CAHN

@

0.2055MG/SPRAY

N 022203 002 Aug 31, 2009 Apr CAHN

AZELASTINE HYDROCHLORIDE

@ BIONPHARMA

0.137MG/SPRAY

A 090176 001 Jul 28, 2015 Jan DISC

>A>	AB	PADAGIS US	0.137MG/SPRAY	A 202609	001	Mar 17, 2017	Jun	CAHN
-----	----	------------	---------------	----------	-----	--------------	-----	------

>D>	AB	UPSHER SMITH LABS	0.137MG/SPRAY	A 202609	001	Mar 17, 2017	Jun	CAHN
-----	----	-------------------	---------------	----------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	TEVA PHARMS USA INC	0.137MG/SPRAY;0.05MG/SPRAY	A 208436	001	Apr 08, 2025	Mar	NEWA
----	---------------------	----------------------------	----------	-----	--------------	-----	------

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE

AB	ALKEM LABS LTD	EQ 40MG MEDOXOMIL;12.5MG	A 217490	001	Jan 21, 2025	Jan	NFTG
----	----------------	--------------------------	----------	-----	--------------	-----	------

AB		EQ 40MG MEDOXOMIL;25MG	A 217490	002	Jan 21, 2025	Jan	NFTG
----	--	------------------------	----------	-----	--------------	-----	------

TABLET;ORAL
EDARBYCLOL

AB	+	AZURITY	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan CFTG
AB	+	!	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan CFTG

AZITHROMYCIN

FOR SUSPENSION;ORAL
AZITHROMYCIN

AB		CHARTWELL RX	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Feb CMFD
AB			EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Feb CMFD
AB		ZHEJIANG POLY PHARM	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Mar CAHN
AB			EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Mar CAHN

ZITHROMAX

@ + PFIZER

			EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994	Apr DISC
--	--	--	--------------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

AZITHROMYCIN

@ HOSPIRA

			EQ 500MG BASE/VIAL	A065511	001	Jun 26, 2009	Apr DISC
--	--	--	--------------------	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
LUMI-SPORYN

AT	+	CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Feb CPOT
----	---	-------------------	--	---------	-----	--	----------

BACLOFEN

GRANULES;ORAL

LYVISPAH

>D>	+	AMNEAL	5MG/PACKET	N215422	001	Nov 22, 2021	Jun DISC
>A>	@ +		5MG/PACKET	N215422	001	Nov 22, 2021	Jun DISC
>D>	+		10MG/PACKET	N215422	002	Nov 22, 2021	Jun DISC
>A>	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Jun DISC
>D>	+	!	20MG/PACKET	N215422	003	Nov 22, 2021	Jun DISC
>A>	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Jun DISC

SOLUTION;ORAL

BACLOFEN

		RUBICON RESEARCH	5MG/5ML	A214445	001	Dec 06, 2024	May CAHN
AA			10MG/5ML	A214445	002	Jun 03, 2025	May NFTG
AA	+	METACEL PHARMS LLC	10MG/5ML	N208193	002	Oct 12, 2023	May CFTG

TABLET;ORAL

BACLOFEN

AB		APPCO	5MG	A090334	003	Jan 31, 2025	Jan NEWA
>D>	AB	UPSHER SMITH LABS	10MG	A074584	001	Aug 19, 1996	Jun CAHN
>D>	AB		20MG	A074584	002	Aug 19, 1996	Jun CAHN
>A>	AB	YILING	10MG	A074584	001	Aug 19, 1996	Jun CAHN
>A>	AB		20MG	A074584	002	Aug 19, 1996	Jun CAHN

BALOXAVIR MARBOXIL

FOR SUSPENSION;ORAL

XOFLUZA

>A>	+	GENENTECH INC	30MG/PACKET	N214410	002	May 30, 2025	Jun NEWA
>A>	+	!	40MG/PACKET	N214410	003	May 30, 2025	Jun NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		CARNEGIE	750MG	A219422	001	Apr 03, 2025	Mar NEWA
----	--	----------	-------	---------	-----	--------------	----------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR 40

@ + TEVA BRANDED PHARM

			0.04MG/INH	N020911	002	Sep 15, 2000	Mar CAHN
--	--	--	------------	---------	-----	--------------	----------

QVAR 80

@ + TEVA BRANDED PHARM

			0.08MG/INH	N020911	001	Sep 15, 2000	Mar CAHN
--	--	--	------------	---------	-----	--------------	----------

AEROSOL, METERED;NASAL

QNASL

+ TEVA BRANDED PHARM

			0.04MG/ACTUATION	N202813	002	Dec 17, 2014	Feb CAHN
--	--	--	------------------	---------	-----	--------------	----------

+!

			0.08MG/ACTUATION	N202813	001	Mar 23, 2012	Feb CAHN
--	--	--	------------------	---------	-----	--------------	----------

BENDAMUSTINE HYDROCHLORIDE

POWDER; INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

@	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	May	DISC
@		100MG/VIAL	A204230	002	Jun 05, 2023	May	DISC

BENZOYL PEROXIDE

CREAM; TOPICAL

EPSOLAY

+	MAYNE PHARMA	5%	N214510	001	Apr 22, 2022	May	CAHN
---	--------------	----	---------	-----	--------------	-----	------

BENZOYL PEROXIDE; TRETINOIN

CREAM; TOPICAL

Twyneo

+	MAYNE PHARMA	3%;0.1%	N214902	001	Jul 26, 2021	May	CAHN
---	--------------	---------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	QUAGEN	0.5MG	A212694	001	Feb 11, 2025	Jan	NEWA
AA		1MG	A212694	002	Feb 11, 2025	Jan	NEWA
AA		2MG	A212694	003	Feb 11, 2025	Jan	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

@	CHARTWELL MOLECULAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Feb	CAHN
---	---------------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION; TOPICAL

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

@	PADAGIS ISRAEL	0.064%;0.005%	A212367	001	Sep 11, 2020	Jan	DISC
---	----------------	---------------	---------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

>A>	@	RENOVA PHARMS	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Jun	CAHN
>D>	@	SCIEGEN PHARMS INC	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Jun	CAHN

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

@	CIPLA	75MG	A210352	001	Dec 10, 2024	Jan	DISC
---	-------	------	---------	-----	--------------	-----	------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

@	APOTEX	50MG	A200274	001	May 21, 2015	Mar	DISC
---	--------	------	---------	-----	--------------	-----	------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AB	MANKIND PHARMA	0.01%	A218196	001	Mar 17, 2025	Mar	NFTG	
AB	LUMIGAN							
AB	+	ABBVIE	0.01%	N022184	001	Aug 31, 2010	Mar	CFTG

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	RUBICON	2.5MG	A075643	003	Mar 07, 2025	Mar	NEWA	
AB	UNIQUE PHARM	5MG	A219044	001	Apr 16, 2025	Apr	NEWA	
AB		10MG	A219044	002	Apr 16, 2025	Apr	NEWA	
	ZEBETA							
	@ +	TEVA BRANDED PHARM	5MG	N019982	002	Jul 31, 1992	Apr	CAHN
	@ +		10MG	N019982	001	Jul 31, 1992	Apr	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Apr CAHN
AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Apr CAHN
AB	+		10MG;6.25MG	N020186	002	Mar 26, 1993	Apr CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP	@	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	May DISC
		MEDICAMEN BIOTECH	3.5MG/VIAL	A218688	001	Jun 02, 2025	May NEWA

BOSENTAN

TABLET, FOR SUSPENSION; ORAL

BOSENTAN

AB		NATCO PHARMA LTD	32MG	A213154	001	Feb 05, 2025	Jan NFTG
		TRACLEER					
AB	+	ACTELION	32MG	N209279	001	Sep 05, 2017	Jan CFTG

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

AB	+	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012	May CFTG
AB	+		EQ 500MG BASE	N203341	002	Sep 04, 2012	May CFTG
		BOSUTINIB MONOHYDRATE					
AB		ALEMBIC	EQ 100MG BASE	A209543	001	May 23, 2025	May NFTG
AB			EQ 500MG BASE	A209543	002	May 23, 2025	May NFTG

BREXANOLONE

SOLUTION; INTRAVENOUS

ZULRESSO

	@ +	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jan DISC
--	-----	-------------	---------------------	---------	-----	--------------	----------

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLE

AB		ALEMBIC	0.25MG	A213683	001	Jan 13, 2025	Jan NEWA
AB			0.5MG	A213683	002	Jan 13, 2025	Jan NEWA
AB			1MG	A213683	003	Jan 13, 2025	Jan NEWA
AB			2MG	A213683	004	Jan 13, 2025	Jan NEWA
AB			3MG	A213683	005	Jan 13, 2025	Jan NEWA
AB			4MG	A213683	006	Jan 13, 2025	Jan NEWA
	@	APOTEX	0.25MG	A213731	001	Feb 24, 2025	Mar DISC
AB			0.25MG	A213731	001	Feb 24, 2025	Feb NEWA
	@		0.5MG	A213731	002	Feb 24, 2025	Mar DISC
AB			0.5MG	A213731	002	Feb 24, 2025	Feb NEWA
	@		1MG	A213731	003	Feb 24, 2025	Mar DISC
AB			1MG	A213731	003	Feb 24, 2025	Feb NEWA
	@		2MG	A213731	004	Feb 24, 2025	Mar DISC
AB			2MG	A213731	004	Feb 24, 2025	Feb NEWA
	@		3MG	A213731	005	Feb 24, 2025	Mar DISC
AB			3MG	A213731	005	Feb 24, 2025	Feb NEWA
		REXULTI					
AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Jan CTEC
AB	+		0.5MG	N205422	002	Jul 10, 2015	Jan CTEC
AB	+		1MG	N205422	003	Jul 10, 2015	Jan CTEC
AB	+		2MG	N205422	004	Jul 10, 2015	Jan CTEC
AB	+		3MG	N205422	005	Jul 10, 2015	Jan CTEC
AB	+		4MG	N205422	006	Jul 10, 2015	Jan CTEC

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

	@	AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Jan DISC
AB		CAPLIN	0.2%;EQ 0.5% BASE	A219093	001	Feb 25, 2025	Feb NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

	BROMFED-DM							
AA	+ XTTRIUM LABS INC	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Feb	CAHN	
	BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE							
AA	BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	May	CMFD	

BUDESONIDE

SUSPENSION; INHALATION

BUDESONIDE

	@ SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Feb	DISC	
	@	0.5MG/2ML	A201966	002	Sep 27, 2013	Feb	DISC	
	@	1MG/2ML	A201966	001	Sep 27, 2013	Feb	DISC	

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	ASPIRO	0.25MG/ML	A218746	001	Feb 27, 2025	Feb	NEWA	
	TABLET; ORAL							
	BUMETANIDE							
AB	MANKIND PHARMA	0.5MG	A219291	001	Apr 03, 2025	Mar	NEWA	
AB		1MG	A219291	002	Apr 03, 2025	Mar	NEWA	
AB		2MG	A219291	003	Apr 03, 2025	Mar	NEWA	

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP	SOMERSET THERAPS LLC	EQ 0.3MG BASE/ML	A219302	001	Jan 30, 2025	Jan	NEWA	
----	----------------------	------------------	---------	-----	--------------	-----	------	--

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>D>	@ NORVIUM BIOSCIENCE	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN	
>D>	@	EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN	
>A>	@ PHARMOBEDIENT	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN	
>A>	@	EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN	

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	DIFGEN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A212756	003	Feb 13, 2025	Feb	NEWA	
AB		EQ 4MG BASE;EQ 1MG BASE	A212756	004	Feb 13, 2025	Feb	NEWA	

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	IPCA LABS LTD	100MG	A207874	001	May 02, 2025	Apr	NEWA	
AB1		150MG	A207874	002	May 02, 2025	Apr	NEWA	
AB1		200MG	A207874	003	May 02, 2025	Apr	NEWA	
	@ SUN PHARM	150MG	A200216	001	Nov 30, 2020	Feb	DISC	
	@	300MG	A203650	001	Dec 31, 2020	Feb	DISC	
>D>	FORFIVO XL							
>D>	+! TWI PHARMS	450MG	N022497	001	Nov 10, 2011	Jun	DISC	
>A>	@ +	450MG	N022497	001	Nov 10, 2011	Jun	DISC	

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPIRONE HYDROCHLORIDE

	EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025	Feb	NEWA	
		10MG	A218628	002	Mar 13, 2025	Feb	NEWA	
		15MG	A218628	003	Mar 13, 2025	Feb	NEWA	

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Apr	CHRS	
>A>	AB AIPING PHARM INC	7.5MG	A202087	005	Jul 03, 2025	Jun	NEWA	
BX	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Mar	CTEC	
BX		7.5MG	A208972	002	Apr 16, 2019	Mar	CTEC	
BX		10MG	A208972	003	Apr 16, 2019	Mar	CTEC	
BX		15MG	A208972	004	Apr 16, 2019	Mar	CTEC	
BX		30MG	A208972	005	Apr 16, 2019	Mar	CTEC	
BX	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Mar	CTEC	
BX		7.5MG	A209696	002	May 03, 2018	Mar	CTEC	
BX		10MG	A209696	003	May 03, 2018	Mar	CTEC	

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE							
BX		15MG	A209696	004	May 03, 2018	Mar	CTEC
BX		30MG	A209696	005	May 03, 2018	Mar	CTEC
AB	! UNICHEM	15MG	A210907	003	Nov 14, 2019	Apr	CHRS

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

@	APOTEX	6MG/ML	A210448	001	May 07, 2019	Jan	DISC
---	--------	--------	---------	-----	--------------	-----	------

BUTORPHANOL TARTRATE

SPRAY, METERED;NASAL

BUTORPHANOL TARTRATE

AB	! HIKMA	1MG/SPRAY	A075824	001	Mar 12, 2002	May	CHRS
	@ RISING	1MG/SPRAY	A075759	001	Aug 08, 2001	May	DISC
	STADOL						
	@ + BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890	001	Dec 12, 1991	May	CRLD

CAFFEINE CITRATE

SOLUTION;ORAL

CAFFEINE CITRATE

@	SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090357	001	Sep 30, 2009	Feb	DISC
---	-----------	------------------------------------	---------	-----	--------------	-----	------

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

>A>	AP	SAGENT	200 IU/ML	A219196	001	Jul 09, 2025	Jun	NEWA
-----	----	--------	-----------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

>A>	AB	ONESOURCE SPECIALTY	0.25MCG	A091356	001	Dec 12, 2014	Jun	CAHN
>A>	AB	!	0.5MCG	A091356	002	Dec 12, 2014	Jun	CAHN
>D>	AB	STRIDES SOFTGELS	0.25MCG	A091356	001	Dec 12, 2014	Jun	CAHN
>D>	AB	!	0.5MCG	A091356	002	Dec 12, 2014	Jun	CAHN

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB	MPP PHARMA	667MG	A203179	001	Oct 26, 2015	May	CAHN
----	------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

@ +	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Feb	CAHN
-----	---------------------	---	---------	-----	--------------	-----	------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Feb	CAHN
---	---------------------	--	---------	-----	--------------	-----	------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Feb	CAHN
----	---------------------	---	---------	-----	--------------	-----	------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

@ +	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Feb	CAHN
-----	---------------------	--	---------	-----	--------------	-----	------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Feb	CAHN
----	---------------------	--	---------	-----	--------------	-----	------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157	N021703	002	Oct 25, 2006	Feb	CAHN
----	---------------------	---	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

GM/1000ML; 3.09GM/1000ML; 6.46GM
/1000ML (5000ML)

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Feb	CAHN
---	--	---------------------	---	---------	-----	--------------	-----	------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Feb	CAHN
---	---	---------------------	---	---------	-----	--------------	-----	------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Feb	CAHN
---	--	---------------------	--	---------	-----	--------------	-----	------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Feb	CAHN
---	--	---------------------	--	---------	-----	--------------	-----	------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

@	+	VANTIVE US HLTHCARE	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Feb	CAHN
---	---	---------------------	---	---------	-----	--------------	-----	------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Feb	CAHN
---	--	---------------------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	001	Nov 30, 1984	Feb	CTEC
---	---	-----------------	---	---------	-----	--------------	-----	------

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	002	Nov 30, 1984	Feb	CTEC
---	---	-----------------	---	---------	-----	--------------	-----	------

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	003	Nov 30, 1984	Feb	CTEC
---	---	-----------------	--	---------	-----	--------------	-----	------

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	001		Feb	CAHN
---	--	---------------------	---	---------	-----	--	-----	------

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	003		Feb	CAHN
---	--	---------------------	---	---------	-----	--	-----	------

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	002		Feb	CAHN
---	--	---------------------	--	---------	-----	--	-----	------

SOLUTION;INTRAPERITONEAL									
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N020183	001	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N020183	002	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
@	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N020183	003	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N020183	004	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N017512	012	Jan 10, 1989	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N017512	013	Jul 11, 1990	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER									
	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N017512	014	Jul 11, 1990	Feb	CTEC	
AT	+		18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N017512	014	Jul 11, 1990	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N017512	015	Jul 11, 1990	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N017512	007	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N017512	008	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N017512	010	Nov 18, 1985	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2 MG/100ML;567MG/100ML;392MG/100 ML	N017512	009	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N017512	004		Feb	CAHN	
AT	+		25.7MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N020163	001	Dec 04, 1992	Feb	CAHN	
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N017512	005		Feb	CAHN	
AT	+		25.7MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N020163	002	Dec 04, 1992	Feb	CAHN	
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
@	+	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N017512	011	Nov 18, 1985	Feb	CAHN	
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N017512	006		Feb	CAHN	
AT	+		25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N020163	003	Dec 04, 1992	Feb	CAHN	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314 GM/1000ML;2.21GM/1000ML;6.95GM /1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb	CAHN
---	---	---------------------	---	---------	-----	--------------	-----	------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

AB		ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017	Jan	CMFD
AB			8MG	A091390	002	Aug 23, 2017	Jan	CMFD
AB			16MG	A091390	003	Aug 23, 2017	Jan	CMFD
AB			32MG	A091390	004	Aug 23, 2017	Jan	CMFD

CAPECITABINE

TABLET; ORAL

CAPECITABINE

BX		TEYRO LABS	150MG	A217237	001	Oct 23, 2023	Mar	CTEC
BX			500MG	A217237	002	Oct 23, 2023	Mar	CTEC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		ANI PHARMS	100MG	A076697	001	May 20, 2011	May	CAHN
AB			200MG	A076697	002	May 20, 2011	May	CAHN
AB			300MG	A076697	003	May 20, 2011	May	CAHN

TABLET; ORAL

CARBAMAZEPINE

AB		ALEMBIC	200MG	A216623	001	Apr 16, 2025	Apr	NEWA
----	--	---------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		ALKEM LABS LTD	100MG	A217277	001	Jan 14, 2025	Jan	NEWA
AB			200MG	A217277	002	Jan 14, 2025	Jan	NEWA
AB			400MG	A217277	003	Jan 14, 2025	Jan	NEWA
>D>	AB	EPIC PHARMA LLC	100MG	A216235	001	Mar 02, 2023	Jun	CAHN
>D>	AB		200MG	A216235	002	Mar 02, 2023	Jun	CAHN
>D>	AB		400MG	A216235	003	Mar 02, 2023	Jun	CAHN
	@	OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024	Apr	DISC
	@		200MG	A215664	002	Oct 22, 2024	Apr	DISC
	@		400MG	A215664	003	Oct 22, 2024	Apr	DISC
>A>	AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Jun	CAHN
>A>	AB		200MG	A216235	002	Mar 02, 2023	Jun	CAHN
>A>	AB		400MG	A216235	003	Mar 02, 2023	Jun	CAHN
AB		TORRENT	100MG	A212524	001	Jan 13, 2025	Jan	NEWA
AB			200MG	A212524	002	Jan 13, 2025	Jan	NEWA
AB			400MG	A212524	003	Jan 13, 2025	Jan	NEWA
AB		YICHANG HUMANWELL	100MG	A219072	001	Jan 16, 2025	Jan	NEWA
AB			200MG	A219072	002	Jan 16, 2025	Jan	NEWA
AB			400MG	A219072	003	Jan 16, 2025	Jan	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		MACLEODS PHARMS LTD	12.5MG;200MG;50MG	A214495	001	Apr 15, 2025	Apr	NEWA
AB			18.75MG;200MG;75MG	A214495	002	Apr 15, 2025	Apr	NEWA
AB			25MG;200MG;100MG	A214495	003	Apr 15, 2025	Apr	NEWA
AB			31.25MG;200MG;125MG	A214495	004	Apr 15, 2025	Apr	NEWA
AB			37.5MG;200MG;150MG	A214495	005	Apr 15, 2025	Apr	NEWA
AB			50MG;200MG;200MG	A214495	006	Apr 15, 2025	Apr	NEWA

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

	@	APOTEX INC	10MG;100MG	A 077120	001	Jun 02, 2008	Mar	DISC
	@		25MG;100MG	A 077120	002	Jun 02, 2008	Mar	DISC
	@		25MG;250MG	A 077120	003	Jun 02, 2008	Mar	DISC
AB		ASCENT PHARMS INC	10MG;100MG	A 218939	001	Jan 14, 2025	Jan	NEWA
AB			25MG;100MG	A 218939	002	Jan 14, 2025	Jan	NEWA
AB			25MG;250MG	A 218939	003	Jan 14, 2025	Jan	NEWA
>D>	AB	NORVIUM BIOSCIENCE	25MG;250MG	A 090324	003	Sep 28, 2009	Jun	DISC
>A>	@		25MG;250MG	A 090324	003	Sep 28, 2009	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

	@	APOTEX	25MG;100MG	A 076212	001	Jun 16, 2004	Mar	DISC
	@		50MG;200MG	A 076212	002	Jun 16, 2004	Mar	DISC

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

	@	SENORES PHARMS	4MG	A 090435	001	Apr 15, 2010	Jan	CAHN
--	---	----------------	-----	----------	-----	--------------	-----	------

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

>D>	+	ONYX PHARMS AMGEN	10MG/VIAL	N 202714	003	Jun 07, 2018	Jun	CHRS
>A>	+	!	10MG/VIAL	N 202714	003	Jun 07, 2018	Jun	CHRS
>D>	+		30MG/VIAL	N 202714	002	Jun 03, 2016	Jun	CHRS
>A>	+	!	30MG/VIAL	N 202714	002	Jun 03, 2016	Jun	CHRS

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

>D>	AB	CHARTWELL RX	250MG	A 205126	001	Jul 08, 2015	Jun	CAHN
>D>	AA		350MG	A 205126	002	Jul 08, 2015	Jun	CAHN
	AA	FOSUN WANBANG	350MG	A 081025	001	Apr 13, 1989	Jan	CAHN
>A>	AB	HERITAGE	250MG	A 205126	001	Jul 08, 2015	Jun	CAHN
>A>	AA		350MG	A 205126	002	Jul 08, 2015	Jun	CAHN
>A>	AB	INDICUS PHARMA	250MG	A 205126	001	Jul 08, 2015	Jun	CAHN
>A>	AA		350MG	A 205126	002	Jul 08, 2015	Jun	CAHN
	AB	MPP PHARMA	250MG	A 207237	001	May 11, 2017	May	CAHN
	AA		350MG	A 207237	002	Sep 21, 2020	May	CAHN
	AA	POINTVIEW HLDINGS	350MG	A 211789	001	Oct 20, 2021	Apr	CAHN

CARVEDILOL

TABLET; ORAL

CARVEDILOL

AB		GRAVITI PHARMS	3.125MG	A 076649	001	Sep 05, 2007	Feb	CAHN
AB			6.25MG	A 076649	002	Sep 05, 2007	Feb	CAHN
AB			12.5MG	A 076649	003	Sep 05, 2007	Feb	CAHN
AB			25MG	A 076649	004	Sep 05, 2007	Feb	CAHN
	@	NORVIUM BIOSCIENCE	3.125MG	A 077316	001	Sep 05, 2007	Feb	CAHN
	@		6.25MG	A 077316	002	Sep 05, 2007	Mar	DISC
AB			6.25MG	A 077316	002	Sep 05, 2007	Feb	CAHN
	@		12.5MG	A 077316	003	Sep 05, 2007	Apr	DISC
AB			12.5MG	A 077316	003	Sep 05, 2007	Feb	CAHN
	@		25MG	A 077316	004	Sep 05, 2007	Apr	DISC
AB			25MG	A 077316	004	Sep 05, 2007	Feb	CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

>D>	@	+	WAYLIS THERAP	10MG	N 022012	001	Oct 20, 2006	Jun	CMFD
>A>	AB	+		10MG	N 022012	001	Oct 20, 2006	Jun	CMFD
>D>	@	+		20MG	N 022012	002	Oct 20, 2006	Jun	CMFD
>A>	AB	+		20MG	N 022012	002	Oct 20, 2006	Jun	CMFD
>D>	@	+		40MG	N 022012	003	Oct 20, 2006	Jun	CMFD
>A>	AB	+		40MG	N 022012	003	Oct 20, 2006	Jun	CMFD
>D>	@	+		80MG	N 022012	004	Oct 20, 2006	Jun	CMFD
>A>	AB	+		80MG	N 022012	004	Oct 20, 2006	Jun	CMFD

<u>CEDAZURIDINE; DECITABINE</u>							
TABLET; ORAL							
INQOVI							
	+	TAIHO ONCOLOGY	100MG; 35MG	N212576	001	Jul 07, 2020	Feb CAHN
<u>CEFAZOLIN SODIUM</u>							
INJECTABLE; INJECTION							
CEFAZOLIN SODIUM							
		QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan CAHN
AP			EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Jan CAHN
			EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Jan CAHN
AP	!		EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Jan CAHN
<u>CEFEPIME HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
CEFEPIME HYDROCHLORIDE							
	!	QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan CAHN
AP	!		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan CAHN
AP	!		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan CAHN
<u>CEFPODOXIME PROXETIL</u>							
FOR SUSPENSION; ORAL							
VANTIN							
	@ +	PFIZER	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992	Mar CAHN
	@ +		EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992	Mar CAHN
TABLET; ORAL							
VANTIN							
	@ +	PFIZER	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar CAHN
	@ +		EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar CAHN
<u>CEFPROZIL</u>							
FOR SUSPENSION; ORAL							
CEFPROZIL							
	@	APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Mar DISC
	@		250MG/5ML	A065351	002	Feb 29, 2012	Mar DISC
TABLET; ORAL							
CEFPROZIL							
	@	APOTEX INC	250MG	A065327	001	Mar 26, 2008	Mar DISC
	@		500MG	A065327	002	Mar 26, 2008	Mar DISC
<u>CEFTOBIPROLE MEDOCARIL SODIUM</u>							
POWDER; INTRAVENOUS							
ZEVTERA							
	+	ISTX	667MG/VIAL	N218275	001	Apr 03, 2024	Apr CMFD
	@ +		667MG/VIAL	N218275	001	Apr 03, 2024	Mar CAHN
<u>CEFTRIAXONE SODIUM</u>							
INJECTABLE; INJECTION							
CEFTRIAXONE							
AP		QILU ANTIBIOTICS	EQ 10GM BASE/VIAL	A209218	001	Oct 17, 2018	Jan CAHN
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS							
CEFTRIAXONE							
AP		QILU ANTIBIOTICS	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jan CAHN
AP			EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jan CAHN
AP			EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jan CAHN
AP			EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jan CAHN
<u>CEFUROXIME AXETIL</u>							
TABLET; ORAL							
CEFUROXIME AXETIL							
	@	APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Mar DISC
	@		EQ 500MG BASE	A065069	002	Oct 02, 2002	Mar DISC
<u>CELECOXIB</u>							
CAPSULE; ORAL							
CELECOXIB							
	@	PANGEA	200MG	A212925	001	Dec 09, 2020	Feb CAHN
	@		400MG	A212925	002	Dec 09, 2020	Feb CAHN
AB		STRIDES PHARMA	100MG	A213127	001	Apr 29, 2025	Apr NEWA
AB			200MG	A213127	002	Apr 29, 2025	Apr NEWA
AB			400MG	A213127	003	Apr 29, 2025	Apr NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

AA	BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	May	CMFD
	ZYRTEC						
	@ + J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CRLD

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP	XIROMED	EQ 0.25MG BASE/VIAL	A218061	001	Jun 03, 2025	May	NEWA
----	---------	---------------------	---------	-----	--------------	-----	------

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

>D>	BX	RUBICON	30MG	A216682	001	Apr 06, 2023	Jun	CTEC
>A>	AB		30MG	A216682	001	Apr 06, 2023	Jun	CTEC
	BX		30MG	A216682	001	Apr 06, 2023	Mar	CTEC

CHENODIOL

TABLET;ORAL

CTEXLI

	+! MIRUM	250MG	N219488	001	Feb 21, 2025	Feb	NEWA
--	----------	-------	---------	-----	--------------	-----	------

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

>D>	@	SUN PHARM	EQ 500MG BASE/VIAL	A091546	001	Jul 26, 2011	Jun	CMFD
>A>	AP		EQ 500MG BASE/VIAL	A091546	001	Jul 26, 2011	Jun	CMFD

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	@	APOZEAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Apr	CAHN
--	---	----------------	--------------------------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	10MG	A216788	001	Apr 25, 2025	Apr	NEWA
AB		25MG	A216788	002	Apr 25, 2025	Apr	NEWA
AB		50MG	A216788	003	Apr 25, 2025	Apr	NEWA
AB		100MG	A216788	004	Apr 25, 2025	Apr	NEWA
AB		200MG	A216788	005	Apr 25, 2025	Apr	NEWA
AB	ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb	CAHN
AB		25MG	A212630	002	Nov 29, 2021	Feb	CAHN
AB		50MG	A212630	003	Nov 29, 2021	Feb	CAHN
AB		100MG	A212630	004	Nov 29, 2021	Feb	CAHN
AB		200MG	A212630	005	Nov 29, 2021	Feb	CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

	@	AIPING PHARM INC	25MG	A087380	001		Jan	CAHN
	@		50MG	A087381	001		Jan	CAHN
	HEMICLOR							
	+! PRM PHARMA	12.5MG	N218647	001	Mar 17, 2025	Mar	NEWA	

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA	AJENAT PHARMS	250MG	A215540	001	Jan 24, 2023	Jan	CAHN	
AB	APPCO	375MG	A212047	001	Jan 27, 2023	Mar	CAHN	
AB		750MG	A212047	002	Jan 27, 2023	Mar	CAHN	
	@	CHARTWELL RX	250MG	A087981	001	Sep 20, 1983	Apr	CAHN

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE LIGHT

>D>	AB	MACLEODS PHARMS LTD	EQ 4GM RESIN/SCOOPFUL	A209109	001	Oct 31, 2024	Jun	DISC
>A>		@	EQ 4GM RESIN/SCOOPFUL	A209109	001	Oct 31, 2024	Jun	DISC
>D>	AB		EQ 4GM RESIN/PACKET	A209109	002	Oct 31, 2024	Jun	DISC

	POWDER;ORAL								
	CHOLESTYRAMINE LIGHT								
>A>	@		EQ 4GM RESIN/PACKET	A209109	002	Oct 31, 2024	Jun	DISC	
AB		PHARMOBEDIENT CNSLTG	EQ 4GM RESIN/PACKET	A209599	001	Nov 12, 2020	Apr	CAHN	
AB			EQ 4GM RESIN/SCOOPFUL	A209599	002	Nov 12, 2020	Apr	CAHN	
	<u>CHOLINE FENOFIBRATE</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	FENOFIBRIC ACID								
AB	!	AUROBINDO PHARMA LTD	EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Apr	CHRS	
		TRILIPIX							
	@ +	ABBVIE	EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Apr	DISC	
	<u>CICLOPIROX</u>								
	SHAMPOO;TOPICAL								
	CICLOPIROX								
AT	!	PADAGIS US	1%	A078594	001	Feb 16, 2010	Mar	CHRS	
		LOPROX							
	@ +	BAUSCH	1%	N021159	001	Feb 28, 2003	Mar	DISC	
	<u>CIDOFOVIR</u>								
	SOLUTION;INTRAVENOUS								
	CIDOFOVIR								
AP		AVET LIFESCIENCES	EQ 75MG BASE/ML	A202501	001	Jul 26, 2012	May	CDFR	
AP			EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A202501	001	Jul 26, 2012	May	CPOT	
AP	!	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May	CDFR	
AP	!		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A201276	001	Jun 27, 2012	May	CPOT	
		VISTIDE							
	@ +	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May	CDFR	
	@ +		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	N020638	001	Jun 26, 1996	May	CPOT	
	<u>CILOSTAZOL</u>								
	TABLET;ORAL								
	CILOSTAZOL								
	@	SANKALP LIFECARE	50MG	A077708	001	Sep 28, 2009	Apr	CAHN	
	@		100MG	A077708	002	Sep 28, 2009	Apr	CAHN	
	<u>CIMETIDINE</u>								
	TABLET;ORAL								
	CIMETIDINE								
>D>	@	HIKMA	200MG	A074890	001	Dec 18, 1998	Jun	CAHN	
>A>	@		200MG	A074890	001	Dec 18, 1998	Jun	CAHN	
>D>	@		300MG	A074890	002	Dec 18, 1998	Jun	CAHN	
>A>	@		300MG	A074890	002	Dec 18, 1998	Jun	CAHN	
>D>	@		400MG	A074890	003	Dec 18, 1998	Jun	CAHN	
>A>	@		400MG	A074890	003	Dec 18, 1998	Jun	CAHN	
>D>	@		800MG	A074890	004	Dec 18, 1998	Jun	CAHN	
>A>	@		800MG	A074890	004	Dec 18, 1998	Jun	CAHN	
	<u>CINACALCET HYDROCHLORIDE</u>								
	TABLET;ORAL								
	CINACALCET HYDROCHLORIDE								
AB		PIRAMAL	EQ 30MG BASE	A210207	001	Aug 01, 2018	Jan	CAHN	
AB			EQ 60MG BASE	A210207	002	Aug 01, 2018	Jan	CAHN	
AB			EQ 90MG BASE	A210207	003	Aug 01, 2018	Jan	CAHN	
	<u>CIPROFLOXACIN; DEXAMETHASONE</u>								
	SUSPENSION/DROPS;OTIC								
	CIPROFLOXACIN AND DEXAMETHASONE								
AB		AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Apr	CTNA	
	<u>CISATRACURIUM BESYLATE</u>								
	INJECTABLE;INJECTION								
	CISATRACURIUM BESYLATE								
AP		GLAND	EQ 2MG BASE/ML	A215516	001	May 24, 2022	Mar	CAHN	
AP			EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CAHN	
AP			EQ 10MG BASE/ML	A215516	002	May 24, 2022	Mar	CAHN	
	@	HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Feb	DISC	
AP		HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb	CMS1	

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE PRESERVATIVE FREE

@	HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Feb	DISC
@		EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Feb	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Mar	DISC
@		EQ 20MG BASE	A077046	002	Nov 24, 2004	Mar	DISC
@		EQ 40MG BASE	A077046	003	Nov 24, 2004	Mar	DISC

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

@	JUBILANT CADISTA	250MG	A206714	001	Apr 25, 2019	Apr	CAHN
@		500MG	A206714	002	Apr 25, 2019	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB	MPP PHARMA	500MG	A203243	001	Feb 29, 2016	May	CAHN
----	------------	-------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

@	ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Feb	DISC
@		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Feb	DISC
>D> AP	FRESENIUS KABI USA	EQ 150MG BASE/ML	A065346	001	Mar 29, 2007	Jun	DISC
>A>	@	EQ 150MG BASE/ML	A065346	001	Mar 29, 2007	Jun	DISC
>D> AP		EQ 150MG BASE/ML	A065347	001	May 09, 2007	Jun	DISC
>A>	@	EQ 150MG BASE/ML	A065347	001	May 09, 2007	Jun	DISC

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>A> AT	CARNEGIE	EQ 1% BASE	A219612	001	Jun 13, 2025	Jun	NEWA
--------	----------	------------	---------	-----	--------------	-----	------

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

@	VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019	Jan	CAHN
---	----------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CLOBAZAM

AB	ESJAY PHARMA	5MG	A209308	003	Oct 19, 2021	Feb	CAHN
		10MG	A209308	001	Oct 22, 2018	Feb	CAHN
	@	20MG	A209308	002	Oct 22, 2018	Feb	CAHN

CLOBETASOL PROPIONATE

LOTION; TOPICAL

CLOBETASOL PROPIONATE

@	BEACH PRODS	0.05%	A208667	001	Nov 29, 2016	May	CAHN
@	IMPEKLO						

@ +	NORVIUM BIOSCIENCE	0.05%	N213691	001	May 19, 2020	Jan	CAHN
-----	--------------------	-------	---------	-----	--------------	-----	------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

>D> AT	MACLEODS PHARMS LTD	0.05%	A214345	001	Dec 02, 2024	Jun	DISC
>A>	@	0.05%	A214345	001	Dec 02, 2024	Jun	DISC

SUSPENSION/DROPS; OPHTHALMIC

BYQLOVI

+	FORMOSA	0.05%	N218158	001	Mar 04, 2024	May	CTNA
+		0.05%	N218158	001	Mar 04, 2024	Feb	CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

>D> AB	CHEMISTRY HLTH	25MG	A211364	001	Feb 07, 2020	Jun	CAHN
>D> AB		50MG	A211364	002	Feb 07, 2020	Jun	CAHN
>D> AB		75MG	A211364	003	Feb 07, 2020	Jun	CAHN
>A> AB	LEADING	25MG	A211364	001	Feb 07, 2020	Jun	CAHN
>A> AB		50MG	A211364	002	Feb 07, 2020	Jun	CAHN
>A> AB		75MG	A211364	003	Feb 07, 2020	Jun	CAHN

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL
CLONAZEPAM

@	SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Jan	DISC
@		0.25MG	A078654	002	Aug 27, 2014	Jan	DISC
@		0.5MG	A078654	003	Aug 27, 2014	Jan	DISC
@		1MG	A078654	004	Aug 27, 2014	Jan	DISC
@		2MG	A078654	005	Aug 27, 2014	Jan	DISC

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

@	RUBICON RESEARCH	0.1MG	A210680	001	Apr 30, 2018	Apr	CAHN
AB1	SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	Mar	CMFD

CLOZAPINE

TABLET;ORAL
CLOZAPINE

@	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Apr	DISC
@		50MG	A075713	003	Aug 19, 2005	Apr	DISC
@		100MG	A075713	002	Nov 15, 2002	Apr	DISC
@		200MG	A075713	004	Nov 07, 2017	Apr	DISC

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL
PREZCOBIX

+	JANSSEN PRODS	150MG;EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar	NEWA
+	!	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Mar	CPOT
+	!	150MG;800MG	N205395	001	Jan 29, 2015	Mar	CAIN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH VC W/ CODEINE

@	CHARTWELL RX	10MG/5ML;5MG/5ML;6.25MG/5ML	A088764	001	Oct 31, 1984	Apr	CAHN
---	--------------	-----------------------------	---------	-----	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	CHARTWELL RX	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Apr	CAHN
AA	!	COSETTE	A200386	001	Jun 29, 2012	May	CAHN
AA	XTRIUM LABS INC	10MG/5ML;6.25MG/5ML	A088875	001	Dec 17, 1984	Feb	CAHN
	PROMETHAZINE WITH CODEINE						
@	PHARM ASSOC	10MG/5ML;6.25MG/5ML	A040650	001	Jan 31, 2006	Jan	DISC

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

>D>	@	HIKMA	30MG/5ML	N202245	001	Jun 30, 2011	Jun	CAHN
>A>	@		30MG/5ML	N202245	001	Jun 30, 2011	Jun	CAHN

TABLET;ORAL

CODEINE SULFATE

>D>	AB	+	HIKMA	15MG	N022402	001	Jul 16, 2009	Jun	CAHN
>A>	AB	+		15MG	N022402	001	Jul 16, 2009	Jun	CAHN
>D>	AB	+		30MG	N022402	002	Jul 16, 2009	Jun	CAHN
>A>	AB	+		30MG	N022402	002	Jul 16, 2009	Jun	CAHN
>D>	AB	+	!	60MG	N022402	003	Jul 16, 2009	Jun	CAHN
>A>	AB	+	!	60MG	N022402	003	Jul 16, 2009	Jun	CAHN

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	625MG	A204893	001	Apr 18, 2025	Apr	NEWA
----	---------------------	-------	---------	-----	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

@	NEXUS	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Apr	DISC
---	-------	--------------------	---------	-----	--------------	-----	------

COPPERSYSTEM; INTRAUTERINE
MIUDELLA

+! SEBELA WOMENS HLTH N/A N218201 001 Feb 24, 2025 Feb NEWA

COPPER CU-64 DOTATATESOLUTION; INTRAVENOUS
DETECTNET

+! CURIUM 4mL (1mCi/ML) N213227 001 Sep 03, 2020 Jan CAHN

CROMOLYN SODIUMCONCENTRATE; ORAL
GASTROCROM

AA +! VIATRIS SPECIALTY 100MG/5ML N020479 001 Feb 29, 1996 Feb CAHN

SOLUTION; INHALATION
CROMOLYN SODIUM

AN		FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Apr CAHN
>D>	@	HIKMA	10MG/ML	A075333	001	Apr 30, 2002	Jun CAHN
>A>	@		10MG/ML	A075333	001	Apr 30, 2002	Jun CAHN

CUPRIC SULFATEINJECTABLE; INJECTION
CUPRIC SULFATE

!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Jan CTEC
@	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024	Jan DISC

CYANOCOBALAMININJECTABLE; INJECTION
CYANOCOBALAMIN

AP		MEITHEAL	1MG/ML	A214316	001	Nov 15, 2024	Apr CAHN
		DODEX					
	@	ACCORD HLTHCARE	1MG/ML	A083022	001		Jan DISC

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CYCLOMYDRIL

+! ALCON LABS INC 0.2%;1% A084300 001 May CRLD

CYCLOPHOSPHAMIDECAPSULE; ORAL
CYCLOPHOSPHAMIDE

AB		TRI-SOURCE PHARMA	25MG	A218282	001	Dec 03, 2024	Apr CAHN
AB			50MG	A218282	002	Dec 03, 2024	Apr CAHN

CYCLOSPORINEEMULSION; OPHTHALMIC
CYCLOSPORINE

	@	APOTEX	0.05%	A207606	001	Jan 12, 2023	Apr DISC
BX			0.05%	A207606	001	Jan 12, 2023	Mar CTEC

SOLUTION; ORAL
CYCLOSPORINE

@ ABBVIE 100MG/ML A065025 001 Mar 03, 2000 Feb DISC

DABIGATRAN ETEXILATE MESYLATECAPSULE; ORAL
DABIGATRAN ETEXILATE MESYLATE

AB		AUROBINDO PHARMA	EQ 75MG BASE	A208039	001	May 14, 2025	May NEWA
AB			EQ 110MG BASE	A208039	002	May 14, 2025	May NEWA
AB			EQ 150MG BASE	A208039	003	May 14, 2025	May NEWA
>D>	AB	BRECKENRIDGE	EQ 75MG BASE	A207922	001	Dec 19, 2024	Jun DISC
>A>	@		EQ 75MG BASE	A207922	001	Dec 19, 2024	Jun DISC
>D>	AB		EQ 110MG BASE	A207922	003	Dec 19, 2024	Jun DISC
>A>	@		EQ 110MG BASE	A207922	003	Dec 19, 2024	Jun DISC
>D>	AB		EQ 150MG BASE	A207922	002	Dec 19, 2024	Jun DISC
>A>	@		EQ 150MG BASE	A207922	002	Dec 19, 2024	Jun DISC
AB		DR REDDYS	EQ 75MG BASE	A208048	001	Jan 28, 2025	Jan NEWA
AB			EQ 110MG BASE	A208048	002	Jan 28, 2025	Jan NEWA
AB			EQ 150MG BASE	A208048	003	Jan 28, 2025	Jan NEWA
AB		MYLAN	EQ 75MG BASE	A208067	001	Feb 03, 2025	Jan NEWA
AB			EQ 150MG BASE	A208067	002	Feb 03, 2025	Jan NEWA

DACARBAZINEINJECTABLE; INJECTION
DACARBAZINE

@	HOSPIRA	200MG/VIAL	A075940	001	Oct 18, 2001	Mar	DISC
---	---------	------------	---------	-----	--------------	-----	------

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL
AMPYRA

AB	+!	MERZ	10MG	N022250	001	Jan 22, 2010	Feb	CAHN
----	----	------	------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

>D> TABLET; ORAL

>D> QTERN

>D>	+	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019	Jun	DISC
-----	---	----------------	-----------------	---------	-----	--------------	-----	------

>A>	@ +		5MG;EQ 5MG BASE	N209091	002	May 02, 2019	Jun	DISC
-----	-----	--	-----------------	---------	-----	--------------	-----	------

>D>	+!		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017	Jun	DISC
-----	----	--	------------------	---------	-----	--------------	-----	------

>A>	@ +		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017	Jun	DISC
-----	-----	--	------------------	---------	-----	--------------	-----	------

DAPSONE

GEL; TOPICAL

DAPSONE

AB		AUROBINDO PHARMA LTD	5%	A218457	001	Apr 04, 2025	Mar	NEWA
----	--	----------------------	----	---------	-----	--------------	-----	------

TABLET; ORAL

DAPSONE

AB		SOLIS PHARMS	25MG	A203887	001	May 06, 2016	Apr	CAHN
----	--	--------------	------	---------	-----	--------------	-----	------

AB			100MG	A203887	002	May 06, 2016	Apr	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

>D>	AP	@	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jan	DISC
-----	----	---	--------------------	------------	---------	-----	--------------	-----	------

>A>		@	HANGZHOU ZHONGMEI	500MG/VIAL	A215215	001	Nov 26, 2021	Jun	DISC
-----	--	---	-------------------	------------	---------	-----	--------------	-----	------

>A>		@		500MG/VIAL	A215215	001	Nov 26, 2021	Jun	DISC
-----	--	---	--	------------	---------	-----	--------------	-----	------

>D>		@ +	MAIA PHARMS INC	350MG/VIAL	N217630	001	Nov 21, 2024	May	DISC
-----	--	-----	-----------------	------------	---------	-----	--------------	-----	------

>D>		@ +		500MG/VIAL	N217630	002	Nov 21, 2024	Jun	CMFD
-----	--	-----	--	------------	---------	-----	--------------	-----	------

>A>		+		500MG/VIAL	N217630	002	Nov 21, 2024	Jun	CMFD
-----	--	---	--	------------	---------	-----	--------------	-----	------

>A>		+!		500MG/VIAL	N217630	002	Nov 21, 2024	Jun	CHRS
-----	--	----	--	------------	---------	-----	--------------	-----	------

>A>		@ +		500MG/VIAL	N217630	002	Nov 21, 2024	May	DISC
-----	--	-----	--	------------	---------	-----	--------------	-----	------

DARUNAVIR

TABLET; ORAL

DARUNAVIR

AB		ANNORA PHARMA	600MG	A216168	001	Jan 21, 2025	Jan	NEWA
----	--	---------------	-------	---------	-----	--------------	-----	------

AB			800MG	A216168	002	Jan 21, 2025	Jan	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

DASATINIB

TABLET; ORAL

DASATINIB

AB		BIOCON PHARMA	20MG	A217217	001	Mar 03, 2025	Feb	NEWA
----	--	---------------	------	---------	-----	--------------	-----	------

AB			50MG	A217217	002	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			70MG	A217217	003	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			80MG	A217217	004	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			100MG	A217217	005	Mar 03, 2025	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			140MG	A217217	006	Mar 03, 2025	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB		DR REDDYS	20MG	A213383	001	Mar 03, 2025	Feb	NEWA
----	--	-----------	------	---------	-----	--------------	-----	------

AB			50MG	A213383	002	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			70MG	A213383	003	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			80MG	A213383	004	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			100MG	A213383	005	Mar 03, 2025	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			140MG	A213383	006	Mar 03, 2025	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB		EUGIA PHARMA	20MG	A216547	001	Apr 22, 2025	Apr	NEWA
----	--	--------------	------	---------	-----	--------------	-----	------

AB			50MG	A216547	002	Apr 22, 2025	Apr	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			70MG	A216547	003	Apr 22, 2025	Apr	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			80MG	A216547	004	Apr 22, 2025	Apr	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			100MG	A216547	005	Apr 22, 2025	Apr	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			140MG	A216547	006	Apr 22, 2025	Apr	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB		ZYDUS PHARMS	20MG	A218719	001	Mar 03, 2025	Feb	NEWA
----	--	--------------	------	---------	-----	--------------	-----	------

AB			50MG	A218719	002	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			70MG	A218719	003	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			80MG	A218719	004	Mar 03, 2025	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			100MG	A218719	005	Mar 03, 2025	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TABLET;ORAL
DASATINIB

AB		140MG	A218719	006	Mar 03, 2025	Feb	NEWA
	PHYRAGO						
	+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023	Jan CAHN
	+		50MG	N216099	002	Dec 05, 2023	Jan CAHN
	+		70MG	N216099	003	Dec 05, 2023	Jan CAHN
	+		80MG	N216099	004	Dec 05, 2023	Jan CAHN
	+		100MG	N216099	005	Dec 05, 2023	Jan CAHN
	+		140MG	N216099	006	Dec 05, 2023	Jan CAHN

DECITABINE

INJECTABLE;INTRAVENOUS
DECITABINE

AP	ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Apr	CHRS
AP	! DR REDDYS	50MG/VIAL	A203131	001	Jul 11, 2013	Apr	CHRS

DEFERASIROX

TABLET;ORAL
DEFERASIROX

AB	JUBILANT GENERICS	90MG	A211660	001	Apr 11, 2025	Apr	NEWA
AB		180MG	A211660	002	Apr 11, 2025	Apr	NEWA
AB		360MG	A211660	003	Apr 11, 2025	Apr	NEWA
	@ SUN PHARM	90MG	A211641	001	Jan 02, 2020	Apr	DISC
	@	180MG	A211641	003	Jun 15, 2020	Apr	DISC
	@	360MG	A211641	002	Jan 02, 2020	Apr	DISC

TABLET, FOR SUSPENSION;ORAL
DEFERASIROX

>D>	AB	TORRENT	125MG	A209426	001	Nov 05, 2024	Jun	DISC
>A>		@	125MG	A209426	001	Nov 05, 2024	Jun	DISC
>D>	AB		250MG	A209426	002	Nov 05, 2024	Jun	DISC
>A>		@	250MG	A209426	002	Nov 05, 2024	Jun	DISC
>D>	AB		500MG	A209426	003	Nov 05, 2024	Jun	DISC
>A>		@	500MG	A209426	003	Nov 05, 2024	Jun	DISC

DEFLAZACORT

SUSPENSION;ORAL
PYQUVI

>A>	AB	AUCTA	22.75MG/ML	A219417	001	Jun 30, 2025	Jun	NEWA
-----	----	-------	------------	---------	-----	--------------	-----	------

TABLET;ORAL
DEFLAZACORT

AB	SUN PHARM	6MG	A217741	001	Mar 18, 2025	Mar	NEWA
AB		18MG	A217741	002	Mar 18, 2025	Mar	NEWA
AB		30MG	A217741	003	Mar 18, 2025	Mar	NEWA
AB		36MG	A217741	004	Mar 18, 2025	Mar	NEWA
	JAYTHARI						
AB	ZYDUS LIFESCIENCES	6MG	A219254	001	Apr 08, 2025	Mar	NEWA
AB		18MG	A219254	002	Apr 08, 2025	Mar	NEWA
AB		30MG	A219254	003	Apr 08, 2025	Mar	NEWA
AB		36MG	A219254	004	Apr 08, 2025	Mar	NEWA

DESLORATADINE

TABLET;ORAL
DESLORATADINE

AB	AJENAT PHARMS	5MG	A078355	001	Apr 19, 2012	Jan	CAHN
----	---------------	-----	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

TABLET;ORAL
DESMOPRESSIN ACETATE

	@	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May	DISC
	@		0.2MG	A201831	002	May 28, 2015	May	DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21
AVERI

	AVION PHARMS	0.15MG;0.03MG	A218933	001	May 02, 2025	Apr	NEWA
	TABLET;ORAL-28						
	AVERI						
AB	AVION PHARMS	0.15MG;0.03MG	A218933	002	May 02, 2025	Apr	NEWA

DESONIDE

OINTMENT; TOPICAL

DESOWEN

@	GALDERMA LABS LP	0.05%	A071425	001	Jun 15, 1988	May DISC
---	------------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	MACLEODS PHARMS LTD	EQ 50MG BASE	A211427	001	Jan 15, 2025	Jan NEWA
AB		EQ 100MG BASE	A211427	002	Jan 15, 2025	Jan NEWA
AB	MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Feb CAHN
AB		EQ 100MG BASE	A204805	002	May 07, 2019	Feb CAHN

DEUTETRABENAZINE

TABLET; ORAL

AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Feb CAHN
+		6MG	N208082	001	Apr 03, 2017	Jan CTEC
+		9MG	N208082	002	Apr 03, 2017	Feb CAHN
+		9MG	N208082	002	Apr 03, 2017	Jan CTEC
+		12MG	N208082	003	Apr 03, 2017	Feb CAHN
+		12MG	N208082	003	Apr 03, 2017	Jan CTEC

DEUTETRABENAZINE

@	AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Jan DISC
@		9MG	A215971	002	Dec 26, 2024	Jan DISC
@		12MG	A215971	003	Dec 26, 2024	Jan DISC

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

AB	+	HIKMA	0.5MG	A084612	002	Apr CMS1
AB	+		0.75MG	A084612	003	Apr CMS1
AB	+		1MG	A084612	004	Sep 15, 1983 Apr CMS1
AB	+		1.5MG	A084612	005	Apr CMS1
AB	+		2MG	A084612	006	Apr CMS1
AB	+		6MG	A084612	007	Sep 15, 1983 Apr CMS1

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

POLMON

!	CARWIN PHARM ASSOC	2MG/5ML	A202520	001	Jul 16, 2018	Mar CAHN
!	CARWIN PHARMS	2MG/5ML	A202520	001	Jul 16, 2018	Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	HIKMA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	A206407	003	May 30, 2025	May NFTG
AP		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	May CAHN
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	May CAHN
AP	PRECEDEX					
AP	+	HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020 May CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Feb CAHN
AB		10MG	A078992	002	Nov 23, 2021	Feb CAHN
AB		15MG	A078992	003	Nov 18, 2013	Feb CAHN
AB		30MG	A078992	004	Nov 18, 2013	Feb CAHN
AB		20MG	A078992	005	Nov 23, 2021	Feb CAHN
AB		40MG	A078992	006	Nov 23, 2021	Feb CAHN

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

@	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Jan DISC
@		5MG	A208756	002	Nov 20, 2017	Jan DISC
@		10MG	A208756	003	Nov 20, 2017	Jan DISC

DEXRAZOXANE HYDROCHLORIDEINJECTABLE; INJECTION
DEXRAZOXANE HYDROCHLORIDE

AP	MSN	EQ 250MG BASE/VIAL	A216748	001	Mar 26, 2025	Mar	NEWA
AP		EQ 500MG BASE/VIAL	A216748	002	Mar 26, 2025	Mar	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

AA	!	PAI HOLDINGS	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Apr	CAHN
AA		PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE		A091687	001	Jun 28, 2012	May	CAHN
AA		COSETTE	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Feb	CAHN
AA		PROMETHAZINE W/ DEXTROMETHORPHAN						
AA		XTRIUM LABS INC	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Feb	CAHN

DIAZEPAMINJECTABLE; INJECTION
DIAZEPAM

AP		GALENICUM HLTH	50MG/10ML (5MG/ML)	A216422	001	May 19, 2025	May	NEWA
----	--	----------------	--------------------	---------	-----	--------------	-----	------

DIAZOXIDE CHOLINETABLET, EXTENDED RELEASE; ORAL
VYKAT XR

	+	SOLENO THERAP	25MG	N216665	001	Mar 26, 2025	Mar	NEWA
	+		75MG	N216665	002	Mar 26, 2025	Mar	NEWA
	+	!	150MG	N216665	003	Mar 26, 2025	Mar	NEWA

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

>A>	AB	ONESOURCE SPECIALTY	25MG	A210078	001	Dec 03, 2019	Jun	CAHN
>D>	AB	STRIDES SOFTGELS	25MG	A210078	001	Dec 03, 2019	Jun	CAHN

FOR SOLUTION; ORAL

DICLOFENAC POTASSIUM

AB		TORRENT	50MG	A215891	001	Jan 22, 2025	Jan	NEWA
----	--	---------	------	---------	-----	--------------	-----	------

TABLET; ORAL

DICLOFENAC POTASSIUM

AB		RK PHARMA	50MG	A075463	001	Jul 26, 1999	Mar	CHRS
AB	!	RUBICON	50MG	A075229	001	Nov 20, 1998	Mar	CHRS
>A>	AB	UMEDICA	25MG	A215750	002	Jun 30, 2025	Jun	NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

BX		ALEMBIC	3%	A212351	001	Jul 27, 2022	Mar	CTEC
----	--	---------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AB		ENCUBE	2%	A217646	001	Apr 09, 2025	Mar	NEWA
----	--	--------	----	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB		AUROBINDO PHARMA USA	50MG	A075281	002	Feb 12, 2002	Apr	CMFD
AB			75MG	A075281	003	Feb 12, 2002	Apr	CMFD

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB		NOVAST LABS	100MG	A216275	001	Sep 23, 2022	Apr	CAHN
----	--	-------------	-------	---------	-----	--------------	-----	------

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

>A>	AB	RISING	10MG	A219242	001	Jun 23, 2025	Jun	NEWA
-----	----	--------	------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

	@	NEXUS	10MG/ML	A206468	001	Feb 01, 2019	Apr	DISC
--	---	-------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

AB		PRINSTON INC	20MG	A218310	001	Jun 06, 2025	May	NEWA
AB		RUBICON RESEARCH	20MG	A216736	001	Dec 14, 2022	Mar	CAHN
	!		40MG	A216736	002	Mar 25, 2025	Mar	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

>A>	@ +	MPP PHARMA	25MG	N011722	002		Jun	CAHN
>D>	@ +	NOSTRUM LABS INC	25MG	N011722	002		Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

	@ +	ANI PHARMS	75MG	N012546	001		Apr	CAHN
--	-----	------------	------	---------	-----	--	-----	------

DIFELIKEFALIN ACETATE

SOLUTION; INTRAVENOUS

KORSUVA

	+	!	VIFOR INTL	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Apr	CAHN
--	---	---	------------	--	---------	-----	--------------	-----	------

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DIFLUPREDNATE

AB		MYLAN LABS LTD	0.05%	A212566	001	Mar 20, 2025	Mar	NEWA
AB		UPSHER SMITH LABS	0.05%	A218191	001	Feb 11, 2025	Jan	NEWA

DIGOXIN

ELIXIR; ORAL

DIGOXIN

>D>	AA	+	!	HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Jun	CAHN
>A>	AA	+	!		0.05MG/ML	N021648	001	Aug 26, 2004	Jun	CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

>D>	AP			BAXTER HLTHCARE CORP	1MG/ML	A216747	001	Jan 07, 2025	Jun	DISC
>A>		@			1MG/ML	A216747	001	Jan 07, 2025	Jun	DISC
		@		CIPLA	1MG/ML	A212334	001	Sep 20, 2024	Jan	DISC

POWDER; NASAL

ATZUMI

	+	!	SATSUMA PHARMS	EQ 5.2MG BASE	N217901	001	Apr 30, 2025	Apr	NEWA
--	---	---	----------------	---------------	---------	-----	--------------	-----	------

SOLUTION; SUBCUTANEOUS

BREKIYA (AUTOINJECTOR)

	+	!	AMNEAL	1MG/ML	N215400	001	May 14, 2025	May	NEWA
--	---	---	--------	--------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

DIHYDROERGOTAMINE MESYLATE

AB				AGGREGA	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Feb	NEWA
----	--	--	--	---------	-------------	---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB1				AMTA	60MG	A219073	001	Mar 24, 2025	Mar	NEWA
AB1					90MG	A219073	002	Mar 24, 2025	Mar	NEWA
AB1					120MG	A219073	003	Mar 24, 2025	Mar	NEWA
>A>	AB1			NOVAST LABS	60MG	A218032	001	Jul 02, 2025	Jun	NEWA
>A>	AB1				90MG	A218032	002	Jul 02, 2025	Jun	NEWA
>A>	AB1				120MG	A218032	003	Jul 02, 2025	Jun	NEWA
		@		SUN PHARM	120MG	A203023	001	Jun 08, 2017	Apr	DISC
		@			180MG	A203023	002	Jun 08, 2017	Mar	DISC
		@			240MG	A203023	003	Jun 08, 2017	Mar	DISC
		@			300MG	A203023	004	Jun 08, 2017	Feb	DISC
AB1				UTOPIIC PHARMS	60MG	A219073	001	Mar 24, 2025	Apr	CAHN
AB1					90MG	A219073	002	Mar 24, 2025	Apr	CAHN
AB1					120MG	A219073	003	Mar 24, 2025	Apr	CAHN

SOLUTION; INTRAVENOUS

DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

	+	!	HQ SPCLT PHARMA	100MG/100ML (1MG/ML)	N218038	001	Feb 21, 2025	Feb	NEWA
	+	!		250MG/250ML (1MG/ML)	N218038	002	Feb 21, 2025	Feb	NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

DIMETHYL FUMARATE

	@			CIPLA	120MG	A210305	001	Sep 24, 2020	Feb	DISC
	@				240MG	A210305	002	Sep 24, 2020	Feb	DISC
>D>	AB			TORRENT	120MG	A210390	001	Jan 06, 2025	Jun	DISC
>A>		@			120MG	A210390	001	Jan 06, 2025	Jun	DISC

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

>D>	AB		240MG	A210390	002	Jan 06, 2025	Jun DISC
>A>	@		240MG	A210390	002	Jan 06, 2025	Jun DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

>A>	AP	AVET LIFESCIENCES	50MG/ML	A205336	001	Jun 24, 2025	Jun NEWA
	AP	! NORVIUM BIOSCIENCE	50MG/ML	A040498	001	Jul 12, 2005	Feb CAHN

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB		BARR LABS	75MG	A087717	001	Oct 03, 1990	Mar CAHN
----	--	-----------	------	---------	-----	--------------	----------

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

	@	APOTEX	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Mar DISC
	@		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Mar DISC
	@		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Mar DISC

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

AP		! AMNEAL	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Apr CHRS
AP		!	80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Apr CHRS
AP		!	160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Apr CHRS
AP		GUANGDONG SUNHO	20MG/ML (20MG/ML)	A213768	001	May 13, 2025	May NEWA
AP			80MG/4ML (20MG/ML)	A213768	002	May 13, 2025	May NEWA
		TAXOTERE					
	@ +	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010	Apr DISC
	@ +		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010	Apr DISC
AP		+	160MG/8ML (20MG/ML)	N020449	005	Apr 13, 2012	Apr CHRS

SOLUTION; INTRAVENOUS

	@ +	ZHUHAI	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Apr DISC
--	-----	--------	--------------------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

	@	INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012	Apr DISC
	@		10MG	A201634	002	Jun 13, 2012	Apr DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		AMNEAL	10MG; 7MG	A208328	003	Feb 27, 2025	Feb NFTG
AB			10MG; 21MG	A208328	004	Feb 27, 2025	Feb NEWA
		NAMZARIC					
AB		+ ABBVIE	10MG; 7MG	N206439	003	Jul 18, 2016	Feb CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

AT		SOMERSET THERAPS LLC	EQ 2% BASE	A215004	001	Feb 11, 2025	Jan NEWA
----	--	----------------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT2		IDENTIRX	EQ 2% BASE; EQ 0.5% BASE	A216308	001	Feb 18, 2025	Feb NEWA
-----	--	----------	--------------------------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

AB		APPCO	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar CAHN
AB			EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar CAHN
AB			EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar CAHN
AB			EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

	@	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Jan	DISC
AB		PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar	CAHN
AB			EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar	CAHN
AB			EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar	CAHN
AB			EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar	CAHN
AB			EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar	CAHN
BX		ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar	CTEC
BX			EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar	CTEC
BX			EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar	CTEC
BX			EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar	CTEC
BX			EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar	CTEC
BX			EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar	CTEC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

>D>	@	AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Jun	CMFD
>A>	AB		EQ 3MG BASE	A216041	001	Jul 25, 2024	Jun	CMFD
>D>	@		EQ 6MG BASE	A216041	002	Jul 25, 2024	Jun	CMFD
>A>	AB		EQ 6MG BASE	A216041	002	Jul 25, 2024	Jun	CMFD
BX		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar	CTEC
BX			EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar	CTEC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

>A>	AB	ALEMBIC	20MG/10ML (2MG/ML)	A219199	001	Jun 27, 2025	Jun	NEWA
>A>	AB		50MG/25ML (2MG/ML)	A219199	002	Jun 27, 2025	Jun	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		MACLEODS PHARMS LTD	40MG	A210381	001	Mar 27, 2025	Mar	NEWA
AB		PRINSTON INC	40MG	A217098	001	Jan 27, 2025	Jan	NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

	@	BIONPHARMA	EQ 50MG BASE	A209393	001	Dec 10, 2020	Apr	CAHN
	@		EQ 100MG BASE	A209393	002	Dec 10, 2020	Apr	CAHN
AB	!	HIKMA INTL PHARMS	EQ 100MG BASE	A062396	001	May 07, 1984	Feb	CHRS
	@ +	PFIZER	EQ 100MG BASE	N050007	002		Feb	DISC

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

>A>	AP	AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Jan	DISC
	AP	DR REDDYS	EQ 100MG BASE/VIAL	A218753	001	Jul 01, 2025	Jun	NEWA
	AP	PRECISION DOSE INC	EQ 100MG BASE/VIAL	A217078	001	Feb 21, 2025	Feb	NEWA

TABLET;ORAL

DOXYCYCLINE HYCLATE

>D>	AB	AVIV PHARMA	EQ 100MG BASE	A209560	001	Apr 15, 2024	May	CAHN
>A>		MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jun	DISC
>A>			EQ 100MG BASE	A062432	001	Feb 15, 1983	Jun	DISC

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB		JUBILANT CADISTA	100MG	A214391	001	Feb 18, 2021	Apr	CAHN
AB			200MG	A214391	002	Feb 18, 2021	Apr	CAHN
AB			300MG	A214391	003	Feb 18, 2021	Apr	CAHN

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

	@	AVIV PHARMA	0.5MG	A204705	001	Nov 20, 2015	May	CAHN
--	---	-------------	-------	---------	-----	--------------	-----	------

EDARAVONE

SOLUTION;INTRAVENOUS

EDARAVONE

@	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	DISC
---	-------------------	-----------------------	---------	-----	--------------	-----	------

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB	NORVIUM BIOSCIENCE	600MG	A204869	001	Mar 12, 2018	May	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@	CHARTWELL RX	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Apr	CAHN
---	--------------	-------------------	---------	-----	--------------	-----	------

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

@ +	ABBVIE	13.9%	N021145	001	Jul 27, 2000	Feb	CAHN
-----	--------	-------	---------	-----	--------------	-----	------

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

>A>	AB	ANNORA PHARMA	EQ 20MG BASE	A219143	001	Jul 07, 2025	Jun	NEWA
>A>	AB		EQ 40MG BASE	A219143	002	Jul 07, 2025	Jun	NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

@	APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jan	DISC
---	--------	--------------	---------	-----	--------------	-----	------

ELTROMBOPAG OLAMINE

TABLET;ORAL

ELTROMBOPAG OLAMINE

AB	HETERO LABS LTD V	EQ 12.5MG ACID	A206788	001	Jan 17, 2025	Jan	NFTG
AB		EQ 25MG ACID	A206788	002	Jan 17, 2025	Jan	NFTG
AB		EQ 50MG ACID	A206788	003	Jan 17, 2025	Jan	NFTG
AB		EQ 75MG ACID	A206788	004	Jan 17, 2025	Jan	NFTG
	PROMACTA						
AB	+ NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Jan	CFTG
AB	+	EQ 25MG ACID	N022291	001	Nov 20, 2008	Jan	CFTG
AB	+	EQ 50MG ACID	N022291	002	Nov 20, 2008	Jan	CFTG
AB	+	EQ 75MG ACID	N022291	003	Sep 08, 2009	Jan	CFTG

ELUXADOLINE

TABLET;ORAL

ELUXADOLINE

AB	ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025	Mar	NFTG
AB		100MG	A213522	002	Mar 14, 2025	Mar	NFTG
	VIBERZI						
AB	+ ABBVIE	75MG	N206940	001	May 27, 2015	Mar	CFTG
AB	+	100MG	N206940	002	May 27, 2015	Mar	CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

COMPLERA

AB	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	May	CFTG
AB		MYLAN	200MG;EQ 25MG BASE;300MG	A208452	001	May 20, 2025	May	NFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	HETERO LABS LTD III	100MG;150MG	A201806	002	Mar 03, 2025	Feb	NEWA
AB		133MG;200MG	A201806	003	Mar 03, 2025	Feb	NEWA
AB		167MG;250MG	A201806	004	Mar 03, 2025	Feb	NEWA

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

>A>	AB	SENORES PHARMS	2.5MG	A 075483	001	Aug 22, 2000	Jun	CAHN
>A>	AB		5MG	A 075483	002	Aug 22, 2000	Jun	CAHN
>A>	AB		10MG	A 075483	003	Aug 22, 2000	Jun	CAHN
>A>	AB		20MG	A 075483	004	Aug 22, 2000	Jun	CAHN
>D>	AB	WOCKHARDT LTD	2.5MG	A 075483	001	Aug 22, 2000	Jun	CAHN
>D>	AB		5MG	A 075483	002	Aug 22, 2000	Jun	CAHN
>D>	AB		10MG	A 075483	003	Aug 22, 2000	Jun	CAHN
>D>	AB		20MG	A 075483	004	Aug 22, 2000	Jun	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>A>	@	MPP PHARMA	5MG; 12.5MG	A 076486	001	Oct 27, 2004	Jun	CAHN
>A>	@		10MG; 25MG	A 076486	002	Oct 27, 2004	Jun	CAHN
>D>	@	NOSTRUM LABS INC	5MG; 12.5MG	A 076486	001	Oct 27, 2004	Jun	CAHN
>D>	@		10MG; 25MG	A 076486	002	Oct 27, 2004	Jun	CAHN

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

@ + ROCHE

90MG/VIAL

N 021481 001 Mar 13, 2003 Mar DISC

ENTECAVIR

TABLET; ORAL

ENTECAVIR

@ BRECKENRIDGE

0.5MG

A 208721 001 Mar 15, 2018 May DISC

@

1MG

A 208721 002 Mar 15, 2018 May DISC

ENZALUTAMIDE

CAPSULE; ORAL

ENZALUTAMIDE

@ ZYDUS PHARMS

40MG

A 209667 001 Sep 26, 2024 Feb DISC

XTANDI

+! ASTELLAS

40MG

N 203415 001 Aug 31, 2012 Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

REZIPRES

@ + DR REDDYS LABS SA

47MG/10ML (4.7MG/ML)

N 213536 004 Dec 07, 2023 May DISC

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

AP3 +! EXELA PHARMA

25MG/5ML (5MG/ML)

N 208289 002 Aug 02, 2021 Mar CTEC

EMERPHED

AP1 +! NEXUS

50MG/10ML (5MG/ML)

N 213407 001 Apr 17, 2020 Mar CTEC

AP +!

50MG/10ML (5MG/ML)

N 213407 001 Apr 17, 2020 Jan CFTG

EPHEDRINE SULFATE

AP2 +! ENDO OPERATIONS

25MG/5ML (5MG/ML)

N 213994 002 Apr 22, 2022 Mar CTEC

AP +!

25MG/5ML (5MG/ML)

N 213994 002 Apr 22, 2022 Feb CFTG

AP2 +!

50MG/10ML (5MG/ML)

N 213994 001 Oct 16, 2020 Mar CTEC

AP +!

50MG/10ML (5MG/ML)

N 213994 001 Oct 16, 2020 Feb CFTG

AP2 FRESENIUS KABI USA

25MG/5ML (5MG/ML)

A 218271 001 Mar 11, 2025 Mar CTEC

AP

25MG/5ML (5MG/ML)

A 218271 001 Mar 11, 2025 Feb NFTG

AP2

50MG/10ML (5MG/ML)

A 218271 002 Mar 11, 2025 Mar CTEC

AP

50MG/10ML (5MG/ML)

A 218271 002 Mar 11, 2025 Feb NFTG

AP1 GLAND

50MG/10ML (5MG/ML)

A 218211 001 Jan 16, 2025 Mar CTEC

AP

50MG/10ML (5MG/ML)

A 218211 001 Jan 16, 2025 Jan NFTG

AP3 HIKMA

25MG/5ML (5MG/ML)

A 217721 001 Oct 11, 2024 Mar CTEC

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

@ RENOVA PHARMS

0.05%

A 090870 001 Mar 14, 2011 Feb CAHN

EPINEPHRINE

	INJECTABLE; INTRAMUSCULAR							
	EPI E Z PEN JR							
	@	VIATRIS	0.15MG/DELIVERY	N019430	004	Aug 03, 1995	May	CAHN
	EPIPEN E Z PEN							
	@	VIATRIS	0.3MG/DELIVERY	N019430	003	Aug 03, 1995	May	CAHN
	INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS							
	EPIPEN							
AB	+	VIATRIS	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	May	CAHN
	EPIPEN JR.							
AB	+	VIATRIS	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	May	CAHN
	TWINJECT							
	@	IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May	CTNA
	@		EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May	CTNA
	SOLUTION; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS							
	EPINEPHRINE							
AP		GLAND PHARMA LTD	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Jan	NFTG
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
	EPINEPHRINE							
AP	+	BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Jan	CFTG
	+	FRESENIUS KABI USA	30MG/30ML (1MG/ML)	N215425	001	Mar 13, 2025	Mar	NEWA
AP		GLAND	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Mar	CDFR
	SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS							
	EPINEPHRINE							
AP		GLAND	1MG/ML (1MG/ML)	A218144	001	Jun 03, 2025	May	NEWA
	SPRAY; NASAL							
	NEFFY							
	+	ARS PHARMS OPERATION	1MG/SPRAY	N214697	002	Mar 05, 2025	Apr	CHRS
	+		1MG/SPRAY	N214697	002	Mar 05, 2025	Mar	NEWA

EPINEPHRINE BITARTRATE

	SOLUTION; INTRAVENOUS							
	EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
	+	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Feb	NEWA

EPLERENONE

	TABLET; ORAL							
	EPLERENONE							
	@	THINKRX	25MG	A203896	001	Feb 02, 2017	Mar	CAHN
	@		50MG	A203896	002	Feb 02, 2017	Mar	CAHN

EPTIFIBATIDE

	INJECTABLE; INJECTION							
	EPTIFIBATIDE							
AP		MEITHEAL	2MG/ML	A213599	001	May 09, 2024	Apr	CAHN
AP			75MG/100ML	A213599	002	May 09, 2024	Apr	CAHN

ERGOALCIFEROL

	CAPSULE; ORAL								
	ERGOALCIFEROL								
>A>	AA	!	ONESOURCE SPECIALTY	50,000 IU	A090455	001	Aug 03, 2010	Jun	CAHN
>D>	AA	!	STRIDES SOFTGELS	50,000 IU	A090455	001	Aug 03, 2010	Jun	CAHN

ERIBULIN MESYLATE

	SOLUTION; INTRAVENOUS								
	ERIBULIN MESYLATE								
AP		CHIA TAI TIANQING	1MG/2ML (0.5MG/ML)	A218743	001	Mar 04, 2025	Feb	NEWA	
>A>	AP		DR REDDYS	1MG/2ML (0.5MG/ML)	A217473	001	Jul 03, 2025	Jun	NEWA
AP		JIANGXI KVVIT PHARM	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Apr	CAHN	
AP		SANDOZ	1MG/2ML (0.5MG/ML)	A214310	001	Jun 09, 2025	May	NEWA	

ERLOTINIB HYDROCHLORIDE

	TABLET; ORAL							
	ERLOTINIB HYDROCHLORIDE							
	@	APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Jan	DISC
	@		EQ 100MG BASE	A208396	002	Nov 05, 2019	Jan	DISC
	@		EQ 150MG BASE	A208396	003	Nov 05, 2019	Jan	DISC
	@	SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Jan	DISC
	@		EQ 100MG BASE	A210300	002	Nov 05, 2019	Feb	DISC
	@		EQ 150MG BASE	A210300	003	Nov 05, 2019	Jan	DISC

ERTUGLIFLOZIN

TABLET;ORAL

ERTUGLIFLOZIN								
	@	HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Apr	DISC
	@		15MG	A217071	002	Sep 17, 2024	Apr	DISC
	@	HIKMA	5MG	A216842	001	Jan 21, 2025	Feb	DISC
AB			5MG	A216842	001	Jan 21, 2025	Jan	NEWA
	@		15MG	A216842	002	Jan 21, 2025	Feb	DISC
AB			15MG	A216842	002	Jan 21, 2025	Jan	NEWA
STEGLATRO								
	+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Apr	CTEC
	+	!	15MG	N209803	002	Dec 19, 2017	Apr	CTEC

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE								
	@	AZURITY	EQ 250MG BASE	A060359	001		Apr	DISC

ESLICARBAZEPINE ACETATE

TABLET;ORAL

ESLICARBAZEPINE ACETATE								
AB		APOTEX	200MG	A211236	001	Dec 07, 2023	Apr	CMFD
AB			400MG	A211236	002	Dec 07, 2023	Apr	CMFD
AB			600MG	A211236	003	Dec 07, 2023	Apr	CMFD
AB			800MG	A211236	004	Dec 07, 2023	Apr	CMFD
AB		LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Mar	CMFD
AB			400MG	A211246	002	Mar 27, 2024	Mar	CMFD
AB			600MG	A211246	003	Mar 27, 2024	Mar	CMFD
AB			800MG	A211246	004	Mar 27, 2024	Mar	CMFD
AB		TORRENT	200MG	A211227	001	Feb 27, 2024	May	CMFD
AB			400MG	A211227	002	Feb 27, 2024	May	CMFD
AB			600MG	A211227	003	Feb 27, 2024	May	CMFD
AB			800MG	A211227	004	Feb 27, 2024	May	CMFD

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Apr	CAHN
AB			EQ 40MG BASE	A213859	002	Nov 18, 2020	Apr	CAHN
	@	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Feb	DISC
	@		EQ 40MG BASE	A078003	002	Jan 26, 2015	Feb	DISC
>D> AB		MACLEODS PHARMS LTD	EQ 20MG BASE	A208511	001	Oct 23, 2024	Jun	DISC
>A>	@		EQ 20MG BASE	A208511	001	Oct 23, 2024	Jun	DISC
>D> AB			EQ 40MG BASE	A208511	002	Oct 23, 2024	Jun	DISC
>A>	@		EQ 40MG BASE	A208511	002	Oct 23, 2024	Jun	DISC

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE/PACKET	A218948	001	Apr 15, 2025	Apr	NEWA
AB			EQ 10MG BASE/PACKET	A219213	001	Apr 15, 2025	Apr	NEWA
AB			EQ 20MG BASE/PACKET	A218948	002	Apr 15, 2025	Apr	NEWA
AB			EQ 40MG BASE/PACKET	A218948	003	Apr 15, 2025	Apr	NEWA
AB		TORRENT	EQ 2.5MG BASE/PACKET	A212651	001	Mar 05, 2025	Feb	NEWA
AB			EQ 5MG BASE/PACKET	A212651	002	Mar 05, 2025	Feb	NEWA
AB			EQ 10MG BASE/PACKET	A212652	001	Mar 05, 2025	Feb	NEWA
AB			EQ 20MG BASE/PACKET	A212651	003	Mar 05, 2025	Feb	NEWA
AB			EQ 40MG BASE/PACKET	A212651	004	Mar 05, 2025	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	@	NORVIUM BIOSCIENCE	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Feb	CAHN
	@		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Feb	CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		YANGTZE	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jan	NEWA
----	--	---------	-------------------	---------	-----	--------------	-----	------

ESTRADIOL

	CREAM;VAGINAL								
	ESTRADIOL								
AB	ENCUBE	0.01%		A209767	001	Mar 05, 2018	Jan	CAHN	
	GEL;TRANSDERMAL								
	ESTRADIOL								
AB	ENCUBE	0.1% (0.25GM/PACKET)		A218507	001	Mar 05, 2025	Feb	NEWA	
AB		0.1% (0.5GM/PACKET)		A218507	002	Mar 05, 2025	Feb	NEWA	
AB		0.1% (0.75GM/PACKET)		A218507	003	Mar 05, 2025	Feb	NEWA	
AB		0.1% (1.25GM/PACKET)		A218507	005	Mar 05, 2025	Feb	NEWA	
AB		0.1% (1GM/PACKET)		A218507	004	Mar 05, 2025	Feb	NEWA	
	GEL, METERED;TRANSDERMAL								
	ELESTRIN								
	+! VIATRIS	0.06% (0.87GM/ACTIVATION)		N021813	001	Dec 15, 2006	Feb	CAHN	
	TABLET;ORAL								
	ESTRADIOL								
	@ RUBICON RESEARCH	0.5MG		A040114	003	Mar 14, 1996	Apr	CAHN	
	@	1MG		A040114	001	Mar 14, 1996	Apr	CAHN	
	@	2MG		A040114	002	Mar 14, 1996	Apr	CAHN	

ESZOPICLONE

	TABLET;ORAL								
	ESZOPICLONE								
	@ AVIV PHARMA	1MG		A203087	001	May 08, 2019	May	CAHN	
	@	2MG		A203087	002	May 08, 2019	May	CAHN	
	@	3MG		A203087	003	May 08, 2019	May	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET;ORAL-28								
	GENCEPT 10/11-28								
	@ BARR LABS	0.035MG,0.035MG;0.5MG,1MG		A072697	001	Feb 28, 1992	Mar	CAHN	
	NORTREL 0.5/35-28								
AB	BARR LABS	0.035MG;0.5MG		A072695	001	Feb 28, 1992	Mar	CAHN	
	NORTREL 1/35-28								
AB	! BARR LABS	0.035MG;1MG		A072696	001	Feb 28, 1992	Mar	CAHN	
	TABLET, CHEWABLE;ORAL								
	KAITLIB FE								
AB	! LUPIN LTD	0.025MG;0.8MG		A203448	001	Dec 17, 2015	Apr	CHRS	
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE								
	@ + TEVA BRANDED PHARM	0.025MG;0.8MG		N022573	001	Dec 22, 2010	Apr	DISC	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL								
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE								
AB	BARR LABS	0.02MG;1MG		A090938	001	Dec 01, 2014	Mar	CAHN	
	TABLET;ORAL-21								
	JUNEL 1/20								
AB	BARR LABS	0.02MG;1MG		A076380	001	May 30, 2003	Mar	CAHN	
	TABLET;ORAL-28								
	BLISOVI FE 1.5/30								
AB	LUPIN LTD	0.03MG;1.5MG		A201585	001	Nov 18, 2015	Apr	CTEC	

ETOPOSIDE

	CAPSULE;ORAL								
	VEPESID								
>A>	@ + ONESOURCE SPECIALTY	50MG		N019557	001	Dec 30, 1986	Jun	CAHN	
>A>	@ +	100MG		N019557	002	Dec 30, 1986	Jun	CAHN	
>D>	@ + STRIDES SOFTGELS	50MG		N019557	001	Dec 30, 1986	Jun	CAHN	
>D>	@ +	100MG		N019557	002	Dec 30, 1986	Jun	CAHN	

EVEROLIMUS

	TABLET;ORAL								
	EVEROLIMUS								
AB	BIOCON PHARMA	0.25MG		A216140	001	Apr 09, 2025	Mar	NEWA	
AB		0.5MG		A216140	002	Apr 09, 2025	Mar	NEWA	
AB		0.75MG		A216140	003	Apr 09, 2025	Mar	NEWA	
AB		1MG		A216140	004	Apr 09, 2025	Mar	NEWA	
	@ MYLAN	2.5MG		A212936	001	Jun 08, 2020	Mar	DISC	
	@	5MG		A212936	002	Jun 08, 2020	Mar	DISC	
	@	7.5MG		A212936	003	Jun 08, 2020	Mar	DISC	

TABLET;ORAL
EVEROLIMUS

	@		10MG		A212936	004	Jun 08, 2020	Mar	DISC
		TABLET, FOR SUSPENSION;ORAL EVEROLIMUS							
AB		AMNEAL	2MG		A218863	001	Jan 10, 2025	Jan	NEWA
AB			3MG		A218863	002	Jan 10, 2025	Jan	NEWA
AB			5MG		A218863	003	Jan 10, 2025	Jan	NEWA
AB		NATCO	2MG		A217640	001	Jan 28, 2025	Jan	NEWA
AB			3MG		A217640	002	Jan 28, 2025	Jan	NEWA
AB			5MG		A217640	003	Jan 28, 2025	Jan	NEWA

EXENATIDE SYNTHETICINJECTABLE;SUBCUTANEOUS
BYETTA

	@ +	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)		N021773	001	Apr 28, 2005	Apr	DISC
	@ +		600MCG/2.4ML (250MCG/ML)		N021773	002	Apr 28, 2005	Apr	DISC
		EXENATIDE SYNTHETIC							
	!	AMNEAL	300MCG/1.2ML (250MCG/ML)		A206697	001	Nov 19, 2024	Apr	CTEC
AP	!		300MCG/1.2ML (250MCG/ML)		A206697	001	Nov 19, 2024	Apr	CHRS
	!		600MCG/2.4ML (250MCG/ML)		A206697	002	Nov 19, 2024	Apr	CTEC
AP	!		600MCG/2.4ML (250MCG/ML)		A206697	002	Nov 19, 2024	Apr	CHRS

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON BCISE

	@ +	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)		N209210	001	Oct 20, 2017	Mar	DISC
--	-----	----------------	-------------------------	--	---------	-----	--------------	-----	------

EZETIMIBETABLET;ORAL
EZETIMIBE

>D>	AB	MACLEODS PHARMS LTD	10MG		A211159	001	Apr 29, 2024	Jun	DISC
>A>		@	10MG		A211159	001	Apr 29, 2024	Jun	DISC

EZETIMIBE; SIMVASTATINTABLET;ORAL
EZETIMIBE AND SIMVASTATIN

>D>	AB	SCIEGEN PHARMS INC	10MG;10MG		A211663	001	Dec 10, 2024	Jun	DISC
>A>		@	10MG;10MG		A211663	001	Dec 10, 2024	Jun	DISC
>D>	AB		10MG;20MG		A211663	002	Dec 10, 2024	Jun	DISC
>A>		@	10MG;20MG		A211663	002	Dec 10, 2024	Jun	DISC
>D>	AB		10MG;40MG		A211663	003	Dec 10, 2024	Jun	DISC
>A>		@	10MG;40MG		A211663	003	Dec 10, 2024	Jun	DISC
>D>	AB		10MG;80MG		A211663	004	Dec 10, 2024	Jun	DISC
>A>		@	10MG;80MG		A211663	004	Dec 10, 2024	Jun	DISC
>D>	AB	TORRENT	10MG;10MG		A209461	001	Jan 27, 2025	Jun	DISC
>A>		@	10MG;10MG		A209461	001	Jan 27, 2025	Jun	DISC
	AB		10MG;10MG		A209461	001	Jan 27, 2025	Jan	NEWA
>D>	AB		10MG;20MG		A209461	002	Jan 27, 2025	Jun	DISC
>A>		@	10MG;20MG		A209461	002	Jan 27, 2025	Jun	DISC
	AB		10MG;20MG		A209461	002	Jan 27, 2025	Jan	NEWA
>D>	AB		10MG;40MG		A209461	003	Jan 27, 2025	Jun	DISC
>A>		@	10MG;40MG		A209461	003	Jan 27, 2025	Jun	DISC
	AB		10MG;40MG		A209461	003	Jan 27, 2025	Jan	NEWA
>D>	AB		10MG;80MG		A209461	004	Jan 27, 2025	Jun	DISC
>A>		@	10MG;80MG		A209461	004	Jan 27, 2025	Jun	DISC
	AB		10MG;80MG		A209461	004	Jan 27, 2025	Jan	NEWA

FAMOTIDINEFOR SUSPENSION;ORAL
FAMOTIDINE

>D>	AB	AKORN	40MG/5ML		A201995	001	May 30, 2014	Jun	CAHN
	AB	APPCO	40MG/5ML		A217655	001	Jun 16, 2023	Mar	CAHN
>A>	AB	AUROBINDO PHARMA LTD	40MG/5ML		A219091	001	Jul 09, 2025	Jun	NEWA
>A>	AB	BIONPHARMA	40MG/5ML		A219153	001	Jun 23, 2025	Jun	NEWA
	AB	LANNETT CO INC	40MG/5ML		A217982	001	Jun 02, 2025	May	NEWA
>A>	AB	NOVITIUM PHARMA	40MG/5ML		A201995	001	May 30, 2014	Jun	CAHN

TABLET;ORAL
FAMOTIDINE

	@	APOTEX	20MG		A075611	001	Jul 23, 2001	Mar	DISC
	@		40MG		A075611	002	Jul 23, 2001	Mar	DISC
AB		BEXIMCO PHARMS USA	20MG		A218631	001	Mar 25, 2025	Mar	NEWA
AB			40MG		A218631	002	Mar 25, 2025	Mar	NEWA

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

>A>	AB	AUROBINDO PHARMA LTD	26.6MG;800MG	A219538	001	Jun 30, 2025	Jun NEWA
	AB	ENDO OPERATIONS	26.6MG;800MG	A203658	001	Mar 22, 2024	Feb CTNA
	@	TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024	Feb CTNA
	AB	ZYDUS PHARMS	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb NEWA

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

	AB	MSN	40MG	A210461	001	Dec 30, 2019	Jan CTEC
	AB		80MG	A210461	002	Dec 30, 2019	Jan CTEC

FELBAMATE

TABLET;ORAL

FELBAMATE

	@	ALVOGEN	400MG	A204595	001	Jan 11, 2016	May DISC
	@		600MG	A204595	002	Jan 11, 2016	May DISC

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

	AB	CHARTWELL RX	43MG	A090859	001	Mar 01, 2012	Apr CAHN
	AB		130MG	A090859	002	Mar 01, 2012	Apr CAHN

TABLET;ORAL

FENOFIBRATE

	AB	CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Mar CTEC
	AB		120MG	A217732	002	Sep 07, 2023	Mar CTEC
	@	MYLAN	54MG	A076520	001	Oct 25, 2007	Feb DISC
	@		160MG	A076520	003	Oct 25, 2007	Feb DISC
	@	SUN PHARM	48MG	A200884	001	Sep 07, 2017	Jan DISC
	@		145MG	A200884	002	Sep 07, 2017	Apr DISC

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

>D>	@ +	ATHENA	105MG	N022418	002	Aug 14, 2009	Jun CMFD
>A>	+	!	105MG	N022418	002	Aug 14, 2009	Jun CMFD

FINASTERIDE; TADALAFIL

CAPSULE;ORAL

FINASTERIDE AND TADALAFIL

NOVITIUM PHARMA

5MG;5MG

A218499 001 Mar 19, 2025 Mar NEWA

FITUSIRAN SODIUM

SOLUTION;SUBCUTANEOUS

QFITLIA

+! GENZYME CORP

EQ 20MG BASE/0.2ML (EQ 20MG
BASE/0.2ML)

N219019 001 Mar 28, 2025 Mar NEWA

+!

EQ 50MG BASE/0.5ML (EQ 50MG
BASE/0.5ML)

N219019 002 Mar 28, 2025 Mar NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

	AP	BAMF	20-400mCi/ML	A216125	001	Mar 11, 2025	Feb NEWA
	AP	SOFIE	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar CAHN

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

	AB1	ENCUBE	0.05%	A211410	001	Oct 16, 2018	Feb CMFD
--	-----	--------	-------	---------	-----	--------------	----------

GEL;TOPICAL

FLUOCINONIDE

	AB	PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Feb CMFD
--	----	------------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL

FLUOCINONIDE

	AT	QUAGEN	0.05%	A216389	001	Feb 26, 2025	Feb NEWA
	@	SAPTALIS PHARMS	0.05%	A207554	001	Mar 18, 2019	Feb CAHN

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 25%

@ + LONG GROVE PHARMS

EQ 500MG BASE/2ML (EQ 250MG
BASE/ML)

N022186 002 Aug 08, 2008 May DISC

FLUORESCEIN SODIUM

AP NEXUS

EQ 500MG BASE/5ML (EQ 100MG
BASE/ML)

A215709 001 Sep 25, 2023 Mar CAHN

!

EQ 500MG BASE/2ML (EQ 250MG
BASE/ML)

A215709 002 Sep 25, 2023 May CTEC

AP

EQ 500MG BASE/2ML (EQ 250MG
BASE/ML)

A215709 002 Sep 25, 2023 Mar CAHN

FLUORODOPA F-18

SOLUTION; INTRAVENOUS

FLUORODOPA F18

+! FEINSTEIN

1-40mCi/ML

N200655 001 Oct 10, 2019 Feb CPOT

FLUOROURACIL

CREAM; TOPICAL

FLUOROURACIL

AB ENCUBE

5%

A216942 001 Feb 12, 2025 Jan NEWA

INJECTABLE; INJECTION

FLUOROURACIL

@ ACCORD HLTHCARE

2.5GM/50ML (50MG/ML)

A040798 002 Apr 26, 2007 May DISC

AP ! ALEMBIC

2.5GM/50ML (50MG/ML)

A217295 001 Mar 03, 2023 May CHRS

AP KINDOS

5GM/100ML (50MG/ML)

A215699 001 Feb 06, 2025 Jan NEWA

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

>D> @ SCIEGEN PHARMS INC

EQ 20MG BASE/5ML

A075525 001 Jun 27, 2002 Jun CMFD

>A> AA

EQ 20MG BASE/5ML

A075525 001 Jun 27, 2002 Jun CMFD

AA SOLIS PHARMS

EQ 20MG BASE/5ML

A075292 001 Feb 07, 2002 Apr CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

@ APCCO

EQ 10MG BASE

A211696 001 Jan 30, 2019 Feb CAHN

@

EQ 20MG BASE

A211696 002 Jan 30, 2019 Feb CAHN

>A> AB

EQ 60MG BASE

A211477 001 Nov 21, 2018 Jun CAHN

>D> AB

AUROBINDO PHARMA LTD

EQ 20MG BASE

A213286 002 Apr 08, 2020 Jun CHRS

>A> AB

!

EQ 20MG BASE

A213286 002 Apr 08, 2020 Jun CHRS

AB

!

EQ 60MG BASE

A213265 001 Jun 10, 2020 Apr CHRS

@ CHARTWELL RX

EQ 10MG BASE

A211444 001 Sep 13, 2022 Mar CAHN

@

EQ 20MG BASE

A211444 002 Sep 13, 2022 Mar CAHN

>D> AB

! DR REDDYS

EQ 20MG BASE

A076006 002 Apr 23, 2018 Jun CHRS

>A> AB

EQ 20MG BASE

A076006 002 Apr 23, 2018 Jun CHRS

>D> AB

TARO

EQ 60MG BASE

A211477 001 Nov 21, 2018 Jun CAHN

@ + TWI PHARMS

EQ 60MG BASE

N202133 001 Oct 06, 2011 Apr DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

>D> AB TEVA PHARMS

EQ 50MG BASE; EQ 6MG BASE

A077528 003 Jun 19, 2012 Jun CHRS

>A> AB

!

EQ 50MG BASE; EQ 6MG BASE

A077528 003 Jun 19, 2012 Jun CHRS

SYMBYAX

@ + LILLY

EQ 25MG BASE; EQ 3MG BASE

N021520 001 Apr 09, 2007 Feb DISC

@ +

EQ 25MG BASE; EQ 6MG BASE

N021520 002 Dec 24, 2003 Feb DISC

@ +

EQ 25MG BASE; EQ 12MG BASE

N021520 004 Dec 24, 2003 Feb DISC

@ +

EQ 50MG BASE; EQ 6MG BASE

N021520 003 Dec 24, 2003 Feb DISC

@ +

EQ 50MG BASE; EQ 12MG BASE

N021520 005 Dec 24, 2003 Feb DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB ZAMEER PHARMS

1MG

A215141 001 Oct 20, 2021 Feb CAHN

AB

2.5MG

A215141 002 Oct 20, 2021 Feb CAHN

AB

5MG

A215141 003 Oct 20, 2021 Feb CAHN

AB

10MG

A215141 004 Oct 20, 2021 Feb CAHN

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

@ + INA PHARMS

0.025%

N012806 003

May CAHN

@ +

0.05%

N012806 002

May CAHN

LOTION; TOPICAL

CORDRAN

@ + INA PHARMS

0.05%

N013790 001

May CAHN

OINTMENT; TOPICAL

CORDRAN

@ + INA PHARMS

0.025%

N012806 004

May CAHN

@ +

0.05%

N012806 001

May CAHN

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

@ CHARTWELL RX

0.005%

A076300 001 May 14, 2004

Mar CAHN

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

AB RUBICON RESEARCH

0.05MG/SPRAY

A218321 001 Jun 05, 2025

May NEWA

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA AIPING PHARM INC

1MG

A091145 001 Jul 12, 2013

Mar CAHN

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

AN DEVA HOLDING AS

0.02MG/2ML

A218308 001 Feb 11, 2025

Jan NEWA

AN DR REDDYS

0.02MG/2ML

A215907 001 Jan 30, 2025

Jan NEWA

PERFORMIST

AN +! VIATRIS SPECIALTY

0.02MG/2ML

N022007 001 May 11, 2007

Feb CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

@ PIRAMAL CRITICAL

EQ 150MG BASE/VIAL

A214683 001 May 16, 2023

Apr DISC

@ PRAXGEN

EQ 150MG BASE/VIAL

A213199 001 Oct 04, 2021

Jan CAHN

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSFOMYCIN TROMETHAMINE

AA PRECISION DOSE INC

EQ 3GM BASE/PACKET

A217187 001 Jun 03, 2025

May NEWA

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ APOTEX

10MG

A076906 001 May 17, 2005

Mar DISC

@

20MG

A076906 002 May 17, 2005

Mar DISC

@

40MG

A076906 003 May 17, 2005

Mar DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB LEADING

EQ 2.5MG BASE

A216998 001 Apr 16, 2025

Apr NEWA

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

>D> AB HIKMA

20MG

N018823 001 Nov 10, 1983

Jun CAHN

>A> AB

20MG

N018823 001 Nov 10, 1983

Jun CAHN

>D> AB

40MG

N018823 002 Nov 10, 1983

Jun CAHN

>A> AB

40MG

N018823 002 Nov 10, 1983

Jun CAHN

@ NORVIUM BIOSCIENCE

80MG

A070082 001 Oct 29, 1986

Feb CAHN

GABAPENTINSOLUTION; ORAL
GABAPENTIN

AA	AJENAT PHARMS	250MG/5ML	A 091286	001	Mar 14, 2016	Jan	CAHN
AA	PAI HOLDINGS PHARM	250MG/5ML	A 211330	001	Dec 03, 2019	Apr	CMFD

TABLET; ORAL

GABAPENTIN

@	APOTEX	100MG	A 077894	001	Oct 10, 2006	Mar	DISC
@		300MG	A 077894	002	Oct 10, 2006	Mar	DISC
@		400MG	A 077894	003	Oct 10, 2006	Mar	DISC
	IVAX SUB TEVA PHARMS	300MG	A 076017	002	Apr 28, 2004	Mar	CTEC

GADOBUTROL

SOLUTION; INTRAVENOUS

GADOBUTROL

AP	HAINAN POLY PHARM	1.20944GM/2ML (604.72MG/ML)	A 217480	003	Apr 16, 2025	Apr	NEWA
AP		6.0472GM/10ML (604.72MG/ML)	A 217480	004	Apr 16, 2025	Apr	NEWA
AP		18.1416GM/30ML (604.72MG/ML)	A 217480	005	Apr 16, 2025	Apr	NEWA
AP		39.3068GM/65ML (604.72MG/ML)	A 217480	006	Apr 16, 2025	Apr	NEWA

GADOTERIDOL

INJECTABLE; INJECTION

GADOTERIDOL

AP	HAINAN POLY	279.3MG/ML	A 218749	001	Feb 11, 2025	Jan	NFTG
AP	PROHANCE						
AP	+! BRACCO	279.3MG/ML	N 020131	001	Nov 16, 1992	Jan	CFTG

GALLIUM GA-68 GOZETOTIDE

POWDER; INTRAVENOUS

GOZELLIX

+!	TELIX INNOVATIONS	N/A	N 219592	001	Mar 20, 2025	Mar	NEWA
----	-------------------	-----	----------	-----	--------------	-----	------

GANCICLOVIR

SOLUTION; INTRAVENOUS

GANZYK-RTU

@ +	EXELA PHARMA	500MG/250ML (2MG/ML)	N 209347	001	Feb 17, 2017	Apr	DISC
-----	--------------	----------------------	----------	-----	--------------	-----	------

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

AP	QILU	250MCG/0.5ML	A 218855	001	Apr 23, 2025	Apr	NEWA
>A>	TRIS PHARMA INC	250MCG/0.5ML	A 219454	001	Jun 27, 2025	Jun	NEWA

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

@	CAPLIN	0.5%	A 213542	001	Nov 03, 2021	May	CAHN
---	--------	------	----------	-----	--------------	-----	------

GEFITINIB

TABLET; ORAL

GEFITINIB

AB	CIPLA	250MG	A 211826	001	May 16, 2025	May	NEWA
----	-------	-------	----------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

@	HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A 206617	001	Jun 25, 2021	May	DISC
@		EQ 1GM BASE/VIAL	A 206617	002	Jun 25, 2021	May	DISC

SOLUTION; INTRAVENOUS

AVGEMSI

>A>	+!	AVYXA HOLDINGS	EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N 219920	001	Jun 27, 2025	Jun	NEWA
>A>	+!		EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML)	N 219920	002	Jun 27, 2025	Jun	NEWA
>A>	+!		EQ 2GM BASE/52.6ML (EQ 38MG BASE/ML)	N 219920	003	Jun 27, 2025	Jun	NEWA

<u>GEMFIBROZIL</u>								
TABLET; ORAL								
GEMFIBROZIL								
	@	APOTEX	600MG	A075034	001	Jul 20, 1998	Mar	DISC
<u>GEPOTIDACIN MESYLATE</u>								
TABLET; ORAL								
BLUJEPA								
	+	GLAXOSMITHKLINE	EQ 750MG BASE	N218230	001	Mar 25, 2025	Mar	NEWA
<u>GLATIRAMER ACETATE</u>								
INJECTABLE; SUBCUTANEOUS								
GLATIRAMER ACETATE								
AP		CHEMI SPA	20MG/ML	A208468	001	May 07, 2025	Apr	NEWA
AP			40MG/ML	A208468	002	May 07, 2025	Apr	NEWA
<u>GLIMEPIRIDE</u>								
TABLET; ORAL								
AMARYL								
	@ +	SANOFI AVENTIS US	1MG	N020496	001	Nov 30, 1995	Feb	DISC
	@ +		2MG	N020496	002	Nov 30, 1995	Feb	DISC
	@ +		4MG	N020496	003	Nov 30, 1995	Feb	DISC
GLIMEPIRIDE								
AB	!	DR REDDYS LABS LTD	1MG	A077091	001	Oct 06, 2005	Feb	CHRS
<u>GLIPIZIDE</u>								
TABLET; ORAL								
GLIPIZIDE								
	@	AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995	Jan	CAHN
	@		10MG	A074305	002	Apr 07, 1995	Jan	CAHN
AB		OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994	Apr	CMFD
AB			10MG	A074378	002	Nov 28, 1994	Apr	CMFD
TABLET, EXTENDED RELEASE; ORAL								
GLUCOTROL XL								
	@ +	PFIZER	2.5MG	N020329	003	Aug 10, 1999	Apr	DISC
AB	+		5MG	N020329	001	Apr 26, 1994	Apr	CMFD
AB	+		10MG	N020329	002	Apr 26, 1994	Apr	CHRS
<u>GLUCAGON</u>								
SOLUTION; INTRAVENOUS								
GVOKE VIALDX								
	+	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	Mar	NEWA
<u>GLYCOPYRROLATE</u>								
INJECTABLE; INJECTION								
GLYCOPYRROLATE								
	@	XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Jan	DISC
POWDER; INHALATION								
SEEBRI NEOHALER								
	@ +	NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015	May	CTNA
SOLUTION; ORAL								
GLYCOPYRROLATE								
AA		MSN	1MG/5ML	A216084	001	Apr 08, 2025	Mar	NEWA
TABLET; ORAL								
GLYCOPYRROLATE								
AA		CHARTWELL RX	1MG	A040847	001	Mar 21, 2008	Feb	CAHN
AA			2MG	A040847	002	Mar 21, 2008	Feb	CAHN
<u>GLYCOPYRROLATE; INDACATEROL MALEATE</u>								
POWDER; INHALATION								
UTIBRON NEOHALER								
	@ +	NOVARTIS	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	May	CTNA
<u>GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>								
SOLUTION/DROPS; OPHTHALMIC								
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN								
AT		SAPTALIS PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Feb	CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION;ORAL

GRANISETRON HYDROCHLORIDE

INTRA SANA LABS

EQ 2MG BASE/10ML

A219282 001 Mar 17, 2025 Mar NEWA

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

@ APOTEX INC

EQ 1MG BASE

A078843 001 Feb 27, 2008 Mar DISC

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

BX RUBICON

EQ 1MG BASE

A216762 001 Oct 17, 2023 Mar CTEC

BX

EQ 2MG BASE

A216762 002 Oct 17, 2023 Mar CTEC

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB FOSUN WANBANG

EQ 1MG BASE

A217638 001 Jun 12, 2024 Mar CMFD

@

EQ 1MG BASE

A217638 001 Jun 12, 2024 Jan CAHN

AB

EQ 2MG BASE

A217638 002 Jun 12, 2024 Mar CMFD

@

EQ 2MG BASE

A217638 002 Jun 12, 2024 Jan CAHN

AB

EQ 3MG BASE

A217638 003 Jun 12, 2024 Mar CMFD

@

EQ 3MG BASE

A217638 003 Jun 12, 2024 Jan CAHN

AB

EQ 4MG BASE

A217638 004 Jun 12, 2024 Mar CMFD

@

EQ 4MG BASE

A217638 004 Jun 12, 2024 Jan CAHN

AB

RUBICON

EQ 1MG BASE

A219689 001 Apr 15, 2025 Apr NEWA

AB

EQ 2MG BASE

A219689 002 Apr 15, 2025 Apr NEWA

AB

EQ 3MG BASE

A219689 003 Apr 15, 2025 Apr NEWA

AB

EQ 4MG BASE

A219689 004 Apr 15, 2025 Apr NEWA

HALCINONIDE

SOLUTION;TOPICAL

HALCINONIDE

! ENCUBE

0.1%

A217671 001 May 29, 2024 Mar CMFD

@

0.1%

A217671 001 May 29, 2024 Jan DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL

ULTRAVATE

+! LACER PHARMA

0.05%

N208183 001 Nov 06, 2015 Apr CMFD

@ +

0.05%

N208183 001 Nov 06, 2015 Jan CAHN

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL

DUOBRII

AB +! BAUSCH

0.01%;0.045%

N209354 001 Apr 25, 2019 Apr CFTG

HALOBETASOL PROPIONATE AND TAZAROTENE

AB

TARO

0.01%;0.045%

A217190 001 May 02, 2025 Apr NFTG

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB APPCO

0.5MG

A211061 001 Jan 08, 2020 Feb CAHN

AB

1MG

A211061 002 Jan 08, 2020 Feb CAHN

AB

2MG

A211061 003 Jan 08, 2020 Feb CAHN

AB

5MG

A211061 004 Jan 08, 2020 Feb CAHN

AB

10MG

A211061 005 Jan 08, 2020 Feb CAHN

AB

20MG

A211061 006 Jan 08, 2020 Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO CAPLIN

EQ 50MG BASE/ML

A219168 001 May 13, 2025 May NEWA

AO

EQ 100MG BASE/ML

A219168 002 May 13, 2025 May NEWA

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

@ FRESENIUS KABI USA

EQ 5MG BASE/ML

A210356 001 Jul 01, 2019 Feb DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	@	B BRAUN MEDICAL	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Jan	DISC
		HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jan	CTEC
AP		NORVIUM BIOSCIENCE	1,000 UNITS/ML	A203851	001	Nov 30, 2017	May	CAHN
AP			5,000 UNITS/ML	A203851	002	Nov 30, 2017	May	CAHN
AP			10,000 UNITS/ML	A203851	003	Nov 30, 2017	May	CAHN
AP			20,000 UNITS/ML	A203852	001	Nov 30, 2017	May	CAHN
AP		PLANO PHARMS	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar	CAHN
AP			5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar	CAHN
AP			10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar	CAHN
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
	+	B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025	Mar	NEWA
	+		10,000 UNITS/100ML	N019953	004	Mar 25, 2025	Mar	NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

	@	APOZEAL PHARMS	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Apr	CAHN
	@	SANKALP LIFECARE	1.5MG/5ML; 5MG/5ML	A210663	001	Jun 11, 2019	Apr	CAHN
AA		XTTRIUM LABS INC	1.5MG/5ML; 5MG/5ML	A088008	001	Mar 03, 1983	Feb	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

>D>	AP	ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Jun	DISC
>A>	@		20MG/ML	A203110	001	Jun 29, 2015	Jun	DISC
AP		KINDOS	20MG/ML	A217501	001	Jun 02, 2025	May	NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>D>	AA	MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024	Jun	DISC
>A>	@		10MG	A211010	001	Aug 21, 2024	Jun	DISC
>D>	AA		25MG	A211010	002	Aug 21, 2024	Jun	DISC
>A>	@		25MG	A211010	002	Aug 21, 2024	Jun	DISC
>D>	AA		50MG	A211010	003	Aug 21, 2024	Jun	DISC
>A>	@		50MG	A211010	003	Aug 21, 2024	Jun	DISC
>D>	AA		100MG	A211010	004	Aug 21, 2024	Jun	DISC
>A>	@		100MG	A211010	004	Aug 21, 2024	Jun	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

MICROZIDE

AB	+	TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Apr	CAHN
----	---	--------------------	--------	---------	-----	--------------	-----	------

FOR SUSPENSION; ORAL

INZIRQO

	+	NOVITIUM PHARMA	10MG/ML	N219141	001	Jan 28, 2025	Jan	NEWA
--	---	-----------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB		UNICHEM	12.5MG	A040907	003	Apr 03, 2025	Mar	NEWA
----	--	---------	--------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB		SENORES PHARMS	25MG; 50MG	A215789	001	Jan 08, 2025	Jan	NEWA
AB			25MG; 100MG	A215789	002	Jan 08, 2025	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	APOTEX	12.5MG; EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan	DISC
	@		12.5MG; EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan	DISC
	@		25MG; EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan	DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		MANKIND PHARMA	12.5MG; 40MG	A218406	001	Mar 03, 2025	Feb	NEWA
AB			12.5MG; 80MG	A218406	002	Mar 03, 2025	Feb	NEWA
AB			25MG; 80MG	A218406	003	Mar 03, 2025	Feb	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>D>	AB	MACLEODS PHARMS LTD	25MG;37.5MG	A214611	001	Jan 28, 2025	Jun	DISC
>A>	@		25MG;37.5MG	A214611	001	Jan 28, 2025	Jun	DISC
	AB		25MG;37.5MG	A214611	001	Jan 28, 2025	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE

@ STRIDES PHARMA 5MG;200MG

A077723 003 Nov 06, 2006 Apr CAHN

HYDROCODONE BITARTRATE AND IBUPROFEN

@ STRIDES PHARMA 7.5MG;200MG

A077723 001 Nov 06, 2006 Apr CAHN

@ 10MG;200MG

A077723 002 Nov 06, 2006 Apr CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ APOZEAL PHARMS 5MG/5ML;60MG/5ML

A206661 001 Jan 23, 2019 Apr CAHN

HYDROCORTISONE

LOTION; TOPICAL

ALA-SCALP

+ LEGACY PHARMA 2%

A083231 001 Mar CRLD

SOLUTION; ORAL

KHINDIVI

+! ETON 1MG/ML

N218980 001 May 28, 2025 May NEWA

TABLET; ORAL

HYDROCORTISONE

AB NOVITIUM PHARMA 5MG

A217881 001 May 02, 2025 Apr NEWA

AB 10MG

A217881 002 May 02, 2025 Apr NEWA

AB 20MG

A217881 003 May 02, 2025 Apr NEWA

HYDROCORTISONE ACETATEAEROSOL, METERED; RECTAL
CORTIFOAM

+! VIATRIS 10%

N017351 001 Feb 10, 1982 Feb CAHN

CREAM; TOPICAL

MICORT-HC

@ LEGACY PHARMA 2%

A040398 001 Mar 29, 2002 Jan CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@ SAPTALIS PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A065216 001 Oct 31, 2005 Feb CAHN

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT SAPTALIS PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A065219 001 May 01, 2006 Feb CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

>A> @ MPP PHARMA 8MG

A076723 001 Oct 18, 2005 Jun CAHN

>D> @ NOSTRUM LABS INC 8MG

A076723 001 Oct 18, 2005 Jun CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA BIONPHARMA 10MG/5ML

A219289 001 Apr 28, 2025 Apr NEWA

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ APPCO 10MG

A040812 001 Mar 12, 2008 Apr CAHN

@ 25MG

A040812 002 Mar 12, 2008 Apr CAHN

@ 50MG

A040812 003 Mar 12, 2008 Apr CAHN

AB ! GRAVITI PHARMS 50MG

A217652 003 Aug 17, 2023 Mar CHRS

AB + PLIVA 50MG

A088619 001 Jan 10, 1986 Mar CHRS

@ + STRIDES PHARMA 50MG

A087604 001 Jan 22, 1982 Mar CRLD

HYDROXYZINE PAMOATE

	CAPSULE;ORAL						
	HYDROXYZINE PAMOATE						
AB	BARR LABS	EQ 50MG HYDROCHLORIDE	A 088487	001	Jun 15, 1984	Mar	CAHN
		EQ 100MG HYDROCHLORIDE	A 088488	001	Jun 15, 1984	Mar	CAHN

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS
ICATIBANT ACETATE

@	CAPLIN	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A 213054	001	Oct 05, 2020	Apr	CAHN
---	--------	---------------------------------------	----------	-----	--------------	-----	------

ICODEXTRIN

SOLUTION;INTRAPERITONEAL
EXTRANEAAL

+	VANTIVE US HLTHCARE	7.5GM/100ML	N 021321	001	Dec 20, 2002	Feb	CAHN
---	---------------------	-------------	----------	-----	--------------	-----	------

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	CSPC OUYI	EQ 100MG BASE	A 212193	001	Apr 21, 2025	Apr	NEWA
AB		EQ 400MG BASE	A 212193	002	Apr 21, 2025	Apr	NEWA
AB	HETERO LABS LTD V	EQ 100MG BASE	A 212975	001	Apr 14, 2025	Apr	NEWA
AB		EQ 400MG BASE	A 212975	002	Apr 14, 2025	Apr	NEWA

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

@	APOTEX INC	5%	A 091308	001	Apr 06, 2012	Mar	DISC
---	------------	----	----------	-----	--------------	-----	------

INDOCYANINE GREEN

INJECTABLE;INJECTION
IC-GREEN

AP	+ RENEW PHARMS	25MG/VIAL	N 011525	001		May	CMFD
AP	! RENEW PHARMS	25MG/VIAL	A 040811	001	Nov 21, 2007	May	CTEC

INDOMETHACIN

SUPPOSITORY;RECTAL

INDOMETHACIN

AB	AMNEAL	50MG	A 215399	001	Feb 24, 2025	Feb	NEWA
>A>	ANNORA PHARMA	50MG	A 216905	001	Jul 03, 2025	Jun	NEWA

IOBENGUANE SULFATE I-123

SOLUTION;INTRAVENOUS
ADREVIEW

>D>	AP	+! GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N 022290	001	Sep 19, 2008	Jun	CTEC
>A>		+!	10mCi/5ML (2mCi/ML)	N 022290	001	Sep 19, 2008	Jun	CTEC
>D>	AP	BWXT MEDCL	10mCi/5ML (2mCi/ML)	A 213637	001	Dec 09, 2024	Jun	DISC
>A>		@	10mCi/5ML (2mCi/ML)	A 213637	001	Dec 09, 2024	Jun	DISC

IOMEPROL

SOLUTION;INTRA-ARTERIAL

IOMERVU

@	+	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N 216016	002	Nov 27, 2024	Mar	DISC
@	+		17.5GM IODINE/50ML (350MG IODINE/ML)	N 216016	006	Nov 27, 2024	Mar	DISC
@	+		20GM IODINE/50ML (400MG IODINE/ML)	N 216016	010	Nov 27, 2024	Mar	DISC
@	+		25GM IODINE/100ML (250MG IODINE/ML)	N 216016	001	Nov 27, 2024	Mar	DISC
@	+		30GM IODINE/100ML (300MG IODINE/ML)	N 216016	003	Nov 27, 2024	Mar	DISC
@	+		35GM IODINE/100ML (350MG IODINE/ML)	N 216016	007	Nov 27, 2024	Mar	DISC
@	+		40GM IODINE/100ML (400MG IODINE/ML)	N 216016	011	Nov 27, 2024	Mar	DISC
@	+		60GM IODINE/150ML (400MG IODINE/ML)	N 216016	012	Nov 27, 2024	Mar	DISC
@	+		45GM IODINE/150ML (300MG IODINE/ML)	N 216016	004	Nov 27, 2024	Mar	DISC

SOLUTION; INTRA-ARTERIAL

IOMERVU

@ +		52.5GM IODINE/150ML (350MG IODINE/ML)	N216016	008	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216016	005	Nov 27, 2024	Mar	DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Mar	DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Mar	DISC

SOLUTION; INTRAVENOUS

IOMERVU

@ +	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216017	002	Nov 27, 2024	Mar	DISC
@ +		17.5GM IODINE/50ML (350MG IODINE/ML)	N216017	006	Nov 27, 2024	Mar	DISC
@ +		20GM IODINE/50ML (400MG IODINE/ML)	N216017	010	Nov 27, 2024	Mar	DISC
@ +		25GM IODINE/100ML (250MG IODINE/ML)	N216017	001	Nov 27, 2024	Mar	DISC
@ +		30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024	Mar	DISC
@ +		35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Mar	DISC
@ +		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Mar	DISC
@ +		45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Mar	DISC
@ +		52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Mar	DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Mar	DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Mar	DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D>	@	NORVIUM BIOSCIENCE	0.02%	A074755	001	Jan 10, 1997	Jun	CAHN
>A>	@	PHARMOBEDIENT	0.02%	A074755	001	Jan 10, 1997	Jun	CAHN

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

AB		LUPIN	0.021MG/SPRAY	A217912	001	Feb 07, 2025	Jan	NEWA
AB			0.042MG/SPRAY	A217886	001	Jan 27, 2025	Jan	NEWA
AB		RUBICON	0.021MG/SPRAY	A219222	001	Jan 14, 2025	Jan	NEWA

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

>A>	+!	LIFSA DRUGS	10MG	N011961	001		Jun	CAHN
>D>	+!	VALIDUS PHARMS INC	10MG	N011961	001		Jun	CAHN

ISONIAZID

SYRUP; ORAL

ISONIAZID

AA		CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Feb	CMFD
AA	+!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Feb	CTEC

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS

ISOSULFAN BLUE

>D>	@	BELOTECA	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	Jun	CAHN
>A>	@	SABA ILAY SANAYI	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	Jun	CAHN

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

AB1		MYLAN PHARMS INC	30MG	A075945	004	Mar 17, 2025	Mar	NEWA
		ISOTRETINOIN						
AB2		ZYDUS PHARMS	10MG	A216633	001	May 22, 2025	May	NEWA
AB2			20MG	A216633	002	May 22, 2025	May	NEWA
AB2			25MG	A216633	003	May 22, 2025	May	NEWA

	CAPSULE;ORAL						
	ISOTRETINOIN						
AB2		30MG	A216633	004	May 22, 2025	May	NEWA
AB2		35MG	A216633	005	May 22, 2025	May	NEWA
AB2		40MG	A216633	006	May 22, 2025	May	NEWA
	<u>ITRACONAZOLE</u>						
	CAPSULE;ORAL						
	ITRACONAZOLE						
AB	RISING	100MG	A205724	001	Dec 13, 2016	Feb	CMFD
	<u>IVABRADINE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	IVABRADINE HYDROCHLORIDE						
AB	MSN	EQ 5MG BASE	A213483	001	Apr 28, 2025	Apr	NEWA
AB		EQ 7.5MG BASE	A213483	002	Apr 28, 2025	Apr	NEWA
	<u>IVERMECTIN</u>						
	TABLET;ORAL						
	IVERMECTIN						
AB	RUBICON	3MG	A215922	001	Jan 22, 2025	Jan	NEWA
		6MG	A215922	002	Jan 22, 2025	Jan	NFTG
	<u>KETAMINE HYDROCHLORIDE</u>						
	INJECTABLE;INJECTION						
	KETAMINE HYDROCHLORIDE						
AP	FRESENIUS KABI USA	EQ 100MG BASE/ML	A215808	003	Apr 18, 2025	Apr	NEWA
	<u>KETOCONAZOLE</u>						
	GEL;TOPICAL						
	XOLEGEL						
	@ + INA PHARMS	2%	N021946	001	Jul 28, 2006	May	CAHN
	SHAMPOO;TOPICAL						
	KETOCONAZOLE						
AB	ZYDUS LIFESCIENCES	2%	A218559	001	Mar 07, 2025	Feb	NEWA
	TABLET;ORAL						
	KETOCONAZOLE						
>A>	AB	ESJAY PHARMA	A219129	001	Jul 03, 2025	Jun	NEWA
	<u>LACOSAMIDE</u>						
	SOLUTION;INTRAVENOUS						
	LACOSAMIDE						
AP	WESTMINSTER PHARMS	200MG/20ML (10MG/ML)	A218706	001	May 23, 2025	May	NEWA
	SOLUTION;ORAL						
	LACOSAMIDE						
>A>	AA	AJENAT PHARMS	A219699	001	Jun 26, 2025	Jun	NEWA
	AA	APOTEX	A206355	001	Sep 26, 2022	May	CMFD
	@	10MG/ML	A206355	001	Sep 26, 2022	Feb	DISC
	<u>LACTULOSE</u>						
	FOR SOLUTION;ORAL						
	LACTULOSE						
AA	!	CUMBERLAND PHARMS	A074712	001	Dec 10, 1997	Mar	CTEC
AA	!		A074712	002	Dec 10, 1997	Mar	CTEC
AA		PAI HOLDINGS	A217914	001	Mar 14, 2025	Mar	NEWA
AA			A217914	002	Mar 14, 2025	Mar	NEWA
	SOLUTION;ORAL						
	LACTULOSE						
	@	VISTAPHARM LLC	A074138	001	Sep 30, 1992	Jan	CAHN
	<u>LAMIVUDINE</u>						
	TABLET;ORAL						
	LAMIVUDINE						
AB	APPCO	150MG	A206974	001	Nov 21, 2016	Mar	CAHN
AB		300MG	A206974	002	Nov 21, 2016	Mar	CAHN
	@	NORVIUM BIOSCIENCE	A078545	001	Mar 05, 2019	Feb	CAHN
	@		A078545	002	Mar 05, 2019	Feb	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	NORVIUM BIOSCIENCE	150MG;300MG	A079128	001	May 13, 2015	May	CAHN
----	--------------------	-------------	---------	-----	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ AIPING PHARM INC

25MG

A078645 001 Jan 27, 2009 Jan CAHN

@

100MG

A078645 002 Jan 27, 2009 Jan CAHN

@

150MG

A078645 003 Jan 27, 2009 Jan CAHN

@

200MG

A078645 004 Jan 27, 2009 Jan CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

>D>	AB	MACLEODS PHARMS LTD	15MG	A208671	001	Nov 04, 2024	Jun	DISC
-----	----	---------------------	------	---------	-----	--------------	-----	------

>A>		@	15MG	A208671	001	Nov 04, 2024	Jun	DISC
-----	--	---	------	---------	-----	--------------	-----	------

>D>	AB		30MG	A208671	002	Nov 04, 2024	Jun	DISC
-----	----	--	------	---------	-----	--------------	-----	------

>A>		@	30MG	A208671	002	Nov 04, 2024	Jun	DISC
-----	--	---	------	---------	-----	--------------	-----	------

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

LANTHANUM CARBONATE

AB	ALKEM LABS LTD	EQ 500MG BASE	A202329	001	Mar 13, 2025	Mar	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

AB		EQ 750MG BASE	A202329	002	Mar 13, 2025	Mar	NEWA
----	--	---------------	---------	-----	--------------	-----	------

AB		EQ 1GM BASE	A202329	003	Mar 13, 2025	Mar	NEWA
----	--	-------------	---------	-----	--------------	-----	------

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

@ CARNEGIE

0.005%

A202077 001 Feb 11, 2013 Apr CAHN

AT	MICRO LABS	0.005%	A219306	001	Apr 14, 2025	Apr	NEWA
----	------------	--------	---------	-----	--------------	-----	------

LATANOPROSTENE BUNOD

SOLUTION/DROPS; OPHTHALMIC

LATANOPROSTENE BUNOD

AB	GLAND	0.024%	A217387	001	Apr 29, 2025	Apr	NFTG
----	-------	--------	---------	-----	--------------	-----	------

AB	VYZULTA						
----	---------	--	--	--	--	--	--

AB	+! BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017	Apr	CFTG
----	--------------------	--------	---------	-----	--------------	-----	------

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

AB	FOSUN WANBANG	10MG	A077087	001	Sep 13, 2005	Jan	CAHN
----	---------------	------	---------	-----	--------------	-----	------

AB		20MG	A077087	002	Sep 13, 2005	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

LENACAPAVIR SODIUM

SOLUTION; SUBCUTANEOUS

YEZTUGO

>A>		+! GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N220018	001	Jun 18, 2025	Jun	NEWA
-----	--	------------------------	--	---------	-----	--------------	-----	------

TABLET; ORAL

YEZTUGO

>A>		+! GILEAD SCIENCES INC	EQ 300MG BASE	N220020	001	Jun 18, 2025	Jun	NEWA
-----	--	------------------------	---------------	---------	-----	--------------	-----	------

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

>D>	AB	AMNEAL	2.5MG	A216213	001	Jan 31, 2025	Jun	DISC
-----	----	--------	-------	---------	-----	--------------	-----	------

>A>		@	2.5MG	A216213	001	Jan 31, 2025	Jun	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

	AB		2.5MG	A216213	001	Jan 31, 2025	Jan	NEWA
--	----	--	-------	---------	-----	--------------	-----	------

>D>	AB		5MG	A216213	002	Jan 31, 2025	Jun	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>		@	5MG	A216213	002	Jan 31, 2025	Jun	DISC
-----	--	---	-----	---------	-----	--------------	-----	------

	AB		5MG	A216213	002	Jan 31, 2025	Jan	NEWA
--	----	--	-----	---------	-----	--------------	-----	------

>D>	AB		10MG	A216213	003	Jan 31, 2025	Jun	DISC
-----	----	--	------	---------	-----	--------------	-----	------

>A>		@	10MG	A216213	003	Jan 31, 2025	Jun	DISC
-----	--	---	------	---------	-----	--------------	-----	------

	AB		10MG	A216213	003	Jan 31, 2025	Jan	NEWA
--	----	--	------	---------	-----	--------------	-----	------

>D>	AB		15MG	A216213	004	Jan 31, 2025	Jun	DISC
-----	----	--	------	---------	-----	--------------	-----	------

>A>		@	15MG	A216213	004	Jan 31, 2025	Jun	DISC
-----	--	---	------	---------	-----	--------------	-----	------

	AB		15MG	A216213	004	Jan 31, 2025	Jan	NEWA
--	----	--	------	---------	-----	--------------	-----	------

CAPSULE;ORAL

LENALIDOMIDE

>D>	AB		20MG	A216213	005	Jan 31, 2025	Jun DISC
>A>	@		20MG	A216213	005	Jan 31, 2025	Jun DISC
	AB		20MG	A216213	005	Jan 31, 2025	Jan NEWA
>D>	AB		25MG	A216213	006	Jan 31, 2025	Jun DISC
>A>	@		25MG	A216213	006	Jan 31, 2025	Jun DISC
	AB		25MG	A216213	006	Jan 31, 2025	Jan NEWA
	AB	BIOCON PHARMA	2.5MG	A215759	001	Mar 03, 2025	Feb NEWA
	AB		5MG	A215759	002	Mar 03, 2025	Feb NEWA
	AB		10MG	A215759	003	Mar 03, 2025	Feb NEWA
	AB		15MG	A215759	004	Mar 03, 2025	Feb NEWA
	AB		20MG	A215759	005	Mar 03, 2025	Feb NEWA
	AB		25MG	A215759	006	Mar 03, 2025	Feb NEWA
	AB	DEVA HOLDING AS	2.5MG	A217554	001	May 22, 2025	May NEWA
	AB		5MG	A217554	002	May 22, 2025	May NEWA
	AB		10MG	A217554	003	May 22, 2025	May NEWA
	AB		15MG	A217554	004	May 22, 2025	May NEWA
	AB		20MG	A217554	005	May 22, 2025	May NEWA
	AB		25MG	A217554	006	May 22, 2025	May NEWA

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS

LEUPROLIDE ACETATE

AP		ENDO OPERATIONS	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	May NEWA
----	--	-----------------	------------------------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

	@	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Apr DISC
	@		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Apr DISC
	@		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Apr DISC

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

AP		CAPLIN	500MG/100ML (5MG/ML)	A219562	001	Jan 16, 2025	Jan NEWA
AP			1GM/100ML (10MG/ML)	A219562	002	Jan 16, 2025	Jan NEWA
AP			1.5GM/100ML (15MG/ML)	A219562	003	Jan 16, 2025	Jan NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA		AJENAT PHARMS	100MG/ML	A090461	001	Sep 30, 2010	Jan CAHN
AA		BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	May CMFD

TABLET;ORAL

LEVETIRACETAM

	@	CHINA RESOURCES	500MG	A205102	004	Dec 16, 2015	Jan CAHN
	@		1GM	A205102	003	Dec 16, 2015	Jan CAHN
>A>	@	MPP PHARMA	250MG	A090511	001	Aug 18, 2011	Jun CAHN
>A>	@		500MG	A090511	002	Aug 18, 2011	Jun CAHN
>A>	@		750MG	A090511	003	Aug 18, 2011	Jun CAHN
>A>	@		1GM	A090511	004	Aug 18, 2011	Jun CAHN
>D>	@	NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Jun CAHN
>D>	@		500MG	A090511	002	Aug 18, 2011	Jun CAHN
>D>	@		750MG	A090511	003	Aug 18, 2011	Jun CAHN
>D>	@		1GM	A090511	004	Aug 18, 2011	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

	@	APOTEX	1GM	A202958	001	Feb 25, 2015	Mar DISC
--	---	--------	-----	---------	-----	--------------	----------

TABLET, FOR SUSPENSION;ORAL

SPRITAM

	+!	APRECIA PHARMS	500MG	N207958	002	Jul 31, 2015	Apr CHRS
	@ +		750MG	N207958	003	Jul 31, 2015	Apr DISC
	@ +		1GM	N207958	004	Jul 31, 2015	Apr DISC

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

>A>	AP	DEVA HOLDING AS	200MG/ML	A217430	001	Jun 30, 2025	Jun NEWA
-----	----	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	SYNTHON BV	5MG	A090229	001	Nov 26, 2010	Feb	CAHN
----	------------	-----	---------	-----	--------------	-----	------

LEVODOPA

POWDER; INHALATION

INBRIJA

+! MERZ

42MG

N209184	001	Dec 21, 2018	Feb	CAHN
---------	-----	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

@ APOTEX INC

250MG

A090787	001	Sep 29, 2011	Mar	DISC
---------	-----	--------------	-----	------

@

500MG

A090787	002	Sep 29, 2011	Mar	DISC
---------	-----	--------------	-----	------

@

750MG

A090787	003	Sep 29, 2011	Mar	DISC
---------	-----	--------------	-----	------

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

AB	ACERTIS PHARMS	2MG	A211484	001	Dec 13, 2018	Apr	CAHN
BX	NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Mar	CTEC
BX		2MG	A213479	001	Jul 01, 2020	Mar	CTEC
BX		3MG	A213479	002	Jan 12, 2021	Mar	CTEC
AB		3MG	A213479	002	Jan 12, 2021	Mar	CHRS
	! SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Mar	CTEC
AB	!	3MG	A213906	002	Apr 25, 2023	Mar	CHRS

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

LEVOTHYROXINE SODIUM

>A>	@ ANI PHARMS	0.075MG	A211369	001	Oct 28, 2020	Jun	CAHN
>A>	@	0.088MG	A213256	001	Jan 06, 2021	Jun	CAHN
>A>	@	0.1MG	A213256	002	Jan 06, 2021	Jun	CAHN
>A>	@	0.112MG	A211369	003	Apr 16, 2021	Jun	CAHN
>A>	@	0.125MG	A213256	003	Jan 06, 2021	Jun	CAHN
>A>	@	0.137MG	A211369	005	May 02, 2023	Jun	CAHN
>A>	@	0.15MG	A211369	002	Oct 28, 2020	Jun	CAHN
>A>	@	0.175MG	A211369	006	May 02, 2023	Jun	CAHN
>A>	@	0.2MG	A211369	004	Nov 09, 2022	Jun	CAHN
>D>	@ TEVA PHARMS USA INC	0.075MG	A211369	001	Oct 28, 2020	Jun	CAHN
>D>	@	0.088MG	A213256	001	Jan 06, 2021	Jun	CAHN
>D>	@	0.1MG	A213256	002	Jan 06, 2021	Jun	CAHN
>D>	@	0.112MG	A211369	003	Apr 16, 2021	Jun	CAHN
>D>	@	0.125MG	A213256	003	Jan 06, 2021	Jun	CAHN
>D>	@	0.137MG	A211369	005	May 02, 2023	Jun	CAHN
>D>	@	0.15MG	A211369	002	Oct 28, 2020	Jun	CAHN
>D>	@	0.175MG	A211369	006	May 02, 2023	Jun	CAHN
>D>	@	0.2MG	A211369	004	Nov 09, 2022	Jun	CAHN

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	ONESOURCE SPECIALTY	100MCG/VIAL	A216729	001	Mar 05, 2025	May	CAHN
AP		200MCG/VIAL	A216729	002	Mar 05, 2025	May	CAHN
AP		500MCG/VIAL	A216729	003	Mar 05, 2025	May	CAHN
AP	STERISCIENCE	100MCG/VIAL	A216729	001	Mar 05, 2025	Feb	NEWA
AP		200MCG/VIAL	A216729	002	Mar 05, 2025	Feb	NEWA
AP		500MCG/VIAL	A216729	003	Mar 05, 2025	Feb	NEWA

SOLUTION; ORAL

THYQUIDITY

+! STEVENS J

100MCG/5ML

N214047	001	Nov 30, 2020	Apr	CAHN
---------	-----	--------------	-----	------

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

EUTHYROX

AB2	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr	CAHN
AB2		0.05MG	N021292	002	May 31, 2002	Apr	CAHN
AB2		0.075MG	N021292	003	May 31, 2002	Apr	CAHN
AB2		0.088MG	N021292	004	May 31, 2002	Apr	CAHN
AB2		0.1MG	N021292	005	May 31, 2002	Apr	CAHN
AB2		0.112MG	N021292	006	May 31, 2002	Apr	CAHN

TABLET; ORAL		EUTHYROX					
AB2		0.125MG		N021292	007	May 31, 2002	Apr CAHN
AB2		0.137MG		N021292	008	May 31, 2002	Apr CAHN
AB2		0.15MG		N021292	009	May 31, 2002	Apr CAHN
AB2		0.175MG		N021292	010	May 31, 2002	Apr CAHN
AB2		0.2MG		N021292	011	May 31, 2002	Apr CAHN
	@	0.3MG		N021292	012	May 31, 2002	Apr CAHN
		LEVOTHYROXINE SODIUM					
	@	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jan DISC
	@		0.15MG	A216414	002	Jul 16, 2024	Jan DISC
	@		0.175MG	A216414	003	Jul 16, 2024	Jan DISC
	@		0.2MG	A216414	004	Jul 16, 2024	Jan DISC
	@		0.3MG	A216414	005	Jul 16, 2024	Jan DISC
AB1, AB2, AB3, AB4	MACLEODS PHARMS LTD	0.025MG		A211417	001	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.025MG		A211417	001	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.05MG		A211417	002	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.05MG		A211417	002	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.075MG		A211417	003	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.075MG		A211417	003	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.088MG		A211417	004	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.088MG		A211417	004	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.1MG		A211417	005	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.1MG		A211417	005	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.112MG		A211417	006	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.112MG		A211417	006	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.125MG		A211417	007	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.125MG		A211417	007	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.137MG		A211417	008	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.137MG		A211417	008	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.15MG		A211417	009	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.15MG		A211417	009	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.175MG		A211417	010	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.175MG		A211417	010	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.2MG		A211417	011	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.2MG		A211417	011	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.3MG		A211417	012	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.3MG		A211417	012	Dec 21, 2022	Feb CTEC
		<u>LIDOCAINE</u>					
		OINTMENT; TOPICAL					
		LIDOCAINE					
BX	ALEMBIC	5%		A211469	001	Nov 23, 2018	Mar CTEC
AT	CHARTWELL RX	5%		A208660	001	Jan 05, 2021	Apr CAHN
		PATCH; TOPICAL					
		LIDOCAINE					
AB	AVEVA	1.8%		A217221	001	Mar 25, 2025	Mar NFTG
		ZTLIDO					
AB	+! SCILEX PHARMS	1.8%		N207962	001	Feb 28, 2018	Mar CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION		LIDOCAINE HYDROCHLORIDE					
AP	ANTHEA PHARMA	1%		A219535	001	Apr 02, 2025	Mar NEWA
SOLUTION; ORAL		LIDOCAINE HYDROCHLORIDE					
AT	XTTRIUM LABS INC	2%		A087872	001	Nov 18, 1982	Feb CAHN
SOLUTION; TOPICAL		LIDOCAINE HYDROCHLORIDE					
AT	XTTRIUM LABS INC	4%		A087881	001	Nov 18, 1982	Feb CAHN

LINEZOLID

SOLUTION; INTRAVENOUS		LINEZOLID					
AP	NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)		A205154	001	Dec 06, 2017	Feb CAHN
AP		600MG/300ML (2MG/ML)		A205154	002	Dec 06, 2017	Feb CAHN
TABLET; ORAL		LINEZOLID					
>D>	AB	MACLEODS PHARMS LTD	600MG	A210378	001	Oct 10, 2024	Jun DISC
>A>		@	600MG	A210378	001	Oct 10, 2024	Jun DISC

LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS		LIRAGLUTIDE					
AP	NANJING KING-FRIEND	18MG/3ML (6MG/ML)		A218115	001	Apr 02, 2025	Mar NEWA

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL		LISDEXAMFETAMINE DIMESYLATE					
AB	GRANULES	10MG		A218987	001	Jan 29, 2025	Jan NEWA
AB		20MG		A218987	002	Jan 29, 2025	Jan NEWA
AB		30MG		A218987	003	Jan 29, 2025	Jan NEWA
AB		40MG		A218987	004	Jan 29, 2025	Jan NEWA
AB		50MG		A218987	005	Jan 29, 2025	Jan NEWA
AB		60MG		A218987	006	Jan 29, 2025	Jan NEWA
AB		70MG		A218987	007	Jan 29, 2025	Jan NEWA
AB	SANDOZ	20MG		A202836	001	Jul 26, 2024	Jan CMFD
AB		30MG		A202836	002	Jul 26, 2024	Jan CMFD
AB		40MG		A202836	003	Jul 26, 2024	Jan CMFD
AB		50MG		A202836	004	Jul 26, 2024	Jan CMFD
AB		60MG		A202836	005	Jul 26, 2024	Jan CMFD
AB		70MG		A202836	006	Jul 26, 2024	Jan CMFD
SOLUTION; ORAL		ARYNTA					
>A>							
>A>		#! AZURITY	10MG/ML	N219847	001	Jun 16, 2025	Jun NEWA

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL		LITHIUM CARBONATE					
AB	@	NORVIUM BIOSCIENCE	450MG	A202219	001	Aug 08, 2012	Mar DISC
			450MG	A202219	001	Aug 08, 2012	Feb CAHN

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC		ALOMIDE					
	@ +	NOVARTIS	EQ 0.1% BASE	N020191	001	Sep 23, 1993	May DISC

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL		LOFEXIDINE HYDROCHLORIDE					
AB	MSN		EQ 0.18MG BASE	A218699	001	Feb 24, 2025	Feb NEWA
AB	#!	BIOCORRX PHARMS	EQ 0.18MG BASE	N209229	001	May 16, 2018	May CAHN

LORAZEPAM

INJECTABLE; INJECTION		LORAZEPAM					
	@	AVIV PHARMA	1MG/0.5ML	A074551	003	Sep 12, 1996	May CAHN
	@		2MG/ML	A074535	001	Sep 12, 1996	Apr CAHN
	@		2MG/ML	A074551	001	Sep 12, 1996	May CAHN
	@		4MG/ML	A074535	002	Sep 12, 1996	Apr CAHN

INJECTABLE; INJECTION

LORAZEPAM

@		4MG/ML	A074551	002	Sep 12, 1996	May	CAHN
@	HOSPIRA	2MG/ML	A074282	001	May 27, 1994	Apr	DISC
@		4MG/ML	A074282	002	May 27, 1994	Apr	DISC

LOSARTAN POTASSIUM

SUSPENSION; ORAL

ARB LI

+!	SCIENTURE	10MG/ML	N218772	001	Mar 13, 2025	Mar	NEWA
----	-----------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

LOSARTAN POTASSIUM

@	APOTEX	25MG	A218551	001	Jun 04, 2024	Jan	DISC
@		50MG	A218551	002	Jun 04, 2024	Jan	DISC
@		100MG	A218551	003	Jun 04, 2024	Jan	DISC

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX SM

>D>	+!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Jun	CFTG
>A>	AB	+!	0.38%	N208219	001	Feb 22, 2019	Jun	CFTG

LOTEPREDNOL ETABONATE

>A>	AB	LUPIN LTD	0.38%	A218087	001	Jun 30, 2025	Jun	NFTG
-----	----	-----------	-------	---------	-----	--------------	-----	------

SUSPENSION/DROPS; OPHTHALMIC

LOTEPREDNOL ETABONATE

AB		AMNEAL	0.5%	A217484	001	May 20, 2025	May	NEWA
AB		PADAGIS US	0.5%	A215204	001	Jan 29, 2025	Jan	NEWA

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

@ +	COVIS	20MG	N021316	002	Jun 26, 2002	May	DISC
@ +		40MG	N021316	003	Jun 26, 2002	May	DISC
@ +		60MG	N021316	004	Jun 26, 2002	May	DISC

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB		CHARTWELL RX	20MG	A212091	001	Dec 28, 2020	Mar	CAHN
AB			40MG	A212091	002	Dec 28, 2020	Mar	CAHN
AB			60MG	A212091	003	Dec 28, 2020	Mar	CAHN
AB			80MG	A212091	004	Dec 28, 2020	Mar	CAHN
AB			120MG	A212091	005	Dec 28, 2020	Mar	CAHN
AB		TORRENT	60MG	A208055	005	Jan 13, 2025	Jan	NEWA

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

>D>	AP	FRESENIUS KABI USA	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	A215370	001	Jun 29, 2022	Jun	DISC
-----	----	--------------------	---	---------	-----	--------------	-----	------

>A>		@	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	A215370	001	Jun 29, 2022	Jun	DISC
-----	--	---	---	---------	-----	--------------	-----	------

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

>D>	AP	+!	BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	001		Jun	CTEC
-----	----	----	-----------------	---	---------	-----	--	-----	------

>A>		+!		30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	001		Jun	CTEC
-----	--	----	--	---	---------	-----	--	-----	------

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP		ASPIRO	1GM/2ML (500MG/ML)	A219777	001	May 28, 2025	May	NFTG	
AP			5GM/10ML (500MG/ML)	A219777	002	May 28, 2025	May	NEWA	
AP			10GM/20ML (500MG/ML)	A219777	003	May 28, 2025	May	NEWA	
AP			25GM/50ML (500MG/ML)	A219777	004	May 28, 2025	May	NFTG	
AP		+!	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	May	CFTG
AP		+!		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	May	CFTG

MANGANESE CHLORIDE

INJECTABLE; INJECTION

>A>	MANGANESE CHLORIDE							
>A>	AP	FRESENIUS KABI USA	EQ 0.1MG MANGANESE/ML	A217583	001	Jul 07, 2025	Jun	NFTG
		MANGANESE CHLORIDE IN PLASTIC CONTAINER						
>D>		+! HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Jun	CFTG
>A>	AP	+!	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Jun	CFTG

MARALIXIBAT CHLORIDE

TABLET; ORAL

LIVMARLI

		+ MIRUM	EQ 10MG BASE	N219485	001	Apr 10, 2025	Apr	NEWA
		+	EQ 15MG BASE	N219485	002	Apr 10, 2025	Apr	NEWA
		+	EQ 20MG BASE	N219485	003	Apr 10, 2025	Apr	NEWA
		+!	EQ 30MG BASE	N219485	004	Apr 10, 2025	Apr	NEWA

MARAVIROC

TABLET; ORAL

MARAVIROC

AB		NAVINTA LLC	150MG	A217880	001	May 13, 2025	May	NEWA
AB			300MG	A217880	002	May 13, 2025	May	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

>D>	@	CHARTWELL RX	12.5MG	A205136	001	Feb 22, 2019	Jun	CAHN
>D>	@		25MG	A205136	002	Feb 22, 2019	Jun	CAHN
>D>	@		50MG	A205136	003	Feb 22, 2019	Jun	CAHN
>A>	@	INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Jun	CAHN
>A>	@		25MG	A205136	002	Feb 22, 2019	Jun	CAHN
>A>	@		50MG	A205136	003	Feb 22, 2019	Jun	CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB		AJENAT PHARMS	250MG	A091608	001	Jun 02, 2014	Jan	CAHN
>A>	@	MPP PHARMA	250MG	A090359	001	Feb 05, 2013	Jun	CAHN
>D>	@	NOSTRUM LABS INC	250MG	A090359	001	Feb 05, 2013	Jun	CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

>D>	@	CHARTWELL RX	250MG	A076175	001	Feb 20, 2002	Jun	CMFD
>A>	AB		250MG	A076175	001	Feb 20, 2002	Jun	CMFD

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

	@ +	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	Feb	DISC
		MEGESTROL ACETATE						
	!	TWI PHARMS	125MG/ML	A203139	001	Aug 27, 2014	Feb	CTEC
AB	!		125MG/ML	A203139	001	Aug 27, 2014	Feb	CHRS
AB		XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Apr	CMFD

MELOXICAM

SOLUTION; INTRAVENOUS

QAMZOVA

		+! NANJING DELOVA	30MG/ML (30MG/ML)	N217593	001	Apr 22, 2025	Apr	NEWA
		XIFYRM						
>A>		+! AZURITY	30MG/ML (30MG/ML)	N218395	001	Jun 05, 2025	Jun	NEWA

TABLET; ORAL

MELOXICAM

AB		GRAVITI PHARMS	7.5MG	A077931	001	Jul 25, 2006	Feb	CAHN
AB			15MG	A077931	002	Jul 25, 2006	Feb	CAHN

MELOXICAM; RIZATRIPTAN BENZOATE

TABLET; ORAL

SYMBRAVO

	+	AXSOME	20MG;EQ 10MG BASE	N215431	001	Jan 30, 2025	Jan NEWA
--	---	--------	-------------------	---------	-----	--------------	----------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

	@	APOTEX	7MG	A206135	001	Nov 22, 2016	Mar DISC
	@		14MG	A206135	002	Nov 22, 2016	Mar DISC
	@		21MG	A206135	003	Nov 22, 2016	Mar DISC
	@		28MG	A206135	004	Nov 22, 2016	Mar DISC
AB		RISING	7MG	A206032	001	Sep 28, 2016	May CMFD
AB			14MG	A206032	002	Sep 28, 2016	May CMFD
AB			21MG	A206032	003	Sep 28, 2016	May CMFD
AB			28MG	A206032	004	Sep 28, 2016	May CMFD

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

	@	APOZEAL PHARMS	2MG/ML	A205446	001	Dec 07, 2015	Apr CAHN
--	---	----------------	--------	---------	-----	--------------	----------

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

	@	POINTVIEW HLDINGS	5MG	A090073	001	Sep 04, 2015	Apr CAHN
	@		10MG	A090073	002	Sep 04, 2015	Apr CAHN
AB		YILING	5MG	A212947	001	Apr 03, 2020	Apr CMFD
AB			10MG	A212947	002	Apr 03, 2020	Apr CMFD

MERCAPTOPYRINE

SUSPENSION; ORAL

MERCAPTOPYRINE

AB		HIKMA	20MG/ML	A216418	001	Feb 26, 2025	Feb NFTG	
		PURIXAN						
AB		+	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	Feb CFTG

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	!	ACS DOBFAR	500MG/VIAL	A091404	001	Oct 26, 2011	Apr CHRS
AP	!		1GM/VIAL	A091404	002	Oct 26, 2011	Apr CHRS
		MERREM IV					
	@ +	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Apr DISC
	@ +		1GM/VIAL	N050706	001	Jun 21, 1996	Apr DISC

POWDER; INTRAVENOUS

MEROPENEM

>A>	AP		BROOKS STERISCIENCE	2GM/VIAL	A219084	001	Jun 23, 2025	Jun NFTG
>D>		+	HQ SPCLT PHARMA	2GM/VIAL	N215212	001	Jul 26, 2023	Jun CFTG
>A>	AP	+		2GM/VIAL	N215212	001	Jul 26, 2023	Jun CFTG

MESALAMINE

ENEMA; RECTAL

MESALAMINE

AB		NOVITIUM PHARMA	4GM/60ML	A215269	001	Apr 16, 2025	Apr NEWA
----	--	-----------------	----------	---------	-----	--------------	----------

SUPPOSITORY; RECTAL

MESALAMINE

AB		NORVIUM BIOSCIENCE	1GM	A204354	001	Nov 24, 2015	May CAHN
AB		RISING	1GM	A219028	001	Apr 14, 2025	Apr NEWA

TABLET, DELAYED RELEASE; ORAL

MESALAMINE

AB		AMNEAL	800MG	A215067	001	Feb 18, 2025	Feb NEWA
----	--	--------	-------	---------	-----	--------------	----------

MESNA

TABLET; ORAL

MESNA

AB		RICONPHARMA LLC	400MG	A218871	001	Jan 13, 2025	Jan NFTG	
		MESNEX						
AB		+	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002	Jan CFTG

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

AB	ANNORA PHARMA	500MG/5ML	A215008	001	Mar 13, 2025	Mar	NEWA
AB	BIONPHARMA	500MG/5ML	A219151	001	Apr 14, 2025	Apr	NEWA
AB	VISTAPHARM LLC	500MG/5ML	A212677	001	Aug 19, 2022	Jan	CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

@	APOTEX	500MG	A075984	001	Apr 23, 2002	Mar	DISC
@		500MG	A090666	001	Dec 07, 2011	Mar	DISC
@		850MG	A075984	002	Apr 23, 2002	Mar	DISC
@		850MG	A090666	002	Dec 07, 2011	Mar	DISC
@		1GM	A075984	003	Apr 23, 2002	Mar	DISC
@		1GM	A090666	003	Dec 07, 2011	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB1	MEDICAP LABS	500MG	A202306	001	Feb 23, 2017	Feb	CAHN
AB		750MG	A202306	002	Feb 23, 2017	Feb	CAHN
AB2	MPP PHARMA	500MG	A203832	001	Dec 26, 2017	May	CAHN
AB2		1GM	A203832	002	Dec 26, 2017	May	CAHN
@	SUN PHARM	500MG	A202917	001	Aug 01, 2016	Jan	DISC
@		1GM	A202917	002	Aug 01, 2016	Jan	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	May	CMFD
AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	May	CMFD

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB	DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jan	CTNA
AB		1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jan	CTNA
AB	!	1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jan	CTNA

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

>D>	AB	+	MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Jun	CTEC
>A>		+		500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Jun	CTEC
	AB	+		500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May	CFTG
>D>	AB	+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Jun	CTEC
>A>		+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Jun	CTEC
	AB	+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May	CFTG
>D>	AB	+	!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Jun	CTEC
>A>		+	!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Jun	CTEC
	AB	+	!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May	CFTG
>D>			SITAGLIPTIN AND METFORMIN HYDROCHLORIDE						
>D>	AB		ENDO OPERATIONS	500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	Jun	DISC
>A>		@		500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	Jun	DISC
	AB			500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	May	NFTG
>D>	AB			1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	Jun	DISC
>A>		@		1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	Jun	DISC
	AB			1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	May	NFTG
>D>	AB			1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	Jun	DISC
>A>		@		1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	Jun	DISC
	AB			1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	May	NFTG

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

AP	HIKMA	10MG/ML	A218609	001	May 05, 2025	Apr	NEWA
----	-------	---------	---------	-----	--------------	-----	------

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	VISTAPHARM LLC	40MG	A075082	001	Mar 25, 1998	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

	@ +	ESJAY PHARMA	1GM		N017681	001		May	DISC
AB		METHENAMINE HIPPURATE							
		ZYDUS LIFESCIENCES	1GM		A219661	001	Mar 10, 2025	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		AIPING PHARM INC	5MG		A040547	001	Feb 18, 2005	Mar	CAHN
AB			10MG		A040547	002	Feb 18, 2005	Mar	CAHN
	@		20MG		A040547	004	Feb 18, 2005	Mar	CAHN
AB		SQUARE PHARMS PLC	5MG		A218830	001	Feb 05, 2025	Jan	NEWA
AB			10MG		A218830	002	Feb 05, 2025	Jan	NEWA

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

>D>	@	NORVIUM BIOSCIENCE	1GM/10ML (100MG/ML)		A204404	001	Dec 05, 2014	Jun	CAHN
>A>	@	PHARMOBEDIENT	1GM/10ML (100MG/ML)		A204404	001	Dec 05, 2014	Jun	CAHN

TABLET; ORAL

METHOCARBAMOL

AA		BOSTAL	500MG		A200958	001	Oct 21, 2011	May	CAHN
AA			750MG		A200958	002	Oct 21, 2011	May	CAHN
AB	!		1GM		A200958	003	Dec 06, 2021	May	CAHN
AA		POINTVIEW HLDINGS	500MG		A212623	001	Apr 30, 2021	Apr	CAHN
AA			750MG		A212623	002	Apr 30, 2021	Apr	CAHN

METHYLENE BLUE

SOLUTION; INTRAVENOUS

METHYLENE BLUE

AP		HIKMA	50MG/10ML (5MG/ML)		A216959	001	Dec 17, 2024	Jan	CAHN
AP		MEITHEAL	50MG/10ML (5MG/ML)		A217380	001	Jan 23, 2025	Jan	CAHN
AP		NANJING KING-FRIEND	50MG/10ML (5MG/ML)		A217380	001	Jan 23, 2025	Jan	NEWA

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

	@	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)		A208112	001	Aug 26, 2024	Mar	DISC
	@		12MG/0.6ML (12MG/0.6ML)		A208112	002	Aug 26, 2024	Mar	DISC
>D>	AP	MYLAN LABS LTD	12MG/0.6ML (12MG/0.6ML)		A208592	001	May 28, 2025	Jun	DISC
>A>	@		12MG/0.6ML (12MG/0.6ML)		A208592	001	May 28, 2025	Jun	DISC
	AP		12MG/0.6ML (12MG/0.6ML)		A208592	001	May 28, 2025	May	NFTG
		RELISTOR							
	+!	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)		N021964	002	Sep 27, 2010	Mar	CTEC
>D>	AP	+!	12MG/0.6ML (12MG/0.6ML)		N021964	001	Apr 24, 2008	Jun	CTEC
>A>		+!	12MG/0.6ML (12MG/0.6ML)		N021964	001	Apr 24, 2008	Jun	CTEC
	AP	+!	12MG/0.6ML (12MG/0.6ML)		N021964	001	Apr 24, 2008	May	CFTG
		+!	12MG/0.6ML (12MG/0.6ML)		N021964	003	Sep 27, 2010	Mar	CTEC

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

COTEMPLA XR-ODT

>D>	+	NEOS THERAPS INC	34.6MG		N205489	004	Aug 19, 2024	Jun	DISC
>A>	@ +		34.6MG		N205489	004	Aug 19, 2024	Jun	DISC
	+		34.6MG		N205489	004	Aug 19, 2024	Apr	CMFD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	ESJAY PHARMA	5MG/5ML		A201466	001	Nov 12, 2013	Feb	CAHN
@		10MG/5ML		A201466	002	Nov 12, 2013	Feb	CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	@	MPP PHARMA	5MG		A207587	001	Mar 03, 2017	Jun	CAHN
>A>	@		10MG		A207587	002	Mar 03, 2017	Jun	CAHN
>A>	@		20MG		A207587	003	Mar 03, 2017	Jun	CAHN
>D>	@	NOSTRUM LABS INC	5MG		A207587	001	Mar 03, 2017	Jun	CAHN
>D>	@		10MG		A207587	002	Mar 03, 2017	Jun	CAHN
>D>	@		20MG		A207587	003	Mar 03, 2017	Jun	CAHN

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	STRIDES PHARMA	2.5MG	A204954	001	Jan 26, 2017	Apr	CAHN
@		5MG	A204954	002	Jan 26, 2017	Apr	CAHN
@		10MG	A204954	003	Jan 26, 2017	Apr	CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB	HIKMA	80MG/ML	A219145	001	Apr 16, 2025	Apr	NEWA
----	-------	---------	---------	-----	--------------	-----	------

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 25

@	BAUSCH	25MG	A087147	001		Apr	DISC
BP		25MG	A087147	001		Mar	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	VISTAPHARM LLC	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001	Jan	CAHN
---	----------------	-----------------	---------	-----	--------------	-----	------

METOLAZONE

TABLET;ORAL

METOLAZONE

>D>	AB	CHEMISTRY HLTH	2.5MG	A218606	001	Apr 17, 2024	Jun	CAHN
>D>	AB		5MG	A218606	002	Apr 17, 2024	Jun	CAHN
>D>	AB		10MG	A218606	003	Apr 17, 2024	Jun	CAHN
>A>	AB	LEADING	2.5MG	A218606	001	Apr 17, 2024	Jun	CAHN
>A>	AB		5MG	A218606	002	Apr 17, 2024	Jun	CAHN
>A>	AB		10MG	A218606	003	Apr 17, 2024	Jun	CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

>A>	AB	IPCA LABS LTD	EQ 25MG TARTRATE	A206980	001	Jun 25, 2025	Jun	NEWA
>A>	AB		EQ 50MG TARTRATE	A206980	002	Jun 25, 2025	Jun	NEWA
>A>	AB		EQ 100MG TARTRATE	A206980	003	Jun 25, 2025	Jun	NEWA
>A>	AB		EQ 200MG TARTRATE	A206980	004	Jun 25, 2025	Jun	NEWA

METOPROLOL TARTRATE

SOLUTION;ORAL

LOPRESSOR

+!	RUBICON	10MG/ML	N219373	001	Apr 10, 2025	Apr	NEWA
----	---------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

METOPROLOL TARTRATE

>D>	@	NORVIUM BIOSCIENCE	50MG	A073666	001	Dec 21, 1993	Jun	CAHN
>D>	@		100MG	A073666	002	Dec 21, 1993	Jun	CAHN
>A>	@	PHARMOBEDIENT	50MG	A073666	001	Dec 21, 1993	Jun	CAHN
>A>	@		100MG	A073666	002	Dec 21, 1993	Jun	CAHN
AB		SCIEGEN PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan	CAHN
AB			50MG	A208955	002	Feb 05, 2020	Jan	CAHN
AB			100MG	A208955	003	Feb 05, 2020	Jan	CAHN
@	SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004	Apr	DISC	

METRONIDAZOLE

CREAM;TOPICAL

METROCREAM

>D>	AB	+!	GALDERMA LABS LP	0.75%	N020531	001	Sep 20, 1995	Jun	CHRS
>A>	AB	+		0.75%	N020531	001	Sep 20, 1995	Jun	CHRS

METRONIDAZOLE

>A>	AB	AUROBINDO PHARMA LTD	0.75%	A219295	001	Jul 09, 2025	Jun	NEWA
>D>	AB	FOUGERA PHARMS	0.75%	A076408	001	May 28, 2004	Jun	CHRS
>A>	AB	!	0.75%	A076408	001	May 28, 2004	Jun	CHRS
BX		ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Mar	CTEC

GEL;VAGINAL

METRONIDAZOLE

@	ENCUBE	1.3%	A216795	001	Mar 18, 2024	Jan	DISC
NUVESSA							
+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Jan	CTEC

METYROSINECAPSULE;ORAL
METYROSINE

AB	CEROVENE INC	250MG	A218620	001	Apr 09, 2025	Mar	NEWA
----	--------------	-------	---------	-----	--------------	-----	------

MICAFUNGIN SODIUMINJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

AP	QILU PHARM HAINAN	EQ 50MG BASE/VIAL	A219273	001	Apr 03, 2025	Mar	NEWA
AP		EQ 100MG BASE/VIAL	A219273	002	Apr 03, 2025	Mar	NEWA

MIDAZOLAMSOLUTION;INTRAVENOUS
MIDAZOLAM IN 0.8% SODIUM CHLORIDE

	B BRAUN MEDICAL	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	May	CAHN
		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	May	CAHN
	STERINOVA INC	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Apr	NFTG
		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Apr	NFTG

MIDAZOLAM HYDROCHLORIDEINJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

>D>	AP	EPIC PHARMA LLC	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jun	CAHN
>A>		@	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jun	CAHN
>D>	AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jun	CAHN
>D>	AP	HIKMA	EQ 1MG BASE/ML	A212847	001	Dec 11, 2020	Jun	CAHN
>A>	AP		EQ 1MG BASE/ML	A212847	001	Dec 11, 2020	Jun	CAHN
>D>	AP		EQ 5MG BASE/ML	A212847	002	Dec 11, 2020	Jun	CAHN
>A>	AP		EQ 5MG BASE/ML	A212847	002	Dec 11, 2020	Jun	CAHN
>A>	AP	RISING	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jun	CAHN
>D>		@	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jun	CAHN
>A>	AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jun	CAHN

MIDODRINE HYDROCHLORIDETABLET;ORAL
ORVATEN

>A>	AB	BEIJING YILING	2.5MG	A076725	001	Nov 03, 2004	Jun	CAHN
>A>	AB	!	5MG	A076725	002	Nov 03, 2004	Jun	CAHN
>A>	AB		10MG	A076725	003	Nov 03, 2004	Jun	CAHN
>D>	AB	UPSHER SMITH LABS	2.5MG	A076725	001	Nov 03, 2004	Jun	CAHN
>D>	AB	!	5MG	A076725	002	Nov 03, 2004	Jun	CAHN
>D>	AB		10MG	A076725	003	Nov 03, 2004	Jun	CAHN

MIGLUSTATCAPSULE;ORAL
MIGLUSTAT

	@	CHARTWELL RX	100MG	A209325	001	Feb 03, 2022	Mar	CAHN
AB		NAVINTA LLC	100MG	A219111	001	Mar 14, 2025	Mar	NEWA
	@	VERANOVA	100MG	A209325	001	Feb 03, 2022	Feb	CAHN

MILNACIPRAN HYDROCHLORIDETABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

	@	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Apr	DISC
	@		25MG	A205147	002	Oct 03, 2024	Apr	DISC
	@		50MG	A205147	003	Oct 03, 2024	Apr	DISC
	@		100MG	A205147	004	Oct 03, 2024	Apr	DISC
		SAVELLA						
	+	ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Apr	CTEC
	+		25MG	N022256	002	Jan 14, 2009	Apr	CTEC
	+	!	50MG	N022256	003	Jan 14, 2009	Apr	CTEC
	+		100MG	N022256	004	Jan 14, 2009	Apr	CTEC

MINOCYCLINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
EMROSI

	+	!	JOURNEY	EQ 40MG BASE	N219015	001	Nov 01, 2024	Mar	CPOT
			INJECTABLE;INJECTION						
			MINOCIN						
	+	!	REMPEX	EQ 100MG BASE/VIAL	N050444	001		May	CTEC

INJECTABLE; INJECTION
MINOCYCLINE HYDROCHLORIDE

AP NEXUS EQ 100MG BASE/VIAL A214934 001 Oct 24, 2024 Mar CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL
MIRABEGRON

@ APOTEX 25MG A209434 001 Jan 02, 2025 May DISC
 @ 50MG A209434 002 Jan 02, 2025 May DISC
 >A> AB QILU 25MG A217989 001 Jun 30, 2025 Jun NEWA
 >A> AB 50MG A217989 002 Jun 30, 2025 Jun NEWA
 >D> AB SAWAI USA 50MG A217061 001 May 06, 2025 Jun DISC
 >A> @ 50MG A217061 001 May 06, 2025 Jun DISC
 AB 50MG A217061 001 May 06, 2025 Apr NEWA

MIRDAMETINIB

CAPSULE; ORAL
GOMEKLI

+ SPRINGWORKS 1MG N219389 001 Feb 11, 2025 Feb NEWA
 +! 2MG N219389 002 Feb 11, 2025 Feb NEWA

TABLET, FOR SUSPENSION; ORAL
GOMEKLI

+! SPRINGWORKS 1MG N219379 001 Feb 11, 2025 Feb NEWA

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP ACCORD HLTHCARE 20MG/VIAL A064144 002 Apr 30, 1998 Apr CMFD
 @ 20MG/VIAL A064144 002 Apr 30, 1998 Jan DISC
 AP ! MEITHEAL 20MG/VIAL A214505 002 Sep 08, 2022 Jan CHRS
 >A> POWDER; INTRAVESICAL
 >A> ZUSDURI
 >A> +! UROGEN PHARMA 40MG/VIAL N215793 001 Jun 12, 2025 Jun NEWA

MODAFINIL

TABLET; ORAL
MODAFINIL

>D> AB WATSON LABS INC 100MG A076715 001 Nov 01, 2012 Jun DISC
 >A> @ 100MG A076715 001 Nov 01, 2012 Jun DISC
 >D> AB 200MG A076715 002 Nov 01, 2012 Jun DISC
 >A> @ 200MG A076715 002 Nov 01, 2012 Jun DISC
 AB + NUVO PHARMS 100MG N020717 001 Dec 24, 1998 Jan CAHN
 AB +! 200MG N020717 002 Dec 24, 1998 Jan CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
MOEXIPRIL HYDROCHLORIDE

@ APOTEX INC 7.5MG A078454 001 Jun 02, 2008 Mar DISC
 @ 15MG A078454 002 Jun 02, 2008 Mar DISC

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

@ CHARTWELL MOLECULAR 0.1% A076591 001 Apr 18, 2007 Feb CAHN
 >D> AB COSETTE 0.1% A077447 001 May 22, 2006 Jun CHRS
 >A> AB ! 0.1% A077447 001 May 22, 2006 Jun CHRS
 >D> AB ! GLENMARK PHARMS INC 0.1% A078541 001 May 28, 2008 Jun DISC
 >A> @ 0.1% A078541 001 May 28, 2008 Jun DISC

OINTMENT; TOPICAL

MOMETASONE FUROATE

>D> AB ! GLENMARK PHARMS INC 0.1% A078571 001 May 28, 2008 Jun DISC
 >A> @ 0.1% A078571 001 May 28, 2008 Jun DISC
 >D> AB PADAGIS US 0.1% A076067 001 Mar 18, 2002 Jun CHRS
 >A> AB ! 0.1% A076067 001 Mar 18, 2002 Jun CHRS

SPRAY, METERED; NASAL
MOMETASONE FUROATE

AB NASPRESS 0.05MG/SPRAY A211706 001 May 15, 2025 May NEWA

MORPHINE SULFATE

SOLUTION; ORAL

MORPHINE SULFATE

AA	+	HIKMA	20MG/5ML	N022195	002	Mar 17, 2008	Apr	CTEC
	+		20MG/5ML	N022195	002	Mar 17, 2008	Feb	CTEC
>D>	@	PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Jun	CMFD
>A>	AA		10MG/5ML	A206573	002	Sep 12, 2023	Jun	CMFD
>D>	@		100MG/5ML	A206573	001	Nov 14, 2016	Jun	CMFD
>A>	AA		100MG/5ML	A206573	001	Nov 14, 2016	Jun	CMFD
	@	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jan	DISC
	@		20MG/5ML	A206420	001	Jul 12, 2016	Jan	DISC
	@		100MG/5ML	A206308	002	Jun 22, 2017	Jan	DISC
	@	SANKALP LIFECARE	10MG/5ML	A201011	001	Feb 05, 2014	Apr	CAHN
	@		20MG/5ML	A201011	002	Feb 05, 2014	Apr	CAHN
	@		100MG/5ML	A201011	003	Oct 06, 2016	Apr	CAHN
AA		WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Apr	CMFD
	@		10MG/5ML	A211454	001	Feb 12, 2021	Feb	DISC
AA			20MG/5ML	A211454	002	Feb 12, 2021	Apr	CMFD
	@		20MG/5ML	A211454	002	Feb 12, 2021	Feb	DISC
AA			100MG/5ML	A211454	003	Feb 12, 2021	Apr	CMFD
	@		100MG/5ML	A211454	003	Feb 12, 2021	Feb	DISC

TABLET; ORAL

MORPHINE SULFATE

>D>	AB	+	HIKMA	15MG	N022207	001	Mar 17, 2008	Jun	CAHN
>A>	AB	+		15MG	N022207	001	Mar 17, 2008	Jun	CAHN
>D>	AB	+	!	30MG	N022207	002	Mar 17, 2008	Jun	CAHN
>A>	AB	+	!	30MG	N022207	002	Mar 17, 2008	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

	@	NOVEL LABS INC	15MG	A203602	001	Dec 16, 2015	Feb	DISC
	@		30MG	A203602	002	Dec 16, 2015	Feb	DISC
	@		60MG	A203602	003	Dec 16, 2015	Feb	DISC
	@		100MG	A203602	004	Dec 16, 2015	Feb	DISC
	@		200MG	A203602	005	Dec 16, 2015	Feb	DISC

MOTIXAFORTIDE ACETATE

POWDER; SUBCUTANEOUS

APHEXDA

	+	!	AYRMID PHARMA	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023	Mar	CAHN
--	---	---	---------------	-------------------	---------	-----	--------------	-----	------

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1			MANKIND PHARMA	EQ 0.5% BASE	A217988	001	Jan 27, 2025	Jan	NEWA
	@		NORVIUM BIOSCIENCE	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Feb	CAHN

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB			ENCUBE	2%	A217943	001	May 13, 2025	May	NEWA
----	--	--	--------	----	---------	-----	--------------	-----	------

MUPIROCIN CALCIUM

CREAM; TOPICAL

MUPIROCIN

BX			ALEMBIC	EQ 2% BASE	A213053	001	Nov 16, 2021	Mar	CTEC
----	--	--	---------	------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

FOR SUSPENSION; ORAL

MYCOPHENOLATE MOFETIL

	@		TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Apr	DISC
AB			VISTAPHARM LLC	200MG/ML	A210370	001	Feb 12, 2019	Jan	CAHN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC SODIUM

AB			FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Jan	CAHN
AB				EQ 360MG BASE	A216637	002	May 29, 2024	Jan	CAHN

NABUMETONE

TABLET; ORAL

NABUMETONE

>A>	@	MPP PHARMA	500MG	A 090427	001	Dec 30, 2011	Jun CAHN
>A>	@		750MG	A 090427	002	Dec 30, 2011	Jun CAHN
>D>	@	NOSTRUM LABS INC	500MG	A 090427	001	Dec 30, 2011	Jun CAHN
>D>	@		750MG	A 090427	002	Dec 30, 2011	Jun CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

@	FRESENIUS	EQ 10GM BASE/VIAL	A 206761	001	Jun 02, 2020	Apr DISC
---	-----------	-------------------	----------	-----	--------------	----------

NALBUPHINE HYDROCHLORIDE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALBUPHINE

@	ABRAXIS PHARM	10MG/ML (10MG/ML)	A 070751	001	Jul 02, 1986	Mar CPOT	
@		10MG/ML	A 070751	001	Jul 02, 1986	Mar CDFR	
@		20MG/ML (20MG/ML)	A 070752	001	Sep 24, 1986	Mar CPOT	
@		20MG/ML	A 070752	001	Sep 24, 1986	Mar CDFR	
@		200MG/10ML (20MG/ML)	A 070752	002	Sep 24, 1986	Mar NEWA	
NALBUPHINE HYDROCHLORIDE							
@	ABBOTT	20MG/ML (20MG/ML)	A 070917	001	Feb 03, 1989	Mar CPOT	
@		20MG/ML	A 070917	001	Feb 03, 1989	Mar CDFR	
@	ABRAXIS PHARM	100MG/10ML (10MG/ML)	A 070751	002	Jul 02, 1986	Mar NEWA	
@	DR REDDYS	10MG/ML	A 074471	001	Mar 19, 1998	Mar CDFR	
@		20MG/ML	A 074471	002	Mar 19, 1998	Mar CDFR	
@		100MG/10ML (10MG/ML)	A 074471	001	Mar 19, 1998	Mar CPOT	
@		200MG/10ML (20MG/ML)	A 074471	002	Mar 19, 1998	Mar CPOT	
AP	!	HOSPIRA	10MG/ML (10MG/ML)	A 070914	001	Feb 03, 1989	Mar CPOT
AP	!		10MG/ML	A 070914	001	Feb 03, 1989	Mar CDFR
AP	!		10MG/ML	A 070915	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML (20MG/ML)	A 070916	001	Feb 03, 1989	Mar CPOT
AP	!		20MG/ML	A 070916	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML	A 070918	001	Feb 03, 1989	Mar CDFR
AP	!		100MG/10ML (10MG/ML)	A 070915	001	Feb 03, 1989	Mar CPOT
AP	!		200MG/10ML (20MG/ML)	A 070918	001	Feb 03, 1989	Mar CPOT
@	IGI LABS INC	10MG/ML (10MG/ML)	A 072070	001	Apr 10, 1989	Mar CPOT	
@		10MG/ML	A 072070	001	Apr 10, 1989	Mar CDFR	
@		10MG/ML (10MG/ML)	A 072071	001	Apr 10, 1989	Mar CPOT	
@		10MG/ML	A 072071	001	Apr 10, 1989	Mar CDFR	
@		10MG/ML (10MG/ML)	A 072072	001	Apr 10, 1989	Mar CPOT	
@		10MG/ML	A 072072	001	Apr 10, 1989	Mar CDFR	
@		20MG/ML (20MG/ML)	A 072073	001	Apr 10, 1989	Mar CPOT	
@		20MG/ML	A 072073	001	Apr 10, 1989	Mar CDFR	
@		20MG/ML (20MG/ML)	A 072074	001	Apr 10, 1989	Mar CPOT	
@		20MG/ML	A 072074	001	Apr 10, 1989	Mar CDFR	
@		20MG/ML (20MG/ML)	A 072075	001	Apr 10, 1989	Mar CPOT	
@		20MG/ML	A 072075	001	Apr 10, 1989	Mar CDFR	
@		100MG/10ML (10MG/ML)	A 072070	002	Apr 10, 1989	Mar NEWA	
@		200MG/10ML (20MG/ML)	A 072073	002	Apr 10, 1989	Mar NEWA	
@	RISING	10MG/ML	A 206506	001	Feb 06, 2019	Mar CDFR	
@		10MG/ML (10MG/ML)	A 207595	001	Jan 11, 2019	Mar CPOT	
@		10MG/ML	A 207595	001	Jan 11, 2019	Mar CDFR	
@		20MG/ML	A 206506	002	Feb 06, 2019	Mar CDFR	
@		20MG/ML (20MG/ML)	A 207595	002	Jan 11, 2019	Mar CPOT	
@		20MG/ML	A 207595	002	Jan 11, 2019	Mar CDFR	
@		100MG/10ML (10MG/ML)	A 206506	001	Feb 06, 2019	Mar CPOT	
@		200MG/10ML (20MG/ML)	A 206506	002	Feb 06, 2019	Mar CPOT	
AP		SOMERSET THERAPS LLC	10MG/ML	A 216049	001	Sep 19, 2024	Mar CDFR
AP			10MG/ML (10MG/ML)	A 216050	001	Sep 19, 2024	Mar CPOT
AP			10MG/ML	A 216050	001	Sep 19, 2024	Mar CDFR
AP			20MG/ML	A 216049	002	Sep 19, 2024	Mar CDFR
AP			20MG/ML (20MG/ML)	A 216050	002	Sep 19, 2024	Mar CPOT
AP			20MG/ML	A 216050	002	Sep 19, 2024	Mar CDFR
AP			100MG/10ML (10MG/ML)	A 216049	001	Sep 19, 2024	Mar CPOT
AP			200MG/10ML (20MG/ML)	A 216049	002	Sep 19, 2024	Mar CPOT
NUBAIN							
@ +	ENDO OPERATIONS	10MG/ML (10MG/ML)	N 018024	001		Mar CPOT	
@ +		10MG/ML	N 018024	001		Mar CDFR	
@ +		20MG/ML (20MG/ML)	N 018024	002	May 27, 1982	Mar CPOT	
@ +		20MG/ML	N 018024	002	May 27, 1982	Mar CDFR	

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
NUBAIN

@ +		20MG/2ML (10MG/ML)	N018024	004		Mar	NEWA
@ +		100MG/10ML (10MG/ML)	N018024	003		Mar	NEWA
@ +		200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Mar	NEWA

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZURNAI (AUTOINJECTOR)

@ +	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Jan	DISC
-----	------------------	---	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	1MG/ML	A214785	002	Jun 03, 2025	May	NEWA
	SPRAY;NASAL KLOXXADO						
	+! HIKMA	8MG/SPRAY	N212045	001	Apr 29, 2021	May	CTEC
AB	+!	8MG/SPRAY	N212045	001	Apr 29, 2021	Apr	CFTG
	NALOXONE HYDROCHLORIDE						
	@ PADAGIS ISRAEL	8MG/SPRAY	A216719	001	Apr 24, 2025	May	DISC
AB		8MG/SPRAY	A216719	001	Apr 24, 2025	Apr	NFTG

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 2.5MG BASE	A212661	001	Jan 28, 2025	Jan	NEWA
AB		EQ 5MG BASE	A212661	002	Jan 28, 2025	Jan	NEWA
AB		EQ 10MG BASE	A212661	003	Jan 28, 2025	Jan	NEWA
AB		EQ 20MG BASE	A212661	004	Jan 28, 2025	Jan	NEWA

NEOMYCIN SULFATE

TABLET;ORAL
NEOMYCIN SULFATE

@	AVIV PHARMA	500MG	A065468	001	Mar 29, 2010	May	CAHN
---	-------------	-------	---------	-----	--------------	-----	------

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

AP	AVET LIFESCIENCES	5MG/10ML (0.5MG/ML)	A208230	001	Nov 25, 2022	May	CTNA
AP		10MG/10ML (1MG/ML)	A208230	002	Nov 25, 2022	May	CTNA

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB	ZYDUS PHARMS	500MG	A203285	001	Apr 28, 2025	Apr	NEWA
AB		750MG	A203285	002	Apr 28, 2025	Apr	NEWA
AB		1GM	A203285	003	Apr 28, 2025	Apr	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL
NICARDIPINE HYDROCHLORIDE

>A>	AB	NAVINTA LLC	20MG	A218638	001	Jun 25, 2025	Jun	NEWA
>A>	AB		30MG	A218638	002	Jun 25, 2025	Jun	NEWA
		INJECTABLE;INJECTION NICARDIPINE HYDROCHLORIDE						
	@	AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Jan	DISC
>A>	AP	MANKIND PHARMA	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Jun	CAHN
>D>	AP	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Jun	CAHN

NILOTINIB D-TARTRATE

CAPSULE;ORAL
NILOTINIB D-TARTRATE

+	CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025	Feb	NEWA
+		EQ 150MG BASE	N218922	002	Feb 19, 2025	Feb	NEWA
+!		EQ 200MG BASE	N218922	003	Feb 19, 2025	Feb	NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

AB	APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr	CMFD
AB		EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr	CMFD
AB		EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr	CMFD
	TASIGNA						
AB	+ NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
AB	+	EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
AB	+	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

AB	ALKEM LABS LTD	6MG/ML	A213409	001	Jan 22, 2025	Jan	NFTG
	NYMALIZE						
AB	+! AZURITY	6MG/ML	N203340	002	Apr 08, 2020	Jan	CFTG

NITAZOXANIDE

TABLET;ORAL

NITAZOXANIDE

AB	ANI PHARMS	500MG	A214844	001	Feb 03, 2025	Apr	CAHN
AB	ANNORA PHARMA	500MG	A218701	001	Apr 15, 2025	Apr	NEWA
AB	! RISING	500MG	A213820	001	Nov 27, 2020	Jan	CTEC
AB	ZENARA	500MG	A214844	001	Feb 03, 2025	Jan	NEWA

NITRIC OXIDE

GAS; INHALATION

NOXIVENT

@	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr	DISC
---	-----------------	--------	---------	-----	--------------	-----	------

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

>A>	AB	ANNORA PHARMA	25MG/5ML	A219495	001	Jul 02, 2025	Jun	NEWA
	AB	APPCO	25MG/5ML	A208909	001	Jan 14, 2025	Jan	NEWA
	AB	STRIDES PHARMA	25MG/5ML	A201355	001	Aug 14, 2013	Apr	CAHN

NITROGLYCERIN

OINTMENT;TRANSDERMAL

NITROGLYCERIN

AB	ENCUBE	2%	A218235	001	Apr 15, 2025	Apr	NFTG
AB	+! FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Apr	CFTG

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP	ASPIRO	EQ 1MG BASE/ML	A219163	001	Jan 31, 2025	Jan	NEWA
AP	BIOCON PHARMA	EQ 1MG BASE/ML	A219443	001	Mar 21, 2025	Mar	NEWA

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT	AUROBINDO PHARMA	100,000 UNITS/GM	A219527	001	Mar 21, 2025	Mar	NEWA
	@ CHARTWELL RX	100,000 UNITS/GM	A065315	001	May 31, 2006	Apr	CAHN

POWDER;TOPICAL

NYSTATIN

>D>	AT	ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Jun	DISC
>A>	@		100,000 UNITS/GM	A065175	001	Dec 17, 2004	Jun	DISC

SUSPENSION;ORAL

NYSTATIN

AA	XTTRIUM LABS INC	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jan	CAHN
----	------------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	CHARTWELL RX	100,000 UNITS/GM;0.1%	A208326	001	Oct 26, 2016	Apr	CAHN
----	--------------	-----------------------	---------	-----	--------------	-----	------

OFLOXACINSOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

@	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	DISC
---	--------	------	---------	-----	--------------	-----	------

OLANZAPINEINJECTABLE; INTRAMUSCULAR
OLANZAPINE

AP	QILU	10MG/VIAL	A218116	001	May 16, 2025	May	NEWA
AP	UBI	10MG/VIAL	A211072	001	Jun 11, 2025	May	NEWA

OLICERIDINESOLUTION; INTRAVENOUS
OLINVYK

@ +	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020	Jan	DISC
@ +		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020	Jan	DISC

OLIVE OIL; SOYBEAN OILEMULSION; INTRAVENOUS
CLINOLIPID 20%

>D>	@ +	BAXTER HLTHCARE CORP	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun	CMFD
>A>	+!		16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun	CMFD

OLMESARTAN MEDOXOMILTABLET; ORAL
OLMESARTAN MEDOXOMIL

AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Mar	CMFD
AB		20MG	A205482	002	Apr 24, 2017	Mar	CMFD
AB		40MG	A205482	003	Apr 24, 2017	Mar	CMFD

OMAVELOXOLONECAPSULE; ORAL
SKYCLARYS

+!	BIOGEN US	50MG	N216718	001	Feb 28, 2023	Jan	CAHN
----	-----------	------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERSCAPSULE; ORAL
LOVAZA

AB	+!	WAYLIS THERAP	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb	CAHN
----	----	---------------	--	---------	-----	--------------	-----	------

OMIDENEPAG ISOPROPYLSOLUTION; OPHTHALMIC
OMLONTI

>D>	@ +	OCUVEX THERAP	0.002%	N215092	001	Sep 22, 2022	Jun	CMFD
>A>	+!		0.002%	N215092	001	Sep 22, 2022	Jun	CMFD

ONDANSETRONTABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

AB	IPCA LABS LTD	4MG	A209389	001	Oct 30, 2023	May	CMFD	
AB		8MG	A209389	002	Oct 30, 2023	May	CMFD	
	@	NORVIUM BIOSCIENCE	4MG	A078139	001	Jun 25, 2007	Feb	CAHN
	@		8MG	A078139	002	Jun 25, 2007	Feb	CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

@	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006	Mar	DISC
---	--------------------	----------------	---------	-----	--------------	-----	------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

	@	APOTEX	EQ 4MG BASE	A077306	001	Jun 25, 2007	Mar	DISC
	@		EQ 8MG BASE	A077306	002	Jun 25, 2007	Mar	DISC
AB	IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	May	CMFD	
AB		EQ 8MG BASE	A203761	002	Jan 23, 2014	May	CMFD	

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

>A>	AB	SHANDONG	EQ 30MG BASE	A217274	001	Jul 09, 2025	Jun	NEWA
>A>	AB		EQ 45MG BASE	A217274	002	Jul 09, 2025	Jun	NEWA
>A>	AB		EQ 75MG BASE	A217274	003	Jul 09, 2025	Jun	NEWA
	AB	ZHEJIANG POLY PHARM	EQ 75MG BASE	A218009	001	Nov 24, 2023	Mar	CAHN
		FOR SUSPENSION;ORAL						
		OSELTAMIVIR PHOSPHATE						
	AB	JUBILANT GENERICS	EQ 6MG BASE/ML	A213695	001	Mar 03, 2025	Feb	NEWA

OSPEMIFENE

TABLET;ORAL

OSPEMIFENE

@ HETERO LABS LTD V

60MG

A215574 001 Feb 13, 2024 Apr DISC

OSPHENA

+! DUCHESNAY

60MG

N203505 001 Feb 26, 2013 Apr CTEC

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

AP HETERO LABS LTD VI

50MG/10ML (5MG/ML)

A217925 001 Jan 27, 2025 Jan NEWA

AP 100MG/20ML (5MG/ML)

A217925 002 Jan 27, 2025 Jan NEWA

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB LEADING

10MG

A218261 001 Mar 03, 2025 Feb NEWA

AB

15MG

A218261 002 Mar 03, 2025 Feb NEWA

AB

30MG

A218261 003 Mar 03, 2025 Feb NEWA

OXCARBAZEPINE

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

AB AJANTA PHARMA LTD

150MG

A217659 001 Feb 22, 2024 Apr CMFD

AB

300MG

A217659 002 Feb 22, 2024 Apr CMFD

AB

600MG

A217659 003 Feb 22, 2024 Apr CMFD

@ AUROBINDO PHARMA LTD

150MG

A219241 001 Apr 30, 2025 May DISC

AB

150MG

A219241 001 Apr 30, 2025 Apr NEWA

@

300MG

A219241 002 Apr 30, 2025 May DISC

AB

300MG

A219241 002 Apr 30, 2025 Apr NEWA

@

600MG

A219241 003 Apr 30, 2025 May DISC

AB

600MG

A219241 003 Apr 30, 2025 Apr NEWA

AB RICONPHARMA LLC

150MG

A215796 001 Nov 22, 2024 Apr CMFD

AB

300MG

A215796 002 Nov 22, 2024 Apr CMFD

AB

600MG

A215796 003 Nov 22, 2024 Apr CMFD

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

@ PHARM ASSOC

100MG/5ML

A206822 001 Aug 15, 2017 Apr DISC

@ VISTAPHARM LLC

100MG/5ML

A202537 001 Jul 30, 2012 Jan CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

@ NOVEL LABS INC

5MG

A204021 001 Jun 12, 2017 Feb DISC

@

10MG

A204021 002 Jun 12, 2017 Feb DISC

@

15MG

A204021 003 Jun 12, 2017 Feb DISC

@

20MG

A204021 004 Jun 12, 2017 Feb DISC

@

30MG

A204021 005 Jun 12, 2017 Feb DISC

PACLITAXEL

POWDER;INTRAVENOUS

PACLITAXEL

AB CIPLA

100MG/VIAL

A209657 001 Apr 10, 2025 Mar NEWA

AB SHUANGCHENG

100MG/VIAL

A216355 001 May 15, 2025 May NEWA

PALBOCICLIB

TABLET; ORAL

PALBOCICLIB

@	ZYDUS LIFESCIENCES	75MG	A215570	001	Jun 05, 2024	Apr CAHN
@		100MG	A215570	002	Jun 05, 2024	Apr CAHN
@		125MG	A215570	003	Jun 05, 2024	Apr CAHN

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

AB	DR REDDYS	3MG	A205559	001	Feb 19, 2025	Feb NEWA
AB		6MG	A205559	002	Feb 19, 2025	Feb NEWA
AB		9MG	A205559	003	Feb 19, 2025	Feb NEWA

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 40MG BASE	A217923	001	Mar 31, 2025	Mar NEWA
AB	CIPLA	EQ 40MG BASE	A217458	001	Mar 31, 2025	Mar NEWA

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	ALEMBIC	EQ 40MG BASE/VIAL	A219230	001	Mar 31, 2025	Mar NEWA
AP	DEVA HOLDING AS	EQ 40MG BASE/VIAL	A215074	001	May 16, 2025	May NEWA

POWDER; INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	May CMFD
	@	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Feb DISC
AP	+! HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	May CTEC
	+!	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Feb CTEC

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	GRAVITI PHARMS	EQ 20MG BASE	A219087	001	Jan 16, 2025	Jan NEWA
AB		EQ 40MG BASE	A219087	002	Jan 16, 2025	Jan NEWA
	@	INGENUS PHARMS LLC	A211368	001	Mar 01, 2019	Jan DISC

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

AB	CHARTWELL RX	1MCG	A091412	001	Jun 24, 2014	Apr CAHN
AB		2MCG	A091412	002	Jun 24, 2014	Apr CAHN
AB		4MCG	A091412	003	Jun 24, 2014	Apr CAHN

SOLUTION; INTRAVENOUS

PARICALCITOL

AP	CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr CAHN
AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr CAHN
AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr CAHN

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

@	BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022	May DISC
@		EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022	May DISC

SOLUTION; INTRAVENOUS

PEMETREXED DISODIUM

>D>	+!	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022	Jun DISC
>A>	@ +		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022	Jun DISC
>D>	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jun DISC
>A>	@ +		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jun DISC
>D>	+!		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jun DISC
>A>	@ +		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jun DISC
>D>	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jun DISC
>A>	@ +		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jun DISC

PENCICLOVIRCREAM; TOPICAL
PENCICLOVIR

BX	TORRENT	1%	A216981	001	Aug 07, 2023	Mar	CTEC
----	---------	----	---------	-----	--------------	-----	------

PERAMPANELTABLET; ORAL
FYCOMPA

AB	+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	May	CFTG
AB	+		4MG	N202834	002	Oct 22, 2012	May	CFTG
AB	+		6MG	N202834	003	Oct 22, 2012	May	CFTG
AB	+		8MG	N202834	004	Oct 22, 2012	May	CFTG
AB	+		10MG	N202834	005	Oct 22, 2012	May	CFTG
AB	+		12MG	N202834	006	Oct 22, 2012	May	CFTG

PERAMPANEL

AB		TEVA PHARMS USA INC	2MG	A209801	001	May 23, 2025	May	NFTG
AB			4MG	A209801	002	May 23, 2025	May	NFTG
AB			6MG	A209801	003	May 23, 2025	May	NFTG
AB			8MG	A209801	004	May 23, 2025	May	NFTG
AB			10MG	A209801	005	May 23, 2025	May	NFTG
AB			12MG	A209801	006	May 23, 2025	May	NFTG

PERPHENAZINETABLET; ORAL
PERPHENAZINE

AB		JUBILANT GENERICS	2MG	A213694	001	Mar 18, 2025	Mar	NEWA
AB			4MG	A213694	002	Mar 18, 2025	Mar	NEWA
AB			8MG	A213694	003	Mar 18, 2025	Mar	NEWA
AB			16MG	A213694	004	Mar 18, 2025	Mar	NEWA

PHENDIMETRAZINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

	+	ACERTIS PHARMS	105MG	N018074	001		May	CAHN
TABLET; ORAL								
BONTRIL PDM								
AA	+	BAUSCH	35MG	A085272	001		Mar	CAHN
PHENDIMETRAZINE TARTRATE								
AA		ACERTIS PHARMS	35MG	A085588	001		May	CAHN
	@	MPP PHARMA	35MG	A203600	001	Dec 27, 2017	May	CAHN

PHENTERMINE HYDROCHLORIDE; TOPIRAMATECAPSULE, EXTENDED RELEASE; ORAL
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

>A>	AB	DR REDDYS LABS SA	EQ 7.5MG BASE; 46MG	A208175	002	Jun 12, 2025	Jun	NEWA
>A>	AB		EQ 11.25MG BASE; 69MG	A208175	003	Jun 12, 2025	Jun	NEWA
>A>	AB		EQ 15MG BASE; 92MG	A208175	004	Jun 12, 2025	Jun	NEWA
>A>	AB		EQ 3.75MG BASE; 23MG	A208175	001	Jun 12, 2025	Jun	NEWA

PHENYLEPHRINE HYDROCHLORIDESOLUTION; INTRAVENOUS
BIORPHEN

AP	+	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb	CFTG
PHENYLEPHRINE HYDROCHLORIDE								
AP		SOMERSET THERAPS LLC	0.5MG/5ML (0.1MG/ML)	A215617	001	Feb 14, 2025	Feb	NFTG
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE								
>A>	+	DR REDDYS LABS SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	Jun	CAHN
>D>	+	SINETICA SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	Jun	CAHN
	+		20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	May	NEWA

PHENYTOINSUSPENSION; ORAL
PHENYTOIN

	@	VISTAPHARM LLC	125MG/5ML	A040342	001	Jan 31, 2001	Jan	CAHN
	@		125MG/5ML	A040342	002	Aug 18, 2005	Jan	CAHN

PHYTONADIONE

	INJECTABLE; INJECTION							
	PHYTONADIONE							
AB1	CAPLIN	10MG/ML	A219212	001	Apr 17, 2025	Apr	NEWA	
	TABLET; ORAL							
	PHYTONADIONE							
	@ HIKMA	5MG	A212112	001	Dec 19, 2024	Feb	DISC	

PILOCARPINE HYDROCHLORIDE

	SOLUTION; OPHTHALMIC							
	PILOCARPINE HYDROCHLORIDE							
AB	AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr	NFTG	
	VUITY							
AB	+! ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr	CFTG	

PINDOLOL

	TABLET; ORAL							
	PINDOLOL							
AB	MPP PHARMA	5MG	A205415	001	Jan 13, 2016	May	CAHN	
AB		10MG	A205415	002	Jan 13, 2016	May	CAHN	

PIOGLITAZONE HYDROCHLORIDE

	TABLET; ORAL							
	PIOGLITAZONE HYDROCHLORIDE							
	@ AVIV PHARMA	EQ 15MG BASE	A078472	001	Feb 13, 2013	May	CAHN	
	@	EQ 30MG BASE	A078472	002	Feb 13, 2013	May	CAHN	
	@	EQ 45MG BASE	A078472	003	Feb 13, 2013	May	CAHN	

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

	POWDER; INTRAVENOUS							
	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER							
	+! B BRAUN MEDICAL	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N206056	001	Apr 03, 2025	Apr	NEWA	
	+!	EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N206056	002	Apr 03, 2025	Apr	NEWA	
	+!	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N206056	003	Apr 03, 2025	Apr	NEWA	

PIROXICAM

	CAPSULE; ORAL							
	PIROXICAM							
AB	SOLIS PHARMS	10MG	A074118	002	Jun 15, 1993	Apr	CAHN	
AB		20MG	A074118	001	Jun 15, 1993	Apr	CAHN	

PITOLISANT HYDROCHLORIDE

	TABLET; ORAL							
	WAKIX							
	+ HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Feb	CAHN	
	+!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Feb	CAHN	

PLERIXAFOR

	SOLUTION; SUBCUTANEOUS							
	PLERIXAFOR							
>A> AP	HETERO LABS LTD VI	24MG/1.2ML (20MG/ML)	A217560	001	Jun 16, 2025	Jun	NEWA	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

	FOR SOLUTION; ORAL							
	PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE							
	@ SOLIS PHARMS	420GM/BOT; 1.48GM/BOT; 5.72GM/BO T; 11.2GM/BOT	A202060	001	Mar 08, 2017	Apr	CAHN	

POLYMYXIN B SULFATE

	INJECTABLE; INJECTION							
	POLYMYXIN B SULFATE							
>D> AP	ADRASTEA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Jun	DISC	
>A>	@	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Jun	DISC	

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

@	APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	DISC
@		2MG	A210164	002	Jun 11, 2024	Jan	DISC
@		3MG	A210164	003	Jun 11, 2024	Jan	DISC
@		4MG	A210164	004	Jun 11, 2024	Jan	DISC
@	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Apr	DISC
@		2MG	A210236	002	Sep 26, 2024	Apr	DISC
@		3MG	A210236	003	Sep 26, 2024	Apr	DISC
@		4MG	A210236	004	Sep 26, 2024	Apr	DISC
<u>POMALYST</u>							
+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Apr	CTEC
+		2MG	N204026	002	Feb 08, 2013	Apr	CTEC
+		3MG	N204026	003	Feb 08, 2013	Apr	CTEC
+	!	4MG	N204026	004	Feb 08, 2013	Apr	CTEC

POSACONAZOLE

TABLET, DELAYED RELEASE; ORAL

POSACONAZOLE

AB	MSN	100MG	A218434	001	Feb 24, 2025	Feb	NEWA
AB	QILU PHARM HAINAN	100MG	A217720	001	Apr 23, 2025	Apr	NEWA

POTASSIUM CHLORIDE

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

AA	AJENAT PHARMS	20MEQ	A212183	001	May 06, 2019	Jan	CAHN
AA	+!	GENUS	N208019	001	Aug 19, 2015	Jan	CHRS
	@ +	40MEQ	N208019	003	Aug 25, 2023	Jan	DISC

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AP	NEXUS	2MEQ/ML	A217704	001	Aug 14, 2023	Mar	CAHN
----	-------	---------	---------	-----	--------------	-----	------

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA	AJENAT PHARMS	20MEQ/15ML	A216156	001	Mar 07, 2023	Jan	CAHN
AA		40MEQ/15ML	A216156	002	Mar 07, 2023	Jan	CAHN
AA	ASCENT PHARMS INC	20MEQ/15ML	A211992	001	Apr 09, 2025	Mar	NEWA
AA		40MEQ/15ML	A211992	002	Apr 09, 2025	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1	GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Apr	CAHN
AB1		20MEQ	A214395	002	Jan 28, 2021	Apr	CAHN
AB2	NORVIUM BIOSCIENCE	8MEQ	A204662	001	Aug 21, 2014	May	CAHN
AB2		10MEQ	A204662	002	Aug 21, 2014	May	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	OTSUKA ICU MEDCL	149MG/100ML; 450MG/100ML	A078446	001	Sep 10, 2008	May	CAHN
----	------------------	--------------------------	---------	-----	--------------	-----	------

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION; INTRAVENOUS

POTASSIUM PHOSPHATES

AP	CIPLA	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	A217892	001	Jan 24, 2025	Jan	NEWA
AP		3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	A217892	002	Jan 24, 2025	Jan	NEWA
AP		11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	A217892	003	Jan 24, 2025	Jan	NEWA
<u>POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>							
	+!	FRESENIUS KABI USA	N212832	004	May 09, 2025	May	NEWA
	+!		N212832	005	May 09, 2025	May	NEWA

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

AP	+ ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Feb	CFTG
AP	+!	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Feb	CFTG
<u>PRALATREXATE</u>							
AP	DR REDDYS	20MG/ML (20MG/ML)	A206183	001	Mar 10, 2025	Feb	NFTG

SOLUTION;INTRAVENOUS
PRALATREXATE

AP 40MG/2ML (20MG/ML) A206183 002 Mar 10, 2025 Feb NFTG

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

@	AVIV PHARMA	0.125MG	A091450	001	Oct 08, 2010	May	CAHN
@		0.25MG	A091450	002	Oct 08, 2010	May	CAHN
@		0.5MG	A091450	003	Oct 08, 2010	May	CAHN
@		1MG	A091450	004	Oct 08, 2010	May	CAHN
@		1.5MG	A091450	005	Oct 08, 2010	May	CAHN

PREDNISOLONE

>A> SOLUTION;ORAL

>A> PREDNISOLONE

>A> AA	!	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun	CDFR
>A>	@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Jun	CDFR
>A>	@	IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999	Jun	CDFR
>A> AA		LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	Jun	CDFR
>A>	@	NESHER PHARMS	15MG/5ML	A040364	001	Apr 10, 2002	Jun	CDFR
>A>	@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Jun	CDFR
>A> AA			15MG/5ML	A040571	001	Aug 25, 2005	Jun	CDFR
>A>	@	PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003	Jun	CDFR
>A>	@	TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000	Jun	CDFR
>A> AA		TULEX PHARMS INC	15MG/5ML	A219509	001	Jun 23, 2025	Jun	NEWA
>A>	@	WE PHARMS	15MG/5ML	A040192	001	May 28, 1998	Jun	CDFR
>A>		PRELONE						
>A> AA		TEVA	15MG/5ML	A089081	001	Feb 04, 1986	Jun	CDFR

>D> SYRUP;ORAL

>D> PREDNISOLONE

>D> AA	!	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun	CDFR
>D>	@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Jun	CDFR
>D>	@	IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999	Jun	CDFR
>D> AA		LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	Jun	CDFR
>D>	@	NESHER PHARMS	15MG/5ML	A040364	001	Apr 10, 2002	Jun	CDFR
>D>	@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Jun	CDFR
>D> AA			15MG/5ML	A040571	001	Aug 25, 2005	Jun	CDFR
>D>	@	PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003	Jun	CDFR
>D>	@	TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000	Jun	CDFR
>D>	@	WE PHARMS	15MG/5ML	A040192	001	May 28, 1998	Jun	CDFR
>D>		PRELONE						
>D> AA		TEVA	15MG/5ML	A089081	001	Feb 04, 1986	Jun	CDFR

PREDNISOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
PREDNISOLONE ACETATE

AB AMNEAL 1% A218256 001 Jun 11, 2025 May NEWA

PREDNISONE

TABLET;ORAL

PREDNISONE

	@	AIPING PHARM INC	5MG	A080336	002		Jan	CAHN
AB	+!	HIKMA	1MG	A080352	002	Apr 22, 1982	Apr	CMS1
AB	+!		2.5MG	A080352	003	Apr 22, 1982	Apr	CMS1
AB	+!		10MG	A080352	004		Apr	CMS1
AB	+!		20MG	A080352	005		Apr	CMS1
AB	+!		50MG	A080352	006		Apr	CMS1
AB		POINTVIEW HLDINGS	5MG	A212629	001	Dec 05, 2023	Apr	CAHN
AB			10MG	A212629	002	Dec 05, 2023	Apr	CAHN
AB			20MG	A212629	003	Dec 05, 2023	Apr	CAHN

PREGABALIN

CAPSULE;ORAL

PREGABALIN

@	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Apr	DISC
@		50MG	A091025	002	Jul 09, 2020	Apr	DISC
@		75MG	A091025	003	Jul 09, 2020	Apr	DISC
@		100MG	A091025	004	Jul 09, 2020	Apr	DISC
@		150MG	A091025	005	Jul 09, 2020	Apr	DISC
@		200MG	A091025	006	Jul 09, 2020	Apr	DISC
@		225MG	A091025	007	Jul 09, 2020	Apr	DISC

CAPSULE;ORAL
PREGABALIN

	@		300MG	A091025	008	Jul 09, 2020	Apr	DISC
	@	APOTEX	25MG	A211685	001	Jul 07, 2021	Apr	DISC
	@		50MG	A211685	002	Jul 07, 2021	Apr	DISC
	@		75MG	A211685	003	Jul 07, 2021	Apr	DISC
	@		100MG	A211685	004	Jul 07, 2021	Apr	DISC
	@		150MG	A211685	005	Jul 07, 2021	Apr	DISC
	@		200MG	A211685	006	Jul 07, 2021	Apr	DISC
	@		225MG	A211685	007	Jul 07, 2021	Apr	DISC
	@		300MG	A211685	008	Jul 07, 2021	Apr	DISC
AB		HLTHCARE	25MG	A091222	001	Feb 21, 2025	Feb	NEWA
AB			50MG	A091222	002	Feb 21, 2025	Feb	NEWA
AB			75MG	A091222	003	Feb 21, 2025	Feb	NEWA
AB			100MG	A091222	004	Feb 21, 2025	Feb	NEWA
AB			150MG	A091222	005	Feb 21, 2025	Feb	NEWA
AB			200MG	A091222	006	Feb 21, 2025	Feb	NEWA
AB			225MG	A091222	007	Feb 21, 2025	Feb	NEWA
AB			300MG	A091222	008	Feb 21, 2025	Feb	NEWA
AB		JUBILANT GENERICS	25MG	A209530	001	May 20, 2025	May	NEWA
AB			50MG	A209530	002	May 20, 2025	May	NEWA
AB			75MG	A209530	003	May 20, 2025	May	NEWA
AB			100MG	A209530	004	May 20, 2025	May	NEWA
AB			150MG	A209530	005	May 20, 2025	May	NEWA
AB			200MG	A209530	006	May 20, 2025	May	NEWA
AB			225MG	A209530	007	May 20, 2025	May	NEWA
AB			300MG	A209530	008	May 20, 2025	May	NEWA
>D>	AB	MACLEODS PHARMS LTD	25MG	A205924	001	Nov 12, 2024	Jun	DISC
>A>	@		25MG	A205924	001	Nov 12, 2024	Jun	DISC
>D>	AB		50MG	A205924	002	Nov 12, 2024	Jun	DISC
>A>	@		50MG	A205924	002	Nov 12, 2024	Jun	DISC
>D>	AB		75MG	A205924	003	Nov 12, 2024	Jun	DISC
>A>	@		75MG	A205924	003	Nov 12, 2024	Jun	DISC
>D>	AB		100MG	A205924	004	Nov 12, 2024	Jun	DISC
>A>	@		100MG	A205924	004	Nov 12, 2024	Jun	DISC
>D>	AB		150MG	A205924	005	Nov 12, 2024	Jun	DISC
>A>	@		150MG	A205924	005	Nov 12, 2024	Jun	DISC
>D>	AB		200MG	A205924	006	Nov 12, 2024	Jun	DISC
>A>	@		200MG	A205924	006	Nov 12, 2024	Jun	DISC
>D>	AB		225MG	A205924	007	Nov 12, 2024	Jun	DISC
>A>	@		225MG	A205924	007	Nov 12, 2024	Jun	DISC
>D>	AB		300MG	A205924	008	Nov 12, 2024	Jun	DISC
>A>	@		300MG	A205924	008	Nov 12, 2024	Jun	DISC
AB		TORRENT	25MG	A206942	001	Feb 21, 2025	Feb	NEWA
AB			50MG	A206942	002	Feb 21, 2025	Feb	NEWA
AB			75MG	A206942	003	Feb 21, 2025	Feb	NEWA
AB			100MG	A206942	004	Feb 21, 2025	Feb	NEWA
AB			150MG	A206942	005	Feb 21, 2025	Feb	NEWA
AB			200MG	A206942	006	Feb 21, 2025	Feb	NEWA
AB			225MG	A206942	007	Feb 21, 2025	Feb	NEWA
AB			300MG	A206942	008	Feb 21, 2025	Feb	NEWA

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

	@	ALVOGEN	82.5MG	A211593	001	Apr 13, 2021	Feb	DISC
	@		165MG	A211593	002	Apr 13, 2021	Feb	DISC
	@		330MG	A211593	003	Apr 13, 2021	Feb	DISC
	@	APOTEX	165MG	A213313	001	Apr 13, 2021	Jan	DISC
	@		330MG	A213313	002	Apr 13, 2021	Jan	DISC
AB		HQ PHARMA	330MG	A217857	001	Jan 28, 2025	Jan	NEWA

PRIMIDONE

TABLET;ORAL
PRIMIDONE

	@	CHARTWELL RX	50MG	A040862	001	Oct 03, 2008	Apr	CAHN
	@		250MG	A040862	002	Oct 03, 2008	Apr	CAHN

PROBENECID; SULOPENEM ETZADROXIL

TABLET;ORAL
ORLYNVAH

	@ +	ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024	Apr	DISC
--	-----	---------------	-------------	---------	-----	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDEINJECTABLE; INJECTION
PROCAINAMIDE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A218674	001	Feb 04, 2025	Jan	NEWA
AP		500MG/ML	A218674	002	Feb 04, 2025	Jan	NEWA

PROCHLORPERAZINESUPPOSITORY; RECTAL
COMPAZINE

@ +	GLAXOSMITHKLINE	2.5MG	N011127	003		Mar	CRLD
@ +		5MG	N011127	001		Mar	CMS1
@ +		5MG	N011127	001		Mar	CRLD
@ +		25MG	N011127	002		Mar	CMS1
@ +		25MG	N011127	002		Mar	CRLD

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

@	NEXUS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Apr	DISC
---	-------	----------------	---------	-----	--------------	-----	------

PROCHLORPERAZINE MALEATETABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	CEROVENE INC	EQ 5MG BASE	A217847	001	May 19, 2025	May	NEWA
AB		EQ 10MG BASE	A217847	002	May 19, 2025	May	NEWA

PROGESTERONECAPSULE; ORAL
PROMETRIUM

AB	+ ACERTIS PHARMS	100MG	N019781	001	May 14, 1998	May	CAHN
AB	+!	200MG	N019781	002	Oct 15, 1999	May	CAHN
	@	300MG	N019781	003	Oct 15, 1999	May	CAHN

PROMETHAZINE HYDROCHLORIDESYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE

>A>	AA	COSETTE	6.25MG/5ML	A091675	001	Jun 28, 2012	Jun	CAHN
	AA	STRIDES PHARMA	6.25MG/5ML	A040891	001	Mar 13, 2009	Apr	CAHN
>D>	AA	TRIS PHARMA INC	6.25MG/5ML	A091675	001	Jun 28, 2012	Jun	CAHN
	AA	PROMETHAZINE PLAIN						
	AA	+! XTTRIUM LABS INC	6.25MG/5ML	A087953	001	Nov 15, 1982	Feb	CAHN

PROPARACAINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
PROPARACAINE HYDROCHLORIDE

AT	MANKIND PHARMA	0.5%	A219136	001	May 21, 2025	May	NEWA
----	----------------	------	---------	-----	--------------	-----	------

PROTAMINE SULFATESOLUTION; INTRAVENOUS
PROTAMINE SULFATE

@	HIKMA	50MG/5ML (10MG/ML)	A089475	002	Jun 07, 1988	May	NEWA
---	-------	--------------------	---------	-----	--------------	-----	------

PROTRIPTYLINE HYDROCHLORIDETABLET; ORAL
PROTRIPTYLINE HYDROCHLORIDE

AB	! EPIC PHARMA LLC	10MG	A202220	002	Nov 19, 2012	Apr	CHRS
	@ HIKMA	5MG	A078913	001	Sep 16, 2008	Apr	DISC
	@	10MG	A078913	002	Sep 16, 2008	Apr	DISC

PRUCALOPRIDE SUCCINATETABLET; ORAL
PRUCALOPRIDE SUCCINATE

>A>	AB	AGGREGA	EQ 1MG BASE	A219193	001	Jun 24, 2025	Jun	NEWA
>A>	AB		EQ 2MG BASE	A219193	002	Jun 24, 2025	Jun	NEWA
>A>	AB	ALKEM LABS LTD	EQ 1MG BASE	A218295	001	Jun 24, 2025	Jun	NEWA
>A>	AB		EQ 2MG BASE	A218295	002	Jun 24, 2025	Jun	NEWA
>A>	AB	ANNORA PHARMA	EQ 1MG BASE	A219160	001	Jun 24, 2025	Jun	NEWA
>A>	AB		EQ 2MG BASE	A219160	002	Jun 24, 2025	Jun	NEWA
>A>	AB	APOTEX	EQ 1MG BASE	A218977	001	Jun 24, 2025	Jun	NEWA
>A>	AB		EQ 2MG BASE	A218977	002	Jun 24, 2025	Jun	NEWA
>A>	AB	APPCO	EQ 1MG BASE	A218963	001	Jun 24, 2025	Jun	NEWA

TABLET;ORAL

PRUCALOPRIDE SUCCINATE

>A>	AB		EQ 2MG BASE	A218963	002	Jun 24, 2025	Jun NEWA
>A>	AB	H2-PHARMA	EQ 1MG BASE	A219216	001	Jun 24, 2025	Jun NEWA
>A>	AB		EQ 2MG BASE	A219216	002	Jun 24, 2025	Jun NEWA
>A>	AB	HIKMA	EQ 1MG BASE	A217662	001	Jun 24, 2025	Jun NEWA
>A>	AB		EQ 2MG BASE	A217662	002	Jun 24, 2025	Jun NEWA
>A>	AB	LUPIN LTD	EQ 1MG BASE	A218847	001	Jun 24, 2025	Jun NEWA
>A>	AB		EQ 2MG BASE	A218847	002	Jun 24, 2025	Jun NEWA
>A>	AB	MSN	EQ 1MG BASE	A218177	001	Jun 24, 2025	Jun NEWA
>A>	AB		EQ 2MG BASE	A218177	002	Jun 24, 2025	Jun NEWA
>A>	AB	SKG PHARMA	EQ 1MG BASE	A218812	001	Jun 24, 2025	Jun NEWA
>A>	AB		EQ 2MG BASE	A218812	002	Jun 24, 2025	Jun NEWA
>A>	AB	SOMERSET THERAP	EQ 1MG BASE	A219078	001	Jun 24, 2025	Jun NEWA
>A>	AB		EQ 2MG BASE	A219078	002	Jun 24, 2025	Jun NEWA
>A>	AB	TORRENT	EQ 1MG BASE	A218778	001	Jun 24, 2025	Jun NEWA
>A>	AB		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jun NEWA
>A>	AB	ZENARA	EQ 1MG BASE	A218795	001	Jun 24, 2025	Jun NEWA
>A>	AB		EQ 2MG BASE	A218795	002	Jun 24, 2025	Jun NEWA

PYRIMETHAMINE

TABLET;ORAL

PYRIMETHAMINE

@	ALVOGEN	25MG		A211271	001	Jul 27, 2021	May DISC
---	---------	------	--	---------	-----	--------------	----------

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB	GRAVITI PHARMS	EQ 25MG BASE		A077380	001	Mar 27, 2012	Feb CAHN
AB		EQ 50MG BASE		A077380	002	Mar 27, 2012	Feb CAHN
AB		EQ 100MG BASE		A077380	003	Mar 27, 2012	Feb CAHN
AB		EQ 150MG BASE		A077380	004	Mar 27, 2012	Feb CAHN
AB		EQ 200MG BASE		A077380	005	Mar 27, 2012	Feb CAHN
AB		EQ 300MG BASE		A077380	006	Mar 27, 2012	Feb CAHN
AB		EQ 400MG BASE		A077380	007	Mar 27, 2012	Feb CAHN
	SEROQUEL						
AB	+! CHEPLAPHARM	EQ 25MG BASE		N020639	001	Sep 26, 1997	Mar CAHN
AB	+	EQ 50MG BASE		N020639	007	Oct 04, 2005	Mar CAHN
AB	+	EQ 100MG BASE		N020639	002	Sep 26, 1997	Mar CAHN
	@ +	EQ 150MG BASE		N020639	004	Dec 20, 1998	Mar CAHN
AB	+	EQ 200MG BASE		N020639	003	Sep 26, 1997	Mar CAHN
AB	+!	EQ 300MG BASE		N020639	005	Jul 26, 2000	Mar CAHN
AB	+	EQ 400MG BASE		N020639	006	Oct 04, 2005	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB	MEDICAP LABS	EQ 50MG BASE		A202939	001	May 09, 2017	Feb CAHN
AB		EQ 150MG BASE		A202939	002	May 09, 2017	Feb CAHN
AB		EQ 200MG BASE		A202939	003	May 09, 2017	Feb CAHN
AB		EQ 300MG BASE		A202939	004	May 09, 2017	Feb CAHN
AB		EQ 400MG BASE		A202939	005	May 09, 2017	Feb CAHN
	SEROQUEL XR						
AB	+ CHEPLAPHARM	EQ 50MG BASE		N022047	001	May 17, 2007	Mar CAHN
AB	+	EQ 150MG BASE		N022047	005	Aug 11, 2008	Mar CAHN
AB	+!	EQ 200MG BASE		N022047	002	May 17, 2007	Mar CAHN
AB	+	EQ 300MG BASE		N022047	003	May 17, 2007	Mar CAHN
AB	+	EQ 400MG BASE		N022047	004	May 17, 2007	Mar CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS

	+! MSD SUB MERCK	EQ 400MG BASE		N022145	001	Oct 12, 2007	Jan CTEC
	ISENTRESS HD						
AB	+! MSD SUB MERCK	EQ 600MG BASE		N022145	002	May 26, 2017	Apr CFTG
	RALTEGRAVIR POTASSIUM						
	@ HETERO LABS LTD III	EQ 400MG BASE		A203540	001	Dec 19, 2024	Jan DISC
AB	LUPIN LTD	EQ 600MG BASE		A217990	001	May 06, 2025	Apr NFTG

RAMELTEON

TABLET;ORAL

RAMELTEON

AB	APPCO	8MG	A213815	001	Oct 26, 2020	Mar	CAHN
BX	AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Mar	CTEC
BX	I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar	CTEC
BX	XIROMED	8MG	A216209	001	Nov 25, 2022	Mar	CTEC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@	APOTEX	EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar	DISC
	@		EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar	DISC
>A>	@	MPP PHARMA	EQ 150MG BASE	A203694	001	Nov 30, 2017	Jun	CAHN
>A>	@		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jun	CAHN
>D>	@	NOSTRUM LABS INC	EQ 150MG BASE	A203694	001	Nov 30, 2017	Jun	CAHN
>D>	@		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jun	CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		ARTHUR GRP	500MG	A212781	001	Mar 23, 2020	Jan	CAHN
AB			1GM	A212781	002	Mar 23, 2020	Jan	CAHN
AB	!	CADILA	1GM	A210188	002	Aug 19, 2019	Mar	CHRS
AB		JUBILANT GENERICS	500MG	A211361	001	Apr 15, 2025	Apr	NEWA
AB			1GM	A211361	002	Apr 15, 2025	Apr	NEWA
	@	SUN PHARM	500MG	A211707	001	May 28, 2019	Mar	DISC
	@		1GM	A211707	002	May 28, 2019	Mar	DISC
>D>	AB	TORRENT	500MG	A210407	001	Feb 04, 2025	Jun	DISC
>A>			500MG	A210407	001	Feb 04, 2025	Jun	DISC
	AB		500MG	A210407	001	Feb 04, 2025	Jan	NEWA
>D>	AB		1GM	A210407	002	Feb 04, 2025	Jun	DISC
>A>			1GM	A210407	002	Feb 04, 2025	Jun	DISC
	AB		1GM	A210407	002	Feb 04, 2025	Jan	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

	@	CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Apr	CAHN
	@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Apr	CAHN
AB		TORRENT	EQ 0.5MG BASE	A210150	001	May 05, 2025	Apr	NEWA
AB			EQ 1MG BASE	A210150	002	May 05, 2025	Apr	NEWA

REGORAFENIB

TABLET;ORAL

REGORAFENIB

AB		ACTAVIS LABS FL	40MG	A209728	001	Jan 13, 2025	Jan	NFTG
		STIVARGA						
AB	+	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Jan	CFTG

>D> REMDESIVIR

>D> SOLUTION;INTRAVENOUS

>D> VEKLURY

>D>	+	GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	N214787	002	Oct 22, 2020	Jun	DISC
>A>	@ +		100MG/20ML (5MG/ML)	N214787	002	Oct 22, 2020	Jun	DISC

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

	@	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Feb	DISC
	@		2MG	A077571	003	Jul 11, 2013	Feb	DISC

RIFAMPIN

CAPSULE;ORAL

RIFADIN

	@ +	SANOFI AVENTIS US	150MG	N050420	002		Apr	CMS1
--	-----	-------------------	-------	---------	-----	--	-----	------

RILPIVIRINE HYDROCHLORIDETABLET, FOR SUSPENSION;ORAL
EDURANT PED

+! JANSSEN PRODS EQ 2.5MG BASE N219016 001 Mar 15, 2024 May CMFD

RILUZOLETABLET;ORAL
RILUZOLE

AB NORVIUM BIOSCIENCE 50MG A203042 001 Jul 01, 2013 Feb CAHN

RISDIPLAMTABLET;ORAL
EVRYSDI

+! GENENTECH INC 5MG N219285 001 Feb 11, 2025 Feb NEWA

RISEDRONATE SODIUMTABLET, DELAYED RELEASE;ORAL
RISEDRONATE SODIUM

@ SUN PHARM 35MG A203925 001 Jul 09, 2019 Apr DISC

RISPERIDONESOLUTION;ORAL
RISPERIDONE

@ APOZEAL PHARMS 1MG/ML A078909 001 Jul 29, 2009 Apr CAHN

@ LANNETT CO INC 1MG/ML A079158 001 Dec 03, 2010 Feb DISC

TABLET;ORAL
RISPERIDONE

@ APOTEX INC 0.25MG A077953 001 Sep 15, 2008 Mar DISC

@ 0.5MG A077953 002 Sep 15, 2008 Mar DISC

@ 1MG A077953 003 Sep 15, 2008 Mar DISC

@ 2MG A077953 004 Sep 15, 2008 Mar DISC

@ 3MG A077953 005 Sep 15, 2008 Mar DISC

@ 4MG A077953 006 Sep 15, 2008 Mar DISC

RIVAROXABANFOR SUSPENSION;ORAL
RIVAROXABAN

>A> AB ALKEM LABS LTD 1MG/ML A218502 001 Jun 26, 2025 Jun NFTG

XARELTO

>D> +! JANSSEN PHARMS 1MG/ML N215859 001 Dec 20, 2021 Jun CFTG

>A> AB +! 1MG/ML N215859 001 Dec 20, 2021 Jun CFTG

TABLET;ORAL
RIVAROXABAN

AB ALEMBIC 2.5MG A210301 001 May 14, 2025 May NEWA

AB 10MG A210301 002 May 14, 2025 May NFTG

AB 15MG A210301 003 May 14, 2025 May NFTG

AB 20MG A210301 004 May 14, 2025 May NFTG

AB APOTEX 2.5MG A217810 001 May 02, 2025 Apr NEWA

AB ASCENT PHARMS INC 2.5MG A219332 001 May 14, 2025 May NEWA

AB 10MG A219332 002 May 14, 2025 May NFTG

AB 15MG A219332 003 May 14, 2025 May NFTG

AB 20MG A219332 004 May 14, 2025 May NFTG

AB AUROBINDO PHARMA LTD 2.5MG A208544 001 Apr 10, 2025 Apr NEWA

AB 10MG A208544 002 May 15, 2025 May NEWA

AB 15MG A208544 003 May 15, 2025 May NEWA

AB 20MG A208544 004 May 15, 2025 May NEWA

AB BIOCON PHARMA 2.5MG A218107 001 May 14, 2025 May NEWA

AB 10MG A218107 002 May 14, 2025 May NFTG

AB 15MG A218107 003 May 14, 2025 May NFTG

AB 20MG A218107 004 May 14, 2025 May NFTG

AB BRECKENRIDGE 10MG A208220 001 May 15, 2025 May NEWA

AB 15MG A208220 002 May 15, 2025 May NEWA

AB 20MG A208220 003 May 15, 2025 May NEWA

AB CHANGZHOU PHARM 10MG A216995 001 May 14, 2025 May NFTG

AB 15MG A216995 002 May 14, 2025 May NFTG

AB 20MG A216995 003 May 14, 2025 May NFTG

AB DR REDDYS 2.5MG A208534 001 May 14, 2025 May NEWA

AB 10MG A208534 002 May 14, 2025 May NFTG

AB 15MG A208534 003 May 14, 2025 May NFTG

AB 20MG A208534 004 May 14, 2025 May NFTG

AB INVAGEN PHARMS 10MG A208543 001 May 14, 2025 May NFTG

TABLET;ORAL

RIVAROXABAN

AB			15MG	A208543	002	May 14, 2025	May	NFTG
AB			20MG	A208543	003	May 14, 2025	May	NFTG
AB	LUPIN LTD		2.5MG	A208555	001	Mar 03, 2025	Feb	NFTG
AB			10MG	A208555	002	May 14, 2025	May	NFTG
AB			15MG	A208555	003	May 14, 2025	May	NFTG
AB			20MG	A208555	004	May 14, 2025	May	NFTG
AB	MACLEODS PHARMS LTD		2.5MG	A213114	001	May 14, 2025	May	NEWA
AB			10MG	A213114	002	May 14, 2025	May	NFTG
AB			15MG	A213114	003	May 14, 2025	May	NFTG
AB			20MG	A213114	004	May 14, 2025	May	NFTG
AB	SUNSHINE		10MG	A213348	001	May 14, 2025	May	NFTG
AB			15MG	A213348	002	May 14, 2025	May	NFTG
AB			20MG	A213348	003	May 14, 2025	May	NFTG
AB	TARO		2.5MG	A208557	001	Mar 03, 2025	Feb	NFTG
<u>XARELTO</u>								
AB	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018	Feb	CFTG
AB	+		10MG	N022406	001	Jul 01, 2011	May	CFTG
AB	+		15MG	N022406	002	Nov 04, 2011	May	CFTG
AB	+		20MG	N022406	003	Nov 04, 2011	May	CFTG

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

@	ALVOGEN		4.6MG/24HR	A204403	001	Sep 03, 2015	Mar	DISC
@			9.5MG/24HR	A204403	002	Sep 03, 2015	Mar	DISC
@			13.3MG/24HR	A204403	003	Aug 31, 2015	Mar	DISC

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	NORVIUM BIOSCIENCE		EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	CAHN
AB			EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

>D>	AB	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun	DISC
>A>	@		EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun	DISC
>D>	AB		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun	DISC
>A>	@		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	MANKIND PHARMA		50MG/5ML (10MG/ML)	A219674	001	May 29, 2025	May	NEWA
AP			100MG/10ML (10MG/ML)	A219674	002	May 29, 2025	May	NEWA

SOLUTION;INTRAVENOUS

ROCURONIUM BROMIDE

>A>	+	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	N217472	001	Jun 09, 2025	Jun	NEWA
>A>	+		100MG/10ML (10MG/ML)	N217472	002	Jun 09, 2025	Jun	NEWA

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB	AUROBINDO PHARMA LTD		250MCG	A213298	002	Jan 31, 2025	Jan	NEWA
@	SENORES PHARMS		250MCG	A208236	002	Oct 19, 2023	Feb	CAHN
@			500MCG	A208236	001	Oct 03, 2018	Feb	CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	ANTHEA PHARMA		40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Mar	NEWA
AP			150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Mar	NEWA
AP			200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Mar	NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	+	ASTRAZENECA	EQ 5MG BASE	N021366	002	Aug 12, 2003	Jan	CAHN
AB	+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Jan	CAHN
AB	+		EQ 20MG BASE	N021366	004	Aug 12, 2003	Jan	CAHN
AB	+		EQ 40MG BASE	N021366	005	Aug 12, 2003	Jan	CAHN

TABLET;ORAL

ROSUVASTATIN CALCIUM

>D>	AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A207296	001	Nov 06, 2024	Jun	DISC
>A>	@		EQ 5MG BASE	A207296	001	Nov 06, 2024	Jun	DISC
>D>	AB		EQ 10MG BASE	A207296	002	Nov 06, 2024	Jun	DISC
>A>	@		EQ 10MG BASE	A207296	002	Nov 06, 2024	Jun	DISC
>D>	AB		EQ 20MG BASE	A207296	003	Nov 06, 2024	Jun	DISC
>A>	@		EQ 20MG BASE	A207296	003	Nov 06, 2024	Jun	DISC
>D>	AB		EQ 40MG BASE	A207296	004	Nov 06, 2024	Jun	DISC
>A>	@		EQ 40MG BASE	A207296	004	Nov 06, 2024	Jun	DISC
	AB	MANKIND PHARMA	EQ 5MG BASE	A206603	001	May 16, 2025	May	NEWA
	AB		EQ 10MG BASE	A206603	002	May 16, 2025	May	NEWA
	AB		EQ 20MG BASE	A206603	003	May 16, 2025	May	NEWA
	AB		EQ 40MG BASE	A206603	004	May 16, 2025	May	NEWA
	AB	ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	May	CMFD
	AB		EQ 10MG BASE	A206513	002	Mar 01, 2019	May	CMFD
	AB		EQ 20MG BASE	A206513	003	Mar 01, 2019	May	CMFD
	AB		EQ 40MG BASE	A206513	004	Mar 01, 2019	May	CMFD

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

>D>	AB	HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Jun	CAHN
>A>	AB		40MG/ML	A207363	001	Apr 23, 2019	Jun	CAHN
	AB	MSN	40MG/ML	A214817	001	Apr 15, 2025	Apr	NEWA

SACUBITRIL; VALSARTAN

TABLET;ORAL

SACUBITRIL AND VALSARTAN

	AB	DR REDDYS	24MG;26MG	A213627	001	Jan 13, 2025	Jan	NEWA
	AB		49MG;51MG	A213627	002	Jan 13, 2025	Jan	NEWA
	AB		97MG;103MG	A213627	003	Jan 13, 2025	Jan	NEWA
	AB	LUPIN	24MG;26MG	A213808	001	Jan 08, 2025	Jan	NEWA
	AB		49MG;51MG	A213808	002	Jan 08, 2025	Jan	NEWA
	AB		97MG;103MG	A213808	003	Jan 08, 2025	Jan	NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

>A>	AB	ZENARA	EQ 50MG BASE	A215913	001	Jun 13, 2025	Jun	NEWA
>A>	AB		EQ 100MG BASE	A215913	002	Jun 13, 2025	Jun	NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

ZELVYSIA

>A>	AB	AUCTA	100MG/PACKET	A218645	001	Apr 29, 2025	Jun	CAHN
>A>	AB		500MG/PACKET	A218645	002	Apr 29, 2025	Jun	CAHN
>D>	AB	SHANGHAI AUCYUN	100MG/PACKET	A218645	001	Apr 29, 2025	Jun	CAHN
	AB		100MG/PACKET	A218645	001	Apr 29, 2025	Apr	NEWA
>D>	AB		500MG/PACKET	A218645	002	Apr 29, 2025	Jun	CAHN
	AB		500MG/PACKET	A218645	002	Apr 29, 2025	Apr	NEWA

TABLET;ORAL

SAPROPTERIN DIHYDROCHLORIDE

	AB	AUROBINDO PHARMA	100MG	A216797	001	Jun 09, 2025	May	NEWA
	AB	ZENARA	100MG	A218797	001	Jun 11, 2025	May	NEWA

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

	AB	AMNEALS PHARMS	1MG/72HR	A218384	001	Jun 09, 2025	May	NEWA
	AB	! RICONPHARMA LLC	1MG/72HR	A212342	001	Nov 24, 2020	Apr	CHRS
	AB	+ BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Apr	CHRS

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID

AP	+!	AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021	May	CFTG
	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Feb	CTEC
AP	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Jan	CFTG

SOLUTION;INTRAVENOUS
SELENIUM ACID

AP	+		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019	Feb CFTG
AP	ASPIRO		EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A219633	001	Jun 11, 2025	May NFTG
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219633	002	Jun 11, 2025	May NEWA
AP	FRESENIUS KABI USA		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jan NFTG
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Feb CMS1
>A>	GLAND		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219629	001	Jul 08, 2025	Jun NEWA
AP	SUN PHARM		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219547	001	Feb 20, 2025	Feb NEWA

SELINEXORTABLET;ORAL
XPOVIO

	+	KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	Mar NEWA
--	---	--------------------	------	---------	-----	--------------	----------

SELPERCATINIBCAPSULE;ORAL
RETEVMO

	+	ELI LILLY AND CO	40MG	N213246	001	May 08, 2020	Jan CAHN
	+	!	80MG	N213246	002	May 08, 2020	Jan CAHN

TABLET;ORAL
RETEVMO

	+	ELI LILLY AND CO	40MG	N218160	001	Apr 10, 2024	Jan CAHN
	+		80MG	N218160	002	Apr 10, 2024	Jan CAHN
	+		120MG	N218160	003	Apr 10, 2024	Jan CAHN
	+	!	160MG	N218160	004	Apr 10, 2024	Jan CAHN

SEVELAMER CARBONATEFOR SUSPENSION;ORAL
SEVELAMER CARBONATE

	@	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jan DISC
	@		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jan DISC
>D>	AB	TORRENT	800MG/PACKET	A215909	001	Feb 27, 2025	Jun DISC
>A>	@		800MG/PACKET	A215909	001	Feb 27, 2025	Jun DISC
	AB		800MG/PACKET	A215909	001	Feb 27, 2025	Feb NEWA
>D>	AB		2.4GM/PACKET	A215909	002	Feb 27, 2025	Jun DISC
>A>	@		2.4GM/PACKET	A215909	002	Feb 27, 2025	Jun DISC
	AB		2.4GM/PACKET	A215909	002	Feb 27, 2025	Feb NEWA

TABLET;ORAL

SEVELAMER CARBONATE

>A>	@	EPIC PHARMA LLC	800MG	A212970	001	Apr 09, 2020	Jun CAHN
>D>	@	SINOTHERAPEUTICS INC	800MG	A212970	001	Apr 09, 2020	Jun CAHN

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

BX		AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Mar CTEC
BX			800MG	A212599	002	Jul 11, 2023	Mar CTEC
AB		NAVINTA LLC	800MG	A218966	001	Feb 03, 2025	Jan NEWA

SILDENAFIL CITRATEFOR SUSPENSION;ORAL
SILDENAFIL CITRATE

AB		APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
AB		CHARTWELL RX	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN

TABLET;ORAL

SILDENAFIL CITRATE

AB		JUBILANT GENERICS	EQ 20MG BASE	A202954	001	Mar 06, 2025	Feb NEWA
----	--	-------------------	--------------	---------	-----	--------------	----------

SILODOSINCAPSULE;ORAL
SILODOSIN

>D>	AB	TORRENT	4MG	A210396	001	Feb 10, 2025	Jun DISC
>A>	@		4MG	A210396	001	Feb 10, 2025	Jun DISC
	AB		4MG	A210396	001	Feb 10, 2025	Jan NEWA
>D>	AB		8MG	A210396	002	Feb 10, 2025	Jun DISC

	CAPSULE;ORAL							
	SILODOSIN							
>A>	@	8MG	A210396	002	Feb 10, 2025	Jun	DISC	
AB		8MG	A210396	002	Feb 10, 2025	Jan	NEWA	
	<u>SIMVASTATIN</u>							
	TABLET;ORAL							
	SIMVASTATIN							
AB	GRAVITI PHARMS	5MG	A077752	005	Jan 23, 2008	Feb	CAHN	
AB		10MG	A077752	001	Dec 20, 2006	Feb	CAHN	
AB		20MG	A077752	002	Dec 20, 2006	Feb	CAHN	
AB		40MG	A077752	003	Dec 20, 2006	Feb	CAHN	
AB		80MG	A077752	004	Dec 20, 2006	Feb	CAHN	
	<u>SIPONIMOD</u>							
	TABLET;ORAL							
	MAYZENT							
	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May	CTEC
AB	+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr	CFTG
	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May	CTEC
AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Apr	CFTG
	+		EQ 2MG BASE	N209884	002	Mar 26, 2019	May	CTEC
AB	+		EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr	CFTG
	SIPONIMOD							
	@	RICONPHARMA LLC	EQ 0.25MG BASE	A218444	001	Apr 22, 2025	May	DISC
AB			EQ 0.25MG BASE	A218444	001	Apr 22, 2025	Apr	NFTG
	@		EQ 1MG BASE	A218444	002	Apr 22, 2025	May	DISC
AB			EQ 1MG BASE	A218444	002	Apr 22, 2025	Apr	NFTG
	@		EQ 2MG BASE	A218444	003	Apr 22, 2025	May	DISC
AB			EQ 2MG BASE	A218444	003	Apr 22, 2025	Apr	NFTG
	<u>SIROLIMUS</u>							
	POWDER;INTRAVENOUS							
	FYARRO							
	+	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Mar	CAHN
	<u>SITAGLIPTIN HYDROCHLORIDE</u>							
	SOLUTION;ORAL							
	BRYNOVIN							
	+	AZURITY	EQ 25MG BASE/ML	N219122	001	Jan 16, 2025	Jan	NEWA
	<u>SODIUM BICARBONATE</u>							
	INJECTABLE;INJECTION							
	SODIUM BICARBONATE							
>A>	AP	ANTHEA PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Jun	NEWA
	<u>SODIUM CHLORIDE</u>							
	INJECTABLE;INJECTION							
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	+	OTSUKA ICU MEDCL	900MG/100ML	N016366	001		May	CAHN
	SOLUTION;INJECTION							
	SODIUM CHLORIDE 0.9%							
AP		NEXUS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Mar	CAHN
AP			180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Mar	CAHN
	<u>SODIUM IODIDE I-131</u>							
	SOLUTION;ORAL							
	SODIUM IODIDE I 131							
>A>	AA	CARDINAL HLTH 414	250-1000mCi	A213615	001	Jun 12, 2025	Jun	NEWA
	<u>SODIUM NITROPRUSSIDE</u>							
	INJECTABLE;INJECTION							
	SODIUM NITROPRUSSIDE							
	@	XIROMED	25MG/ML	A211277	001	Oct 29, 2020	Jan	DISC
	<u>SODIUM POLYSTYRENE SULFONATE</u>							
	POWDER;ORAL, RECTAL							
	SODIUM POLYSTYRENE SULFONATE							
AA		AJENAT PHARMS	454GM/BOT	A205727	001	Feb 23, 2016	Jan	CAHN

		SUSPENSION;ORAL, RECTAL SODIUM POLYSTYRENE SULFONATE						
AA		LYNE	15GM/60ML	A214912	001	Jun 10, 2025	May	NEWA
		<u>SOLIFENACIN SUCCINATE</u>						
		TABLET;ORAL SOLIFENACIN SUCCINATE						
>D>	AB	TORRENT	5MG	A209424	001	Mar 04, 2025	Jun	DISC
>A>		@	5MG	A209424	001	Mar 04, 2025	Jun	DISC
	AB		5MG	A209424	001	Mar 04, 2025	Feb	NEWA
>D>	AB		10MG	A209424	002	Mar 04, 2025	Jun	DISC
>A>		@	10MG	A209424	002	Mar 04, 2025	Jun	DISC
	AB		10MG	A209424	002	Mar 04, 2025	Feb	NEWA
		<u>SORAFENIB TOSYLATE</u>						
		TABLET;ORAL SORAFENIB TOSYLATE						
		@ APOTEX	EQ 200MG BASE	A212228	001	Jan 27, 2025	Mar	DISC
AB			EQ 200MG BASE	A212228	001	Jan 27, 2025	Jan	NEWA
		<u>SPIRONOLACTONE</u>						
		SUSPENSION;ORAL SPIRONOLACTONE						
AB		HETERO LABS LTD III	25MG/5ML	A218085	001	Feb 21, 2025	Feb	NEWA
		TABLET;ORAL SPIRONOLACTONE						
AB		GRAVITI PHARMS	25MG	A219494	001	Jan 23, 2025	Jan	NEWA
AB			50MG	A219494	002	Jan 23, 2025	Jan	NEWA
AB			100MG	A219494	003	Jan 23, 2025	Jan	NEWA
		<u>STREPTOZOCIN</u>						
		INJECTABLE;INJECTION ZANOSAR						
		@ + TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Feb	DISC
		<u>SUCCINYLCHOLINE CHLORIDE</u>						
		INJECTABLE;INJECTION SUCCINYLCHOLINE CHLORIDE						
AP		FRESENIUS KABI USA	20MG/ML	A217885	001	Feb 21, 2025	Feb	NEWA
		SOLUTION;INTRAMUSCULAR, INTRAVENOUS SUCCINYLCHOLINE CHLORIDE						
AP		FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Jan	NEWA
		<u>SUCRALFATE</u>						
		SUSPENSION;ORAL SUCRALFATE						
AB		PADAGIS US	1GM/10ML	A211780	001	Apr 14, 2025	Apr	NEWA
		TABLET;ORAL SUCRALFATE						
AB		CHARTWELL RX	1GM	A074415	001	Jun 08, 1998	Apr	CAHN
		<u>SULINDAC</u>						
		TABLET;ORAL SULINDAC						
AB		EPIC PHARMA	150MG	A072711	002	Mar 25, 1991	Mar	CMS1
		<u>SUMATRIPTAN SUCCINATE</u>						
		INJECTABLE;SUBCUTANEOUS SUMATRIPTAN SUCCINATE						
>D>		@ SUN PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun	CMFD
>A>	AB		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun	CMFD
		<u>SUNITINIB MALATE</u>						
		CAPSULE;ORAL SUNITINIB MALATE						
AB		FOSUN WANBANG	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Jan	CAHN
AB			EQ 25MG BASE	A218012	002	Aug 21, 2023	Jan	CAHN
AB			EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Jan	CAHN
AB			EQ 50MG BASE	A218012	004	Aug 21, 2023	Jan	CAHN
AB		MSN	EQ 12.5MG BASE	A214824	001	Feb 14, 2025	Feb	NEWA

CAPSULE;ORAL

SUNITINIB MALATE							
AB		EQ 25MG BASE	A214824	002	Feb 14, 2025	Feb	NEWA
AB		EQ 37.5MG BASE	A214824	003	Feb 14, 2025	Feb	NEWA
AB		EQ 50MG BASE	A214824	004	Feb 14, 2025	Feb	NEWA

SUZETRIGINE

TABLET;ORAL

JOURNAVX								
	+!	VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025	Jan	NEWA

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS								
AB		AJENAT PHARMS	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Jan	CAHN
AB			EQ 1MG BASE	A206651	002	Nov 30, 2017	Jan	CAHN
AB			EQ 5MG BASE	A206651	003	Nov 30, 2017	Jan	CAHN

INJECTABLE;INJECTION

PROGRAF								
AP	+!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Jan	CTEC
AP		NEXUS	EQ 5MG BASE/ML	A217108	001	Feb 12, 2025	Jan	NEWA
OINTMENT;TOPICAL								
TACROLIMUS								
BX		ENCUBE	0.1%	A212387	001	Oct 10, 2023	Mar	CTEC

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA								
@ +		PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Feb	DISC
@ +			EQ 0.25MG BASE	N211651	001	Oct 16, 2018	Feb	DISC
@ +			EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Feb	DISC
@ +			EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Feb	DISC
@ +			EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Feb	DISC
@ +			EQ 1MG BASE	N211651	002	Oct 16, 2018	Feb	DISC

>A> TALETRECTINIB ADIPATE

>A> CAPSULE;ORAL

IBTROZI								
>A>	+!	NUVATION	EQ 200MG BASE	N219713	001	Jun 11, 2025	Jun	NEWA

TAMOXIFEN CITRATE

TABLET;ORAL

TAMOXIFEN CITRATE								
@		APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011	Mar	DISC
@			EQ 20MG BASE	A090878	002	Sep 23, 2011	Mar	DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

FLOMAX								
@ +		SANOFI	0.4MG	N020579	001	Apr 15, 1997	Feb	DISC
TAMSULOSIN HYDROCHLORIDE								
AB		ASCENT PHARMS INC	0.4MG	A214730	001	May 04, 2022	Feb	CMFD
AB		GRAVITI PHARMS	0.4MG	A219767	001	May 01, 2025	Apr	NEWA
AB	!	ZYDUS PHARMS USA INC	0.4MG	A078225	001	Apr 27, 2010	Feb	CHRS

TAPINAROF

CREAM;TOPICAL

VTAMA								
	+!	ORGANON LLC	1%	N215272	001	May 23, 2022	May	CAHN

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE								
AB		COSETTE	0.05%	A208662	002	Mar 10, 2025	Feb	NEWA

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION
OSTEOLITE

@	SUN PHARM INDS INC	N/A	N017972	001		Feb	CAHN
---	--------------------	-----	---------	-----	--	-----	------

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION
DRAXIMAGE DTPA

AP	+	JUBILANT	N/A	N018511	001	Dec 29, 1989	Mar	CFTG
AP		CURIUM	N/A	A215146	001	Mar 26, 2025	Mar	NFTG

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE; INJECTION
TECHNETIUM TC 99M SESTAMIBI

@	SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009	May	DISC
---	--------------------	----------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SODIUM PERTECHNETATESOLUTION; INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M

@	SUN PHARM INDS INC	12mCi/ML	N017321	001		May	CAHN
@		24mCi/ML	N017321	002		May	CAHN
@		48mCi/ML	N017321	003		May	CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

>D>		ULTRA-TECHNEKOW FM						
>D>	+	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jun	CTNA
>D>	@		0.25-3 CI/GENERATOR	N017243	002		Jun	CTNA
>A>		ULTRA-TECHNEKOW V4						
>A>	+	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jun	CTNA
>A>	@		0.25-3 CI/GENERATOR	N017243	002		Jun	CTNA
		SOLUTION; INTRAVENOUS, ORAL						
>A>		DRYTEC						
>A>	@ +	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Jun	CTNA
>A>	@		830-16600mCi/GENERATOR	N017693	001		Jun	CTNA
>D>		TECHNETIUM TC 99M GENERATOR						
>D>	@ +	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Jun	CTNA
>D>	@		830-16600mCi/GENERATOR	N017693	001		Jun	CTNA

TELMISARTANTABLET; ORAL
MICARDIS

AB	+	BOEHRINGER INGELHEIM	80MG	N020850	002	Nov 10, 1998	Feb	CHRS
		TELMISARTAN						
AB	!	INVENTIA	80MG	A205150	003	Oct 30, 2015	Feb	CHRS
AB		MACLEODS PHARMS LTD	20MG	A203986	001	Jan 15, 2025	Jan	NEWA
AB			40MG	A203986	002	Jan 15, 2025	Jan	NEWA
AB			80MG	A203986	003	Jan 15, 2025	Jan	NEWA

TEMAZEPAMCAPSULE; ORAL
TEMAZEPAM

@	SUN PHARM INDUSTRIES	7.5MG	A078581	001	Sep 08, 2009	Mar	DISC
---	----------------------	-------	---------	-----	--------------	-----	------

TEMOZOLOMIDECAPSULE; ORAL
TEMOZOLOMIDE

	@	NEXTSOURCE	5MG	A203898	001	Feb 10, 2016	Mar	CAHN
	@		20MG	A203898	002	Feb 10, 2016	Mar	CAHN
	@		100MG	A203898	003	Feb 10, 2016	Mar	CAHN
AB			100MG	A203898	003	Feb 10, 2016	Mar	CMFD
	@		140MG	A203898	004	Feb 10, 2016	Mar	CAHN
AB			140MG	A203898	004	Feb 10, 2016	Mar	CMFD
	@		180MG	A203898	005	Feb 10, 2016	Mar	CAHN
AB			180MG	A203898	005	Feb 10, 2016	Mar	CMFD
	@		250MG	A203898	006	Feb 10, 2016	Mar	CAHN
AB			250MG	A203898	006	Feb 10, 2016	Mar	CMFD
	@	TRI-SOURCE PHARMA	5MG	A203898	001	Feb 10, 2016	Apr	CAHN
	@		20MG	A203898	002	Feb 10, 2016	Apr	CAHN
AB			100MG	A203898	003	Feb 10, 2016	Apr	CAHN

CAPSULE;ORAL
TEMOZOLOMIDE

AB		140MG	A203898	004	Feb 10, 2016	Apr	CAHN
AB		180MG	A203898	005	Feb 10, 2016	Apr	CAHN
AB		250MG	A203898	006	Feb 10, 2016	Apr	CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219482	001	May 12, 2025	May	NEWA
AB			EQ 2MG BASE	A219482	002	May 12, 2025	May	NEWA
AB			EQ 5MG BASE	A219482	003	May 12, 2025	May	NEWA
AB			EQ 10MG BASE	A219482	004	May 12, 2025	May	NEWA
>D>	@	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun	CAHN
>A>	@		EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun	CAHN
>D>	@		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun	CAHN
>A>	@		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun	CAHN
>D>	@		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun	CAHN
>A>	@		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun	CAHN
>D>	@		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun	CAHN
>A>	@		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun	CAHN

TERBINAFFINE HYDROCHLORIDE

TABLET;ORAL
TERBINAFFINE HYDROCHLORIDE

@	BRECKENRIDGE PHARM	EQ 250MG BASE	A077714	001	Jun 04, 2010	Mar	DISC
---	--------------------	---------------	---------	-----	--------------	-----	------

TERIFLUNOMIDE

TABLET;ORAL
TERIFLUNOMIDE

@	APOTEX	7MG	A209601	001	Nov 02, 2018	Feb	DISC	
@		14MG	A209601	002	Nov 02, 2018	Feb	DISC	
AB	CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Mar	NEWA	
AB		14MG	A218663	002	Apr 07, 2025	Mar	NEWA	
>D>	@	MYLAN	7MG	A209702	001	Feb 28, 2020	Jun	CAHN
>D>	@		14MG	A209702	002	Feb 28, 2020	Jun	CAHN
>A>	@	WELDING	7MG	A209702	001	Feb 28, 2020	Jun	CAHN
>A>	@		14MG	A209702	002	Feb 28, 2020	Jun	CAHN

TERIPARATIDE

SOLUTION;SUBCUTANEOUS
BONSITY

	ALVOGEN	0.56MG/2.24ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Feb	CPOT
	FORTEO						
AP	+! LILLY	0.56MG/2.24ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Feb	CPOT
	TERIPARATIDE						
AP	+! ALMAJECT	0.56MG/2.24ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb	CPOT
AP	+!	0.6MG/2.4ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb	CTEC
AP	APOTEX	0.56MG/2.24ML (0.25MG/ML)	A211097	001	Nov 16, 2023	Feb	CPOT
AP	TEVA PHARMS USA	0.56MG/2.24ML (0.25MG/ML)	A208569	001	Nov 16, 2023	Feb	CPOT

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL
TESTOSTERONE

>D>	AT	@ ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan	DISC
>A>		@ TWI PHARMS	30MG/1.5ML ACTUATION	A209836	001	Sep 03, 2021	Jun	DISC
>A>		@	30MG/1.5ML ACTUATION	A209836	001	Sep 03, 2021	Jun	DISC

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

AA	+!	SOLIS PHARMS	80MG/15ML	A085186	001		Apr	CAHN
----	----	--------------	-----------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB		AJANTA PHARMA LTD	300MG	A218401	002	Mar 26, 2025	Mar	NEWA
AB			450MG	A218401	001	Jan 13, 2025	Jan	NEWA
>A>	AB	MPP PHARMA	400MG	A040560	003	Apr 21, 2006	Jun	CAHN
>A>	AB	!	600MG	A040560	002	Apr 21, 2006	Jun	CAHN
>D>	AB	NOSTRUM LABS INC	400MG	A040560	003	Apr 21, 2006	Jun	CAHN
>D>	AB	!	600MG	A040560	002	Apr 21, 2006	Jun	CAHN
		@ RHODES PHARMS	300MG	A214113	001	May 11, 2023	Jan	DISC

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

AP	GLAND	100MG/ML	A217800	001	Feb 24, 2025	Feb	NEWA
----	-------	----------	---------	-----	--------------	-----	------

THIOTEPAPOWDER; INTRAVENOUS
TEPADINA AND SODIUM CHLORIDE

+! ADIENNE SA 200MG

N208264 003 Apr 10, 2025 May NEWA

SOLUTION; INTRAVENOUS
TEPYLUTE

+! SHORLA 100MG/10ML (10MG/ML)

N216984 002 Feb 26, 2025 Mar NEWA

TIAGABINE HYDROCHLORIDETABLET; ORAL
TIAGABINE HYDROCHLORIDE

>D>	AB	SUN PHARM INDS	2MG	A077555	001	Nov 04, 2011	Jun	DISC
-----	----	----------------	-----	---------	-----	--------------	-----	------

>A>	@		2MG	A077555	001	Nov 04, 2011	Jun	DISC
-----	---	--	-----	---------	-----	--------------	-----	------

>D>	AB		4MG	A077555	002	Nov 04, 2011	Jun	DISC
-----	----	--	-----	---------	-----	--------------	-----	------

>A>	@		4MG	A077555	002	Nov 04, 2011	Jun	DISC
-----	---	--	-----	---------	-----	--------------	-----	------

TICAGRELORTABLET; ORAL
BRILINTA

AB	+	ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Mar	CTEC
----	---	-------------	------	---------	-----	--------------	-----	------

AB		ALEMBIC	90MG	A208576	001	May 01, 2025	Apr	NEWA
----	--	---------	------	---------	-----	--------------	-----	------

AB		APOTEX	90MG	A208584	001	May 01, 2025	Apr	NEWA
----	--	--------	------	---------	-----	--------------	-----	------

AB		INVAGEN PHARMS	90MG	A208537	001	May 05, 2025	Apr	NEWA
----	--	----------------	------	---------	-----	--------------	-----	------

AB		MSN	90MG	A208596	001	Apr 07, 2020	Mar	CMFD
----	--	-----	------	---------	-----	--------------	-----	------

	@		90MG	A208596	001	Apr 07, 2020	Feb	CAHN
--	---	--	------	---------	-----	--------------	-----	------

AB		SUNSHINE	90MG	A208508	001	Apr 06, 2020	Mar	CMFD
----	--	----------	------	---------	-----	--------------	-----	------

AB		WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Mar	CMFD
----	--	-----------------	------	---------	-----	--------------	-----	------

AB			90MG	A208390	002	Sep 04, 2018	Mar	CMFD
----	--	--	------	---------	-----	--------------	-----	------

TICLOPIDINE HYDROCHLORIDETABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

@ APOTEX 250MG

A075089 001 Jul 01, 1999 Mar DISC

TIMOLOLSOLUTION/DROPS; OPHTHALMIC
BETIMOL

>D>		+! THEA PHARMA	0.25%	N020439	001	Mar 31, 1995	Jun	DISC
-----	--	----------------	-------	---------	-----	--------------	-----	------

>A>		@ +	0.25%	N020439	001	Mar 31, 1995	Jun	DISC
-----	--	-----	-------	---------	-----	--------------	-----	------

TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

@ APOTEX EQ 0.5% BASE

A204936 001 Apr 17, 2015 May DISC

TOBRAMYCINPOWDER; INHALATION
TOBI PODHALER

+! VIATRIS 28MG

N201688 001 Mar 22, 2013 Feb CAHN

SOLUTION; INHALATION
TOBI

AN		+! VIATRIS	300MG/5ML	N050753	001	Dec 22, 1997	Feb	CAHN
----	--	------------	-----------	---------	-----	--------------	-----	------

TOFACITINIB CITRATETABLET, EXTENDED RELEASE; ORAL
TOFACITINIB CITRATE

@ DEXCEL EQ 11MG BASE

A218668 001 Dec 16, 2024 Apr DISC

XELJANZ XR

+ PFIZER EQ 11MG BASE

N208246 001 Feb 23, 2016 Apr CTEC

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

AB	PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar	CAHN
AB		2MG	A204721	002	Jan 24, 2020	Mar	CAHN

TOLVAPTAN

TABLET;ORAL

JYNARQUE

AB2	+ OTSUKA	15MG	N204441	001	Apr 23, 2018	Apr	CFTG
AB2	+	30MG	N204441	002	Apr 23, 2018	Apr	CFTG
AB	+!	45MG	N204441	003	Apr 23, 2018	Apr	CFTG
AB2	+	60MG	N204441	004	Apr 23, 2018	Apr	CFTG
AB	+	90MG	N204441	005	Apr 23, 2018	Apr	CFTG

SAMSCA

AB1	+ OTSUKA	15MG	N022275	001	May 19, 2009	Apr	CTEC
AB1	+!	30MG	N022275	002	May 19, 2009	Apr	CTEC

TOLVAPTAN

AB1	ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Apr	CTEC
AB1		30MG	A211891	001	May 19, 2020	Apr	CTEC
AB1	APOTEX	15MG	A207605	002	Sep 06, 2022	Apr	CTEC
AB1		30MG	A207605	001	May 19, 2020	Apr	CTEC
AB1	ENDO OPERATIONS	15MG	A206119	001	Feb 15, 2022	Apr	CTEC
AB1		30MG	A206119	002	Feb 15, 2022	Apr	CTEC
AB1	HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Apr	CTEC
AB1		30MG	A205646	001	Jul 16, 2021	Apr	CTEC
AB2	LUPIN LTD	15MG	A216063	001	Apr 23, 2025	Apr	NFTG
AB2		30MG	A216063	002	Apr 23, 2025	Apr	NFTG
AB		45MG	A216063	003	Apr 23, 2025	Apr	NFTG
AB2		60MG	A216063	004	Apr 23, 2025	Apr	NFTG
AB		90MG	A216063	005	Apr 23, 2025	Apr	NFTG
AB1	MSN	15MG	A216949	001	Jun 21, 2023	Apr	CTEC
AB1		30MG	A216949	002	Jun 21, 2023	Apr	CTEC

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

AB	RUBICON	15MG	A216683	001	May 27, 2025	May	NEWA
AB		25MG	A216683	002	May 27, 2025	May	NEWA
AB		50MG	A216683	003	May 27, 2025	May	NEWA
AB	ZYDUS PHARMS USA INC	50MG	A078877	003	Oct 23, 2024	May	CTEC

TABLET;ORAL

TOPIRAMATE

	@ SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	May	CAHN
	@	50MG	A090353	002	Sep 01, 2010	May	CAHN
	@	100MG	A090353	003	Sep 01, 2010	May	CAHN
	@	200MG	A090353	004	Sep 01, 2010	May	CAHN
	@ SUN PHARM	200MG	A090278	004	Mar 27, 2009	May	DISC

TORSEMIDE

TABLET;ORAL

TORSEMIDE

AB	COREPHARMA	5MG	A076894	001	May 31, 2005	Apr	CAHN
AB		10MG	A076894	002	May 31, 2005	Apr	CAHN
AB		20MG	A076894	003	May 31, 2005	Apr	CAHN
AB		100MG	A076894	004	May 31, 2005	Apr	CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

>D>	AB	APDM PHARMS	50MG	A090404	001	Jan 31, 2011	Jun	CAHN
	AB		50MG	A090404	001	Jan 31, 2011	Feb	CAHN
		@ APOTEX	50MG	A075981	001	Jul 10, 2002	Mar	DISC
		@ MERRO PHARM USA	50MG	A206706	001	Jul 02, 2019	Feb	DISC
>A>	AB	SENORES PHARMS	50MG	A090404	001	Jan 31, 2011	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

AB1	! LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Jan	CTEC
AB1		200MG	A200503	002	Aug 29, 2011	Jan	CTEC
AB1		300MG	A200503	003	Aug 29, 2011	Jan	CTEC
AB1	MACLEODS PHARMS LTD	100MG	A209404	001	Jan 31, 2025	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL
TRAMADOL HYDROCHLORIDE

AB1		200MG	A209404	002	Jan 31, 2025	Jan NEWA
AB1		300MG	A209404	003	Jan 31, 2025	Jan NEWA

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

TRAMETINIB DIMETHYL SULFOXIDE

@	HIKMA	EQ 0.5MG	A219002	001	Aug 06, 2024	Feb CAHN
@		EQ 2MG	A219002	002	Aug 06, 2024	Feb CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

@	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Jan DISC
---	--------------------	----------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS

TRANEXAMIC ACID

AP	RTU PHARMA SA	1GM/100ML (10MG/ML)	A218896	001	Jun 02, 2025	May NEWA
----	---------------	---------------------	---------	-----	--------------	----------

TABLET;ORAL

TRANEXAMIC ACID

AB	APPCO	650MG	A218729	001	Jun 11, 2025	May NEWA
----	-------	-------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

AT2	! SANDOZ	0.004%	N021994	001	Sep 21, 2006	Feb CTEC
-----	----------	--------	---------	-----	--------------	----------

TRAVOPROST

@	ALEMBIC	0.004%	A210458	001	Dec 20, 2019	Feb DISC
---	---------	--------	---------	-----	--------------	----------

AT2	! APOTEX	0.004%	A203431	001	Jul 10, 2015	Feb CTEC
-----	----------	--------	---------	-----	--------------	----------

AT2	! CHARTWELL RX	0.004%	A091340	001	Mar 01, 2013	Feb CTEC
-----	----------------	--------	---------	-----	--------------	----------

AT2	GLAND	0.004%	A218159	001	Jul 12, 2024	Feb CTEC
-----	-------	--------	---------	-----	--------------	----------

AT2	MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Feb CTEC
-----	------------	--------	---------	-----	--------------	----------

AT2	MYLAN	0.004%	A205050	001	Jul 07, 2017	Feb CTEC
-----	-------	--------	---------	-----	--------------	----------

AT2	SOMERSET THERAPS LLC	0.004%	A217228	001	Sep 23, 2024	Feb CTEC
-----	----------------------	--------	---------	-----	--------------	----------

TREOSULFAN

POWDER; INTRAVENOUS

GRAFAPEX

+	MEDEXUS	1GM/VIAL	N214759	001	Jan 21, 2025	Jan CAHN
---	---------	----------	---------	-----	--------------	----------

+		5GM/VIAL	N214759	002	Jan 21, 2025	Jan CAHN
---	--	----------	---------	-----	--------------	----------

+	MGFKSMB	1GM/VIAL	N214759	001	Jan 21, 2025	Jan NEWA
---	---------	----------	---------	-----	--------------	----------

+		5GM/VIAL	N214759	002	Jan 21, 2025	Jan NEWA
---	--	----------	---------	-----	--------------	----------

TREPROSTINIL

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

REMODULIN

>D>	+	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Jun DISC
-----	---	---------------	----------	---------	-----	--------------	----------

>A>	@ +		0.1MG/ML	N021272	006	Sep 28, 2023	Jun DISC
-----	-----	--	----------	---------	-----	--------------	----------

>D>	+		0.2MG/ML	N021272	007	Sep 28, 2023	Jun DISC
-----	---	--	----------	---------	-----	--------------	----------

>A>	@ +		0.2MG/ML	N021272	007	Sep 28, 2023	Jun DISC
-----	-----	--	----------	---------	-----	--------------	----------

>D>	+		20MG/ML	N021272	005	Jul 30, 2021	Jun DISC
-----	---	--	---------	---------	-----	--------------	----------

>A>	@ +		20MG/ML	N021272	005	Jul 30, 2021	Jun DISC
-----	-----	--	---------	---------	-----	--------------	----------

POWDER; INHALATION

TYVASO DPI

+	UNITED THERAP	0.032MG/INH	N214324	002	May 23, 2022	Jan CHRS
---	---------------	-------------	---------	-----	--------------	----------

+		0.048MG/INH	N214324	003	May 23, 2022	Jan CHRS
---	--	-------------	---------	-----	--------------	----------

+		0.08MG/INH	N214324	005	Oct 24, 2024	Jan CHRS
---	--	------------	---------	-----	--------------	----------

TREPROSTINIL SODIUM

POWDER; INHALATION

YUTREPIA

+	LIQUIDIA TECH	EQ 0.0265MG BASE/INH	N213005	001	May 23, 2025	May NEWA
---	---------------	----------------------	---------	-----	--------------	----------

+		EQ 0.053MG BASE/INH	N213005	002	May 23, 2025	May NEWA
---	--	---------------------	---------	-----	--------------	----------

+		EQ 0.0795MG BASE/INH	N213005	003	May 23, 2025	May NEWA
---	--	----------------------	---------	-----	--------------	----------

+		EQ 0.106MG BASE/INH	N213005	004	May 23, 2025	May NEWA
---	--	---------------------	---------	-----	--------------	----------

TRETINOIN

		CAPSULE;ORAL							
		TRETINOIN							
	@	BARR LABS INC	10MG	A077684	001	Jun 22, 2007	Feb	DISC	
AB	!	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Feb	CHRS	
		GEL;TOPICAL							
		RETIN-A							
AB	+!	BAUSCH	0.01%	N017955	001		Jan	CAHN	
		TRETINOIN							
AB		AUROBINDO PHARMA LTD	0.01%	A218246	001	Jan 13, 2025	Jan	NEWA	
AB			0.025%	A218245	001	Feb 27, 2025	Feb	NEWA	
AB		ENCUBE	0.01%	A217588	001	Mar 03, 2025	Feb	NEWA	
AB			0.025%	A217587	001	Mar 03, 2025	Feb	NEWA	

TRIAMCINOLONE ACETONIDE

		GEL;TOPICAL							
		ARISTOGEL							
	@ +	ASTELLAS	0.1%	A083380	001		Feb	CRLD	
		INJECTABLE; INJECTION							
		KENALOG-10							
AB	+	APOTHECON	10MG/ML	N012041	001		Feb	CTEC	
		TRIAMCINOLONE ACETONIDE							
AB		DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	Feb	NEWA	
AB			40MG/ML	A218421	001	Apr 11, 2025	Apr	NEWA	
		LOTION;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
	@	BEACH PRODS	0.025%	A204608	001	Jul 07, 2016	May	CAHN	
AT	!	XTTRIUM LABS INC	0.025%	A088450	001	Apr 01, 1985	Feb	CAHN	
AT	!		0.1%	A088451	001	Apr 03, 1985	Feb	CAHN	

TRIAMCINOLONE HEXACETONIDE

		INJECTABLE; INJECTION							
		ARISTOSPAN							
	@ +	ETHYPHARM INC	5MG/ML	N016466	001		May	CAHN	
	@ +		20MG/ML	N016466	002		May	CAHN	

TRIMIPRAMINE MALEATE

		CAPSULE;ORAL							
		SURMONTIL							
>D>	@ +	ODYSSEY PHARMS	EQ 25MG BASE	N016792	001		Jun	CAHN	
>D>	@ +		EQ 50MG BASE	N016792	002		Jun	CAHN	
>D>	@ +		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CAHN	
>A>	@ +	TEVA WOMENS	EQ 25MG BASE	N016792	001		Jun	CAHN	
>A>	@ +		EQ 50MG BASE	N016792	002		Jun	CAHN	
>A>	@ +		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CAHN	

TROSPIUM CHLORIDE

		TABLET;ORAL							
		TROSPIUM CHLORIDE							
AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb	CAHN	

URSODIOL

		TABLET;ORAL							
		URSO 250							
>A>	AB	+	ABBVIE	250MG	N020675	001	Dec 10, 1997	Jun	CAHN
>A>		@ +		250MG	N020675	001	Dec 10, 1997	Jun	DISC
>D>	AB	+	ALLERGAN	250MG	N020675	001	Dec 10, 1997	Jun	CAHN
		URSO FORTE							
>A>	AB	+!	ABBVIE	500MG	N020675	002	Jul 21, 2004	Jun	CAHN
>A>		@ +		500MG	N020675	002	Jul 21, 2004	Jun	DISC
>D>	AB	+!	ALLERGAN	500MG	N020675	002	Jul 21, 2004	Jun	CAHN
		URSODIOL							
>D>	AB		ZYDUS LIFESCIENCES	500MG	A211145	002	Oct 30, 2018	Jun	CHRS
>A>	AB	!		500MG	A211145	002	Oct 30, 2018	Jun	CHRS

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

@	APOTEX	EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar	DISC
---	--------	---------------	---------	-----	--------------	-----	------

VALBENAZINE TOSYLATE

CAPSULE; ORAL

INGREZZA

+	NEUROCRINE	EQ 60MG BASE	N209241	003	Apr 23, 2021	Feb	CTEC
---	------------	--------------	---------	-----	--------------	-----	------

VALBENAZINE TOSYLATE

@	ZYDUS LIFESCIENCES	EQ 40MG BASE	A216137	001	Aug 07, 2024	Feb	DISC
---	--------------------	--------------	---------	-----	--------------	-----	------

@		EQ 60MG BASE	A216137	002	Aug 07, 2024	Feb	DISC
---	--	--------------	---------	-----	--------------	-----	------

@		EQ 80MG BASE	A216137	003	Aug 07, 2024	Feb	DISC
---	--	--------------	---------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	SPH ZHONGXI PHARM	EQ 450MG BASE	A218027	001	Apr 16, 2025	Apr	NEWA
----	-------------------	---------------	---------	-----	--------------	-----	------

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

@	PAI HOLDINGS	250MG/5ML	A077105	001	Jul 29, 2005	Apr	CAHN
---	--------------	-----------	---------	-----	--------------	-----	------

VALSARTAN

SOLUTION; ORAL

PREXXARTAN

@	+	CARMEL BIOSCIENCES	4MG/ML	N209139	001	Dec 19, 2017	May	CPOT
---	---	--------------------	--------	---------	-----	--------------	-----	------

VALSARTAN

AB	!	NOVITIUM PHARMA	4MG/ML	A214102	001	Nov 02, 2021	May	CTEC
----	---	-----------------	--------	---------	-----	--------------	-----	------

!			4MG/ML	A214102	001	Nov 02, 2021	May	CPOT
---	--	--	--------	---------	-----	--------------	-----	------

AB		RUBICON	4MG/ML	A216460	001	Jun 05, 2025	May	NEWA
----	--	---------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

VALSARTAN

@	RENATA	40MG	A218169	001	Aug 05, 2024	Feb	DISC
---	--------	------	---------	-----	--------------	-----	------

AB		40MG	A218169	001	Aug 05, 2024	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

@		80MG	A218169	002	Aug 05, 2024	Feb	DISC
---	--	------	---------	-----	--------------	-----	------

AB		80MG	A218169	002	Aug 05, 2024	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

@		160MG	A218169	003	Aug 05, 2024	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

AB		160MG	A218169	003	Aug 05, 2024	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

@		320MG	A218169	004	Aug 05, 2024	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

AB		320MG	A218169	004	Aug 05, 2024	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Apr	CAHN
---	--------------	--------------------	---------	-----	--	-----	------

@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Apr	CAHN
---	--	--------------------	---------	-----	--------------	-----	------

@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Apr	CAHN
---	--	--------------------	---------	-----	--------------	-----	------

@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Apr	CAHN
---	--	--------------------	---------	-----	--------------	-----	------

@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Apr	CAHN
---	--	------------------	---------	-----	--------------	-----	------

@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Apr	CAHN
---	--	------------------	---------	-----	--------------	-----	------

@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Apr	CAHN
---	--	------------------	---------	-----	--------------	-----	------

@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Apr	CAHN
---	--	------------------	---------	-----	--------------	-----	------

@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Apr	CAHN
---	--	-------------------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

AP		MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CMFD
----	--	--------------------	--------------------	---------	-----	--------------	-----	------

AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CMFD
----	--	--	------------------	---------	-----	--------------	-----	------

@	PLANO PHARMS	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Mar	CAHN
---	--------------	--------------------	---------	-----	--------------	-----	------

@		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Mar	CAHN
---	--	------------------	---------	-----	--------------	-----	------

@		EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Mar	CAHN
---	--	------------------	---------	-----	--------------	-----	------

@		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Mar	CAHN
---	--	-------------------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP		GLAND	EQ 750MG BASE/VIAL	A218140	001	Mar 21, 2025	Mar	NEWA
----	--	-------	--------------------	---------	-----	--------------	-----	------

AP			EQ 1.25GM BASE/VIAL	A218140	002	Mar 21, 2025	Mar	NEWA
----	--	--	---------------------	---------	-----	--------------	-----	------

AP			EQ 1.5GM BASE/VIAL	A218140	003	Mar 21, 2025	Mar	NEWA
----	--	--	--------------------	---------	-----	--------------	-----	------

AP	+	MYLAN LABS LTD	EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018	Mar	CFTG
----	---	----------------	--------------------	---------	-----	--------------	-----	------

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

AB	AUROBINDO PHARMA	EQ 0.5MG BASE	A214595	001	May 02, 2025	Apr	NEWA
AB		EQ 1MG BASE	A214595	002	May 02, 2025	Apr	NEWA
AB	HANDA PHARMS LLC	EQ 0.5MG BASE	A213268	001	May 21, 2025	May	NEWA
AB		EQ 1MG BASE	A213268	002	May 21, 2025	May	NEWA
AB	NORVIUM BIOSCIENCE	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May	CAHN
AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	May	CAHN
	@ PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Feb	DISC
	@	EQ 1MG BASE	A217115	002	Jul 23, 2024	Feb	DISC
AB	SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Mar	NEWA
AB		EQ 1MG BASE	A216615	002	Apr 08, 2025	Mar	NEWA
AB	VIWIT PHARM	EQ 0.5MG BASE	A212879	001	May 06, 2025	Apr	NEWA
AB		EQ 1MG BASE	A212879	002	May 06, 2025	Apr	NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN IN SODIUM CHLORIDE 0.9%

@ + LONG GROVE PHARMS 50UNITS/50ML (1UNIT/ML) N217766 003 Jul 11, 2024 May DISC

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Feb	CAHN
AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Feb	CAHN
AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ABON PHARMS LLC	EQ 150MG BASE	A217841	001	Feb 07, 2025	Jan	NEWA
AB		EQ 225MG BASE	A217841	002	Feb 07, 2025	Jan	NEWA
AB	MPP PHARMA	EQ 150MG BASE	A205468	002	Mar 24, 2017	May	CAHN
AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	May	CAHN
>D> AB	TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jun	DISC
>A>	@	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jun	DISC
AB		EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jan	NEWA
>D> AB		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jun	DISC
>A>	@	EQ 75MG BASE	A218180	002	Jan 28, 2025	Jun	DISC
AB		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jan	NEWA
>D> AB		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jun	DISC
>A>	@	EQ 150MG BASE	A218180	003	Jan 28, 2025	Jun	DISC
AB		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jan	NEWA
>D> AB		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jun	DISC
>A>	@	EQ 225MG BASE	A218180	004	Jan 28, 2025	Jun	DISC
AB		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jan	NEWA

VIGABATRIN

TABLET; ORAL

VIGABATRIN

@	AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Feb	DISC
@	CARNEGIE	500MG	A215519	001	Apr 28, 2023	May	CAHN
@	RYAN LABS	500MG	A215519	001	Apr 28, 2023	Jan	DISC

VIMSELTINIB

CAPSULE; ORAL

ROMVIMZA

+	DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025	Feb	NEWA
+		20MG	N219304	002	Feb 14, 2025	Feb	NEWA
+	!	30MG	N219304	003	Feb 14, 2025	Feb	NEWA

VORICONAZOLE

FOR SUSPENSION; ORAL

VORICONAZOLE

AB	ZHEJIANG POLY PHARM	200MG/5ML	A216805	001	Jan 02, 2024	Mar	CAHN
----	---------------------	-----------	---------	-----	--------------	-----	------

ZANUBRUTINIB

CAPSULE; ORAL

BRUKINSA

+	!	BEONE MEDICINES USA	80MG	N213217	001	Nov 14, 2019	Apr	CAHN
---	---	---------------------	------	---------	-----	--------------	-----	------

	TABLET;ORAL								
	BRUKINSA								
>A>	+!	BEONE MEDICINES USA	160MG		N218785	001	Jun 10, 2025	Jun	NEWA
	<u>ZINC ACETATE</u>								
	CAPSULE;ORAL								
	GALZIN								
	+	ETON	EQ 25MG ZINC		N020458	001	Jan 28, 1997	Jan	CAHN
	+	!	EQ 50MG ZINC		N020458	002	Jan 28, 1997	Jan	CAHN
	<u>ZINC CHLORIDE</u>								
	INJECTABLE;INJECTION								
	ZINC CHLORIDE								
AP		RK PHARMA	EQ 1MG ZINC/ML		A217625	001	Apr 14, 2025	May	CAHN
AP		STIRA	EQ 1MG ZINC/ML		A217625	001	Apr 14, 2025	Apr	NEWA
	<u>ZINC SULFATE</u>								
	SOLUTION;INTRAVENOUS								
	ZINC SULFATE								
AP		ASPIRO	EQ 10MG BASE/10ML (EQ 1MG		A219585	001	May 01, 2025	Apr	NEWA
			BASE/ML)						
AP			EQ 25MG BASE/5ML (EQ 5MG		A219585	002	May 01, 2025	Apr	NEWA
			BASE/ML)						
AP			EQ 30MG BASE/10ML (EQ 3MG		A219585	003	May 01, 2025	Apr	NEWA
			BASE/ML)						
AP		STIRA	EQ 10MG BASE/10ML (EQ 1MG		A217624	001	Jun 10, 2025	May	NEWA
			BASE/ML)						
AP			EQ 25MG BASE/5ML (EQ 5MG		A217624	002	Jun 10, 2025	May	NEWA
			BASE/ML)						
AP			EQ 30MG BASE/10ML (EQ 3MG		A217624	003	Jun 10, 2025	May	NEWA
			BASE/ML)						
	<u>ZOLEDRONIC ACID</u>								
	INJECTABLE;INTRAVENOUS								
	ZOLEDRONIC ACID								
	@	APOTEX	EQ 5MG BASE/100ML		A204367	001	Dec 24, 2015	Mar	DISC
	<u>ZOLMITRIPTAN</u>								
	SPRAY;NASAL								
	ZOLMITRIPTAN								
AB		PADAGIS ISRAEL	5MG/SPRAY		A212469	002	Sep 30, 2021	Apr	CHRS
		ZOMIG							
AB		+!	AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Apr	CHRS
	<u>ZOLPIDEM TARTRATE</u>								
	TABLET;ORAL								
	AMBIEN								
AB		+ COSETTE	5MG		N019908	001	Dec 16, 1992	Jan	CAHN
AB		+	10MG		N019908	002	Dec 16, 1992	Jan	CAHN
		ZOLPIDEM TARTRATE							
	@	APOTEX INC	5MG		A077884	001	Apr 23, 2007	Mar	DISC
	@		10MG		A077884	002	Apr 23, 2007	Mar	DISC
	TABLET;SUBLINGUAL								
	EDLUAR								
AB		+ VIATRIS	5MG		N021997	001	Mar 13, 2009	Feb	CAHN
AB		+	10MG		N021997	002	Mar 13, 2009	Feb	CAHN
	TABLET, EXTENDED RELEASE;ORAL								
	AMBIEN CR								
AB		+ COSETTE	6.25MG		N021774	002	Sep 02, 2005	Jan	CAHN
AB		+	12.5MG		N021774	001	Sep 02, 2005	Jan	CAHN
		ZOLPIDEM TARTRATE							
	@	APOTEX	6.25MG		A200266	001	Sep 10, 2013	Mar	DISC
	@		12.5MG		A200266	002	Sep 10, 2013	Mar	DISC
	<u>ZONISAMIDE</u>								
	CAPSULE;ORAL								
	ZONISAMIDE								
	@	APOTEX	25MG		A077642	001	Dec 22, 2005	Mar	DISC
	@		50MG		A077642	002	Dec 22, 2005	Mar	DISC
	@		100MG		A077642	003	Dec 22, 2005	Mar	DISC
AB		MACLEODS PHARMS LTD	25MG		A219507	001	May 12, 2025	May	NEWA
AB			50MG		A219507	002	May 12, 2025	May	NEWA
AB			100MG		A219507	003	May 12, 2025	May	NEWA

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

STRIDES PHARMA 250MG;125MG A217241 001 Jan 17, 2025 Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA 0.2055MG/SPRAY A216561 001 Jan 27, 2025 Jan NEWA

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

ZYRTEC ALLERGY

+ KENVUE BRANDS 5MG N019835 003 Nov 16, 2007 Apr CMFD

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D> UNICHEM 5MG;120MG A210507 001 Sep 10, 2024 Jun DISC
>A> @ 5MG;120MG A210507 001 Sep 10, 2024 Jun DISC

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ APOTEX 100MG A074948 001 Jun 19, 1998 Mar DISC
@ 200MG A074948 002 Jul 26, 2002 Mar DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

GUARDIAN DRUG EQ 20MG BASE A216149 001 Mar 15, 2023 May CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

CONTRACT PHARMACAL 60MG A219032 001 Feb 28, 2025 Feb NEWA
180MG A219032 002 Feb 28, 2025 Feb NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 180MG;240MG A215232 001 Apr 17, 2025 Apr NEWA

IBUPROFEN

SUSPENSION/DROPS;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD 40MG/ML A213506 001 Apr 08, 2024 May CMFD

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

STRIDES PHARMA 200MG;30MG A077628 001 Aug 14, 2006 Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX 5MG A211443 001 Apr 21, 2021 Jan DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

IMODIUM A-D

@ + KENVUE BRANDS 1MG/5ML N019487 001 Mar 01, 1988 Apr DISC

LOPERAMIDE HYDROCHLORIDE

@ PAI HOLDINGS 1MG/5ML A074352 001 Nov 17, 1995 Feb CAHN

@ WOCKHARDT BIO AG 1MG/5ML A074730 001 Aug 28, 1997 Apr DISC

LORATADINE

CAPSULE; ORAL

LORATADINE

>D>	@	AUROBINDO PHARMA	10MG	A211900	001	Mar 24, 2023	Jun CMFD
>A>			10MG	A211900	001	Mar 24, 2023	Jun CMFD
>D>		CATALENT PHARMA	10MG	A215127	001	Feb 28, 2025	Jun DISC
>A>	@		10MG	A215127	001	Feb 28, 2025	Jun DISC
			10MG	A215127	001	Feb 28, 2025	Feb NEWA

TABLET, CHEWABLE; ORAL

LORATADINE

SUN PHARM

10MG

A210088 002 Apr 25, 2025 Apr NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

>A>		TARO	5%	A217998	001	Jun 30, 2025	Jun NEWA
-----	--	------	----	---------	-----	--------------	----------

MOMETASONE FUROATE

SPRAY, METERED; NASAL

MOMETASONE FUROATE

@ AUROBINDO PHARMA

0.05MG/SPRAY

A217498 001 Nov 22, 2024 May DISC

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ NOVELGENIX THERAPS

220MG

A207612 001 Nov 16, 2018 Apr DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

BAUSCH AND LOMB INC

EQ 0.1% BASE

A206046 001 Jul 26, 2017 May CMFD

EQ 0.2% BASE

A206087 001 Dec 05, 2017 Feb CMFD

GLENMARK PHARMS INC

EQ 0.2% BASE

A219557 001 Feb 28, 2025 Feb NEWA

RISING

EQ 0.1% BASE

A204392 001 Mar 21, 2018 May CMFD

EQ 0.2% BASE

A204620 001 Jun 16, 2020 Apr CMFD

OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL

OMEPRAZOLE

@ APOTEX

20MG

A210070 001 Feb 11, 2019 Jan DISC

POTASSIUM IODIDE

TABLET; ORAL

THYROSAFE

BTG INTL

130MG

A076350 002 Apr 02, 2025 Mar NFTG

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2025

NO JUNE 2025 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2025 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
	10167291	Jul 01, 2036	DP U-2519			
	10167291	Jul 01, 2036	DP U-2666			
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10167291	Jul 01, 2036	DP U-2682			
	10167291	Jul 01, 2036	DP U-2683			
	10167291	Jul 01, 2036	DP U-2684			
	10167291	Jul 01, 2036	DP U-2685			
	10167291	Jul 01, 2036	DP U-2686			
	10167291	Jul 01, 2036	DP U-2687			
	10167291	Jul 01, 2036	DP U-4109			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
	9796721	Jul 01, 2036	DS DP U-4108			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	10272083	Jan 21, 2035	U-2519		I-960	Jan 16, 2028
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	11059829	Jul 01, 2036	DS DP U-4108			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8748413	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8748413	Jul 01, 2030	DS DP			
<u>ACOLTREMOM - TRYPTYR</u>						
N 217370 001	>A> 10028920	Sep 08, 2031	U-1900		>A> NCE	May 28, 2030
	>A> 11850221	Dec 16, 2042	DP U-1900			
	>A> 9095609	Sep 08, 2031	DP U-1900			
	>A> 9433679	Sep 08, 2031	U-1900			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACOLTREMONE - TRYPTYR</u>						
N 217370 001	>A> 10028920	Sep 08, 2031	U-1900		>A> NCE	May 28, 2030
	>A> 11850221	Dec 16, 2042	DP U-1900			
	>A> 9095609	Sep 08, 2031	DP U-1900			
	>A> 9433679	Sep 08, 2031	U-1900			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	9913826	May 05, 2031	U-4046		ODE-506	Nov 22, 2031
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	12281113	Sep 10, 2041	DS DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899 001					NPP	May 09, 2028
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	7396341	Oct 10, 2026	DP	Y		
	7837235	Mar 13, 2028	DP	Y		
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	12233033	Aug 23, 2038	U-2106			
	12233033	Aug 23, 2038	U-2224			
	12233033	Aug 23, 2038	U-3180			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12168021	May 15, 2035	U-2414			
	12168022	May 15, 2035	U-2414			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	11179574	Oct 13, 2036	U-804			
	11446512	Jan 17, 2037	U-804			
	11697028	Oct 13, 2036	U-804			
	12290700	Oct 13, 2036	U-804			
	12296011	Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	12280146	Dec 08, 2043	DP			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
	>A> 12329740	Feb 09, 2038	U-2754			
	>A> 12329740	Feb 09, 2038	U-3467			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
	>A> 12329740	Feb 09, 2038	U-2754			
	>A> 12329740	Feb 09, 2038	U-3467			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	>A> 12336984	Oct 06, 2037	U-3447			
	>A> 12336984	Oct 06, 2037	U-3448			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
	12005141	Feb 24, 2041	DP U-3311			
	12226528	Feb 24, 2041	DP U-3309			
	12226528	Feb 24, 2041	DP U-3310			
	12226528	Feb 24, 2041	DP U-3311			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 001	>A> 10322117	Jan 23, 2038	DP			
	>A> 10799487	Jan 23, 2038	DP U-3448			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 002	>A> 10322117	Jan 23, 2038	DP			
	>A> 10799487	Jan 23, 2038	DP U-3448			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 003	>A> 10322117	Jan 23, 2038	DP			
	>A> 10799487	Jan 23, 2038	DP U-3448			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	>A> 12303493	Dec 03, 2035	DP			
	>A> 12303497	Jan 30, 2040	U-4201			
	>A> 12303497	Jan 30, 2040	U-4202			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	>A> 12303493	Dec 03, 2035	DP			
	>A> 12303497	Jan 30, 2040	U-4201			
	>A> 12303497	Jan 30, 2040	U-4202			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167		NPP	Apr 17, 2028
	6967208	Nov 21, 2026	DS DP U-1200		PED	Oct 17, 2028
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
	6967208	Nov 21, 2026	DS DP U-4178			
	6967208*PED	May 21, 2027				
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200		NPP	Apr 17, 2028
	6967208	Nov 21, 2026	DS DP U-1301		PED	Oct 17, 2028
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-4178			
	6967208*PED	May 21, 2027				
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				
<u>APIXABAN - ELIQUIS</u>						
N 202155 003	6967208	Nov 21, 2026	DS DP U-4179		NS	Apr 17, 2028
	6967208*PED	May 21, 2027			PED	Oct 17, 2028
	9326945	Feb 24, 2031	DP			
	9326945*PED	Aug 24, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS SPRINKLE</u>						
N 220073 001	11896586	Nov 22, 2040	DP U-4180		NP	Apr 17, 2028
	11896586*PED	May 22, 2041			PED	Oct 17, 2028
	6967208	Nov 21, 2026	DS DP U-4180			
	6967208*PED	May 21, 2027				
<u>APOMORPHINE HYDROCHLORIDE - ONAPGO</u>						
N 214056 001					NP	Feb 03, 2028
<u>APREPITANT - CINVANTI</u>						
N 209296 001	12290520	Sep 18, 2035	DP			
<u>APREPITANT - APONVIE</u>						
N 216457 001	12290520	Sep 18, 2035	DP			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	>A> 12297189	Feb 26, 2038	DP			
<u>ARIPIRAZOLE - MEZOFY</u>						
N 211448 001	9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE - MEZOFY</u>						
N 211448 002	9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE - MEZOFY</u>						
N 211448 003	9694008	Aug 07, 2033	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	12251381	Apr 09, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	12251381	Apr 06, 2039	U-543			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	12251381	Apr 06, 2039	U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	10016393	Jul 07, 2034	DP		NCE	Apr 02, 2030
	11491137	Dec 16, 2040	U-3980			
	11874283	Feb 18, 2032	U-3980			
	11998526	Dec 16, 2040	U-3980			
	12121509	Dec 16, 2040	U-3980			
	8623819	Aug 22, 2028	U-3980			
	9364458	Jul 07, 2034	DP U-3980			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2026	DS			
	9617546	Feb 14, 2026	DS	U-3673		
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	12252494	Apr 10, 2040		U-3506		
<u>AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO</u>						
N 217906 001	7112592	Jan 07, 2026	DS DP	U-4147	NP	Feb 07, 2028
	7612087	Nov 12, 2026		DP	GAIN	Feb 07, 2033
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030		DP		
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS DP			
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	>A> 11400090	Oct 29, 2038		U-4196	NCE	May 08, 2030
	>A> 11517573	Sep 11, 2040		U-4196		
	>A> 11517573	Sep 11, 2040		U-4205		
	>A> 11873296	Dec 29, 2042	DP	U-4196		
	>A> 7897792	Feb 09, 2027	DS DP			
	>A> 7928109	Aug 21, 2029	DS DP			
	>A> 8247411	Apr 17, 2028	DS DP			
<u>BACLOFEN - BACLOFEN</u>						
A 214445 001					PC	Jul 14, 2025
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 002	>A> 10392406	Apr 27, 2036	DS			
	>A> 10633397	Apr 27, 2036		U-2816		
	>A> 10633397	Apr 27, 2036		U-3000		
	>A> 10759814	Aug 09, 2037	DS DP			
	>A> 11261198	Sep 25, 2038		DP		
	>A> 11306106	Aug 09, 2037		U-2816		
	>A> 11306106	Aug 09, 2037		U-3000		
	>A> 11925648	Apr 21, 2041		DP		
	>A> 8927710	May 05, 2031		DP		
	>A> 8987441	Sep 21, 2031	DS DP			
	>A> 9815835	Jun 14, 2030		DP		
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	>A> 10392406	Apr 27, 2036	DS			
	>A> 10633397	Apr 27, 2036		U-2816		
	>A> 10633397	Apr 27, 2036		U-3000		
	>A> 10759814	Aug 09, 2037	DS DP			
	>A> 11261198	Sep 25, 2038		DP		
	>A> 11306106	Aug 09, 2037		U-2816		
	>A> 11306106	Aug 09, 2037		U-3000		
	>A> 11925648	Apr 21, 2041		DP		
	>A> 8927710	May 05, 2031		DP		
	>A> 8987441	Sep 21, 2031	DS DP			
	>A> 9815835	Jun 14, 2030		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	>A> 10392406	Apr 27, 2036	DS			
	>A> 10633397	Apr 27, 2036			U-2816	
	>A> 10633397	Apr 27, 2036			U-3000	
	>A> 10759814	Aug 09, 2037	DS DP			
	>A> 11261198	Sep 25, 2038	DP			
	>A> 11306106	Aug 09, 2037			U-2816	
	>A> 11306106	Aug 09, 2037			U-3000	
	>A> 11925648	Apr 21, 2041	DP			
	>A> 8927710	May 05, 2031	DP			
	>A> 8987441	Sep 21, 2031	DS DP			
	>A> 9815835	Jun 14, 2030	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	9463289	May 18, 2031	DP		Y	
	9808587	May 18, 2031	DP		Y	
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	9463289	May 18, 2031	DP		Y	
	9808587	May 18, 2031	DP		Y	
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP		Y	
	11395889	May 18, 2031	DP		Y	
	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP		Y	
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP		Y	
	11395889	May 18, 2031	DP		Y	
	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP		Y	
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					ODE*	Aug 09, 2026
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	>A> 9908845	Sep 05, 2034	DS DP U-3201		>A> I-968	May 14, 2028
	>A> 9908845	Sep 05, 2034	DS DP U-4176			
	>A> 9908845	Sep 05, 2034	DS DP U-4195			
	>A> RE49948	Sep 05, 2034	DS DP U-3201			
	>A> RE49948	Sep 05, 2034	DS DP U-4176			
	>A> RE49948	Sep 05, 2034	DS DP U-4195			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	12138248	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	12138248	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA</u>						
N 212209 001	12208086	Jul 29, 2042	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12208167	Feb 26, 2044	DP U-713			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	12257348	May 23, 2041	DP U-3947			
	12295935	Dec 27, 2040	U-3356			
	>A> 12350382	Feb 03, 2028	DP			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	12257348	May 23, 2041	DP U-3987			
	12295935	Dec 27, 2040	U-3987			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2026	DS DP			
<u>BIRCH TRITERPENES - FILSUEVZ</u>						
N 215064 001	12268695	Jan 04, 2039	U-3811			
	8828444	Jun 21, 2026	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001					>A> M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002					>A> M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003					>A> M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004					>A> M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005					>A> M-315	May 09, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006					>A> M-315	May 09, 2028
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	12171882	Jan 23, 2043	U-4085			
	12171882	Jan 23, 2043	U-4086			
	12171883	Jan 23, 2043	DP			
	>A> 12311057	Jan 23, 2043	DP U-4085			
	>A> 12311057	Jan 23, 2043	DP U-4086			
	>A> 12311057	Jan 23, 2043	DP U-4204			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
	12296047	Jan 22, 2041	DP U-4184			
	12318483	Jul 02, 2044	U-4152			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
	12296047	Jan 22, 2041	DP U-4184			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	12318483	Jul 02, 2044	U-4152			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					M-314	Feb 21, 2028
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					M-314	Feb 21, 2028
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	12161640	Jul 26, 2032	DP U-4100			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	12310961	Jan 20, 2043	U-3419			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001	12233042	Aug 22, 2038	DP U-3663			
	12290651	Feb 19, 2041	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 001	12252495	Oct 10, 2028	U-3762			
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 002	12252495	Oct 10, 2028	U-3762			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DP			
	12208101	Jul 22, 2035	DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	10596178	Jul 22, 2035	DP			
	12208101	Jul 22, 2035	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
>A>	12303481	Dec 21, 2041	U-1649			
>A>	12303481	Dec 21, 2041	U-219			
>A>	12303481	Dec 21, 2041	U-4004			
>A>	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
>A>	12303481	Dec 21, 2041	U-1649			
>A>	12303481	Dec 21, 2041	U-219			
>A>	12303481	Dec 21, 2041	U-4004			
>A>	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	12303605	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
>A>	12303481	Dec 21, 2041	U-1649			
>A>	12303481	Dec 21, 2041	U-219			
>A>	12303481	Dec 21, 2041	U-4004			
>A>	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
>A>	12303481	Dec 21, 2041	U-1649			
>A>	12303481	Dec 21, 2041	U-219			
>A>	12303481	Dec 21, 2041	U-4004			
>A>	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7417042	Jul 20, 2026	DS DP			
	7417042*PED	Jan 20, 2027				
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7417042	Jul 20, 2026	DS DP			
	7417042*PED	Jan 20, 2027				
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029		U-3449		
	RE47954*PED	Apr 21, 2030				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	7417042	Jul 20, 2026	DS DP			
	7417042*PED	Jan 20, 2027				
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029		U-3449		
	RE47954*PED	Apr 21, 2030				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	7417042	Jul 20, 2026	DS DP			
	7417042*PED	Jan 20, 2027				
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029		U-3449		
	RE47954*PED	Apr 21, 2030				
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	RE48960	Feb 16, 2029	DS DP	U-3087		
	RE48960	Feb 16, 2029	DS DP	U-3088		
<u>CEDAZURIDINE; DECITABINE - INOOVI</u>						
N 212576 001	12195496	Oct 07, 2040	DP			
	12239653	Feb 24, 2041		U-2865		
	12239653	Feb 24, 2041		U-2866		
<u>CHENODIOL - CTEXLI</u>						
N 219488 001					NP	Feb 21, 2028
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001	11969403	May 14, 2039	DP			
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	>A> 12303563	Sep 22, 2036	DP			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	8148374	Sep 03, 2029	DS DP	U-1279		
	8148374	Sep 03, 2029	DS DP	U-2939		
	8148374	Sep 03, 2029	DS DP	U-4162		
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 002	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP	U-4162		
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12274751	Nov 22, 2036	U-2814			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	12233035	Nov 01, 2033	U-4132			
	12280025	Nov 01, 2033	U-4168			
<u>COPPER - MIUDELLA</u>						
N 218201 001	10022264	Mar 22, 2034	DP		NP	Feb 24, 2028
	10159596	Aug 14, 2032	DP			
	10166141	Jun 13, 2034	DP			
	10188546	Aug 14, 2032	DP			
	10398588	Feb 24, 2034	DP U-4155			
	10918516	Jan 23, 2037	DP			
	11207209	Aug 16, 2034	DP			
	11850181	Aug 14, 2032	DP			
	12138199	Oct 18, 2033	DP			
	9089418	Apr 09, 2033	DP			
	9265652	Apr 28, 2034	U-4155			
	9427351	Aug 14, 2032	DP			
	9610191	Feb 24, 2034	U-4155			
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	10383961	Jul 02, 2033	U-2951			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL</u>						
N 008372 008	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12233105	Oct 27, 2043	U-3904			
	12233105	Oct 27, 2043	U-3905			
	12233105	Oct 27, 2043	U-3906			
	12233105	Oct 27, 2043	U-3907			
	12233105	Oct 27, 2043	U-3908			
	12233105	Oct 27, 2043	U-3909			
	12233105	Oct 27, 2043	U-3910			
	12233105	Oct 27, 2043	U-3911			
	12233105	Oct 27, 2043	U-3912			
	12233105	Oct 27, 2043	U-3913			
	12233105	Oct 27, 2043	U-3914			
	12233105	Oct 27, 2043	U-3915			
	12233105	Oct 27, 2043	U-3916			
	12233105	Oct 27, 2043	U-3917			
	12233105	Oct 27, 2043	U-3918			
	12233105	Oct 27, 2043	U-3919			
	12233105	Oct 27, 2043	U-3920			
	12233105	Oct 27, 2043	U-3921			
	12233105	Oct 27, 2043	U-3922			
	12233105	Oct 27, 2043	U-3923			
	12233105	Oct 27, 2043	U-3924			
	12233105	Oct 27, 2043	U-3925			
	12233105	Oct 27, 2043	U-3926			
>A>	12324787	Oct 27, 2043	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP	Y		
	8561859	Apr 16, 2032	DP	Y		
	9669974	May 11, 2034	DP	Y		
	9676525	Feb 07, 2034	DP	Y		
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	7772243	May 05, 2028	DS DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	12213988	Apr 01, 2041	U-4140			
<u>DARIDOREXANT HYDROCHLORIDE - OUVIVIO</u>						
N 214985 001					M-200	Sep 30, 2027
<u>DARIDOREXANT HYDROCHLORIDE - OUVIVIO</u>						
N 214985 002					M-200	Sep 30, 2027
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	>A> 10835515	Jan 28, 2036	DP U-2605			
	>A> 10835515	Jan 28, 2036	DP U-4208			
	>A> 10835515	Jan 28, 2036	DP U-4209			
	>A> 10835515	Jan 28, 2036	DP U-4210			
	>A> 12329742	May 14, 2042	DP			
	>A> 8975254	Mar 25, 2033	DS DP U-4208			
	>A> 8975254	Mar 25, 2033	DS DP U-4209			
	>A> 8975254	Mar 25, 2033	DS DP U-4210			
	>A> 9657003	Oct 27, 2030	DS DP U-4208			
	>A> 9657003	Oct 27, 2030	DS DP U-4209			
	>A> 9657003	Oct 27, 2030	DS DP U-4210			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	12161653	Feb 17, 2032	U-1940			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEURUXOLITINIB PHOSPHATE - LEQSELVI</u>						
N 217900 001	12247034	May 10, 2044	DS DP			
	12285432	Aug 11, 2042	U-3976			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10081621	Mar 25, 2031	DP U-4087			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
>A>	RE50453	May 01, 2027	DS DP			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10058546	Jul 15, 2033	U-4093			
	10081621	Mar 25, 2031	DP U-4087			
	10206877	Apr 14, 2035	DP U-4092			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	11951212	Apr 14, 2035	DP U-4089			
	12186306	Jan 10, 2043	U-4088			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9012496	Jul 15, 2033	U-4097			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	>A> RE50453	May 01, 2027	DS DP			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001					NPP	Apr 07, 2028
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	>A> 12324852	Oct 16, 2032	U-4173			
	>A> 12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	>A> 12324852	Oct 16, 2032	U-4173			
	>A> 12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	>A> 12324852	Oct 16, 2032	U-4173			
	>A> 12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 001	12178823	Nov 12, 2035		U-4167	NP	Mar 26, 2028
	>A> 12343348	Nov 12, 2035		U-4211		
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035		U-4167		
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 002	12178823	Nov 12, 2035		U-4167	NP	Mar 26, 2028
	>A> 12343348	Nov 12, 2035		U-4211		
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035		U-4167		
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 003	12178823	Nov 12, 2035		U-4167	NP	Mar 26, 2028
	>A> 12343348	Nov 12, 2035		U-4211		
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035		U-4167		
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u>						
N 215400 001	10532049	Feb 26, 2039	DP			
	11304942	Feb 26, 2039	DP			
	11819501	Feb 26, 2039		U-4188		
	11819501	Feb 26, 2039		U-848		
<u>DIHYDROERGOTAMINE MESYLATE - ATZUMI</u>						
N 217901 001	10758532	Dec 11, 2039	DP		>A> NP	Apr 30, 2028
	10792253	Aug 04, 2037	DP			
	11744967	Oct 12, 2041	DP			
	11872314	Aug 04, 2037	DP			
	12102754	Oct 12, 2041	DP			
	12263162	Dec 11, 2039	DP			
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001	8669281	Oct 29, 2033	DS DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	12161767	Dec 30, 2036	DS DP	U-3334		
	12168075	Dec 30, 2036		U-3334		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 001					PC	Jul 15, 2025
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 002					PC	Jul 15, 2025
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 001					>A> M-14	Jun 11, 2028
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 002					>A> M-14	Jun 11, 2028
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 003					>A> M-14	Jun 11, 2028
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	12280151	Jun 28, 2031	DP			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	12233074	Feb 09, 2043	DP U-3152			
	7732430	Jan 15, 2028	DP U-3152			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	12171742	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	12213983	Apr 26, 2035	U-2412			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	12213983	Apr 26, 2035	U-2412			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12194025	Nov 12, 2041	U-4111			
	12285409	Nov 01, 2039	DP			
	>A> 12310946	Nov 12, 2041	U-4111			
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	12233038	Mar 30, 2037	U-1854			
	12295927	Mar 30, 2037	U-1854			
	12295928	Mar 30, 2037	U-1854			
	12310935	Mar 30, 2037	U-1854			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3157		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4075			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4075		ODE*	Oct 21, 2026
	10239867	Apr 09, 2027	DS DP U-3158		ODE*	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-4056		ODE-512	Dec 20, 2031
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4065		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 001					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 002					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 003					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 004					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 216620 001					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 216620 002					PC	Nov 09, 2025
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	12263153	Apr 03, 2034	U-4171			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12263153	Apr 03, 2034	U-4171			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	12178819	May 04, 2027	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	12178819	May 04, 2027	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	11666590	Apr 03, 2034	U-4154			
	12263153	Apr 03, 2034	U-4154			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 208452 001					PC	Nov 23, 2025
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-957	Dec 20, 2027
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-957	Dec 20, 2027
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 001	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 002	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	12251384	Jun 25, 2044	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001 >A>	8299057	Mar 10, 2032	DS DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002 >A>	8299057	Mar 10, 2032	DS DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 218550 001					ODE* ODE*	Aug 15, 2026 Aug 15, 2026
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 213708 001					PC	Jun 03, 2025
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 219239 001					CGT	Sep 03, 2025
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	12280024	Mar 13, 2035	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	12280024	Mar 13, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - NEFFY</u>						
N 214697 001 >A>	12324838	Feb 06, 2039	DP			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 002	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039		U-3979		
	11173209	Feb 06, 2038		U-3979		
	11191838	Feb 06, 2039	DP	U-3979		
	11717571	Feb 06, 2039		U-3979		
	11744895	Feb 06, 2039		U-3979		
	11918655	Feb 06, 2039		U-3979		
>A>	12324838	Feb 06, 2039	DP			
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	8101743	Apr 01, 2026	DS DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 001					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 002					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 003					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 004					PC	Nov 02, 2025
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001 >A>	12325714	Sep 27, 2033	DS DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001	12178824	Jun 24, 2041	DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001 >A>	12303518	Jun 21, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2026	DS DP			
<u>FITUSIRAN SODIUM - QFITLIA</u>						
N 219019 001	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
<u>FITUSIRAN SODIUM - QFITLIA</u>						
N 219019 002	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	9849027	Nov 07, 2028	DP U-4157			
	9849027	Nov 07, 2028	DP U-708			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
<u>FOSCARBIDOPA; FOSLEVODOPA - VYALEV</u>						
N 216962 001	12251365	Jun 10, 2040	U-4030		NP	Oct 16, 2027
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	12208109	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	12208109	Jun 02, 2037	DP			
<u>GALLIUM GA-68 GOZETOTIDE - GOZELLIX</u>						
N 219592 001	11027031	Jul 28, 2035	U-3317			
<u>GEPOTIDACIN MESYLATE - BLUJEPA</u>						
N 218230 001	8389524	Feb 12, 2029	DS DP U-4166		NCE GAIN	Mar 25, 2030 Mar 25, 2035
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001					>A> I-967	Jun 10, 2028
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001					>A> I-967	Jun 10, 2028
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001	7696182	May 16, 2026	DS DP U-3774			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002	7696182	May 16, 2026	DS DP U-3774			
<u>HYDROCHLOROTHIAZIDE - INZIROO</u>						
N 219141 001	11878022	Jan 23, 2044	DP U-4138			
	11878022	Jan 23, 2044	DP U-4139			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	12201690	Jun 14, 2039	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	12171738	Feb 09, 2030	U-4105			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	12171738	Feb 09, 2030	U-4105			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IOMEPROL - IOMERVU</u>						
N 216016 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 004					NCE	Nov 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IOMEPROL - IOMERVU</u> N 216016 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 009					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216016 013					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 009					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u> N 216017 011					NCE	Nov 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IOMEPROL - IOMERVU</u>						
N 216017	012				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	013				NCE	Nov 27, 2029
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527	001	8474447	Jan 17, 2030	DP	Y	
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276	001	10093663	Jul 14, 2034	U-3980	I-963	Mar 20, 2028
		10093663	Jul 14, 2034	U-4161		
		12285422	Aug 30, 2038	U-4181		
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	001				PC	Jan 11, 2025
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	002				PC	Jan 11, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	10646481	Aug 13, 2029	DP	>A> ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030		>A> PED	Jun 21, 2028
		11564916	Aug 13, 2029	U-3530		
		11564916*PED	Feb 13, 2030			
	>A>	8354427	Jul 06, 2026	U-1311		
	>A>	8354427	Jul 06, 2026	U-1905		
	>A>	8354427*PED	Jan 06, 2027			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		9670163	Dec 28, 2026	DP U-1311		
		9670163*PED	Jun 28, 2027			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	>A> 10272046	Feb 27, 2033	DP U-2531	>A> ODE-236	Apr 29, 2026
	>A>	10272046*PED	Aug 27, 2033		>A> ODE-338	Dec 21, 2027
		10646481	Aug 13, 2029	DP	>A> PED	Oct 29, 2026
		10646481*PED	Feb 13, 2030		>A> PED	Jun 21, 2028
	>A>	11147770	Feb 27, 2033	DP U-3339		
	>A>	11147770*PED	Aug 27, 2033			
		11564916	Aug 13, 2029	U-3528		
		11564916*PED	Feb 13, 2030			
	>A>	11752106	Feb 27, 2033	DP U-3697		
	>A>	11752106*PED	Aug 27, 2033			
	>A>	12214083	Feb 27, 2033	DP U-4126		
	>A>	12214083*PED	Aug 27, 2033			
		7495103	May 20, 2027	DS DP		
		7495103*PED	Nov 20, 2027			
		8324242	Aug 05, 2027	U-1311		
		8324242	Aug 05, 2027	U-1906		
		8324242	Aug 05, 2027	U-2527		
		8324242*PED	Feb 05, 2028			
	>A>	8354427	Jul 06, 2026	U-1311		
	>A>	8354427	Jul 06, 2026	U-1905		
	>A>	8354427	Jul 06, 2026	U-2528		
	>A>	8354427*PED	Jan 06, 2027			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
	>A>	8883206	Feb 27, 2033	DP		
	>A>	8883206*PED	Aug 27, 2033			
		9670163	Dec 28, 2026	DP U-1311		
		9670163	Dec 28, 2026	DP U-2530		
		9670163*PED	Jun 28, 2027			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	>A> 10272046	Feb 27, 2033	DP U-2531		>A> ODE-236	Apr 29, 2026
	>A> 10272046*PED	Aug 27, 2033			>A> ODE-338	Dec 21, 2027
	10646481	Aug 13, 2029	DP		>A> PED	Oct 29, 2026
	10646481*PED	Feb 13, 2030			>A> PED	Jun 21, 2028
	>A> 11147770	Feb 27, 2033	DP U-3339			
	>A> 11147770*PED	Aug 27, 2033				
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	>A> 11752106	Feb 27, 2033	DP U-3697			
	>A> 11752106*PED	Aug 27, 2033				
	>A> 12214083	Feb 27, 2033	DP U-4126			
	>A> 12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	>A> 8354427	Jul 06, 2026	U-1311			
	>A> 8354427	Jul 06, 2026	U-1905			
	>A> 8354427	Jul 06, 2026	U-2528			
	>A> 8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	>A> 8883206	Feb 27, 2033	DP			
	>A> 8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	>A> 10272046	Feb 27, 2033	DP U-2531		>A> ODE-236	Apr 29, 2026
	>A> 10272046*PED	Aug 27, 2033			>A> ODE-338	Dec 21, 2027
	10646481	Aug 13, 2029	DP		>A> PED	Oct 29, 2026
	10646481*PED	Feb 13, 2030			>A> PED	Jun 21, 2028
	>A> 11147770	Feb 27, 2033	DP U-3339			
	>A> 11147770*PED	Aug 27, 2033				
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	>A> 11752106	Feb 27, 2033	DP U-3697			
	>A> 11752106*PED	Aug 27, 2033				
	>A> 12214083	Feb 27, 2033	DP U-4126			
	>A> 12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	>A> 8354427	Jul 06, 2026	U-1311			
	>A> 8354427	Jul 06, 2026	U-1905			
	>A> 8354427	Jul 06, 2026	U-2528			
	>A> 8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	>A> 8883206	Feb 27, 2033	DP			
	>A> 8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	>A> 10272046	Feb 27, 2033	DP U-2967		>A> ODE-236	Apr 29, 2026
	>A> 10272046*PED	Aug 27, 2033			>A> ODE-338	Dec 21, 2027
	10646481	Aug 13, 2029	DP		>A> PED	Oct 29, 2026
	10646481*PED	Feb 13, 2030			>A> PED	Jun 21, 2028
	>A> 11147770	Feb 27, 2033	DP U-3339			
	>A> 11147770*PED	Aug 27, 2033				
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	>A> 11752106	Feb 27, 2033	DP U-3697			
	>A> 11752106*PED	Aug 27, 2033				
	>A> 12214083	Feb 27, 2033	DP U-4128			
	>A> 12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2963			
	8324242*PED	Feb 05, 2028				
	>A> 8354427	Jul 06, 2026	U-1311			
	>A> 8354427	Jul 06, 2026	U-1905			
	>A> 8354427	Jul 06, 2026	U-2964			
	>A> 8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	>A> 8883206	Feb 27, 2033	DP			
	>A> 8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	>A> 10272046	Feb 27, 2033	DP U-3605		>A> NPP	May 03, 2026
	>A> 10272046*PED	Aug 27, 2033			>A> ODE-435	May 03, 2030
	10646481	Aug 13, 2029	DP		>A> PED	Nov 03, 2026
	10646481*PED	Feb 13, 2030			>A> PED	Nov 03, 2030
	>A> 11147770	Feb 27, 2033	DP U-3604			
	>A> 11147770*PED	Aug 27, 2033				
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	>A> 11752106	Feb 27, 2033	DP U-3697			
	>A> 11752106*PED	Aug 27, 2033				
	>A> 12214083	Feb 27, 2033	DP U-4127			
	>A> 12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	>A> 8354427	Jul 06, 2026	U-3608			
	>A> 8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	>A> 8883206	Feb 27, 2033	DP			
	>A> 8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	>A> 10272046	Feb 27, 2033	DP U-3605		>A> NPP	May 03, 2026
	>A> 10272046*PED	Aug 27, 2033			>A> ODE-435	May 03, 2030
	10646481	Aug 13, 2029	DP		>A> PED	Nov 03, 2026
	10646481*PED	Feb 13, 2030			>A> PED	Nov 03, 2030
	>A> 11147770	Feb 27, 2033	DP U-3604			
	>A> 11147770*PED	Aug 27, 2033				
	11564916	Aug 13, 2029	U-3603			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	11564916*PED	Feb 13, 2030				
	>A> 11752106	Feb 27, 2033	DP U-3697			
	>A> 11752106*PED	Aug 27, 2033				
	>A> 12214083	Feb 27, 2033	DP U-4127			
	>A> 12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	>A> 8354427	Jul 06, 2026	U-3608			
	>A> 8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	>A> 8883206	Feb 27, 2033	DP			
	>A> 8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	>A> RE50453	May 01, 2027	DS DP			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	>A> RE50453	May 01, 2027	DS DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMEI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411			
	10076513*PED	Jun 04, 2029				
	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DS DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	8846718	Jul 02, 2029	U-3427			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-3427			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-3428			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-3429			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-3429			
	9931334*PED	Jun 28, 2027				
<u>IVERMECTIN - IVERMECTIN</u>						
A 215922 002					CGT	Oct 01, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914 001					CGT	Sep 13, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914 002					CGT	Sep 13, 2025
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001 >A>	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002 >A>	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003 >A>	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004 >A>	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005 >A>	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006 >A>	8637512	Jan 07, 2029	DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	12257246	Jul 07, 2030	U-2718			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	12257246	Jul 07, 2030	U-2718			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	12257246	Jul 07, 2030	U-2718			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	12138351	Apr 13, 2041	DP			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	12138351	Apr 13, 2041	DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	>A> 8071643	Mar 25, 2033	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	12121582	Jun 14, 2036	DP			
	>A> 8071643	Mar 25, 2033	DS DP			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
<u>LEVACETYLLAUCINE - AQNEURSA</u>						
N 219132 001	11400067	Aug 11, 2037	U-4170			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	>A> 9918984	May 03, 2028	U-3283		NCE*	Dec 30, 2026
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	12178819	May 04, 2027	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - ARYNTE</u>						
N 219847 001	>A> 11576878	Aug 30, 2040	DP			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	12186360	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2029	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2029	U-3070			
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	11890273	Oct 07, 2041	DP			
	12156869	Oct 07, 2041	DP U-4158			
	12156869	Oct 07, 2041	DP U-4159			
	12156869	Oct 07, 2041	DP U-4160			
<u>LOTILANER - XDEMVI</u>						
N 217603 001	12171750	Dec 14, 2038	U-3674			
	12213964	Dec 14, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	>A> 11753419	Dec 10, 2040	DP	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	>A> 11753419	Dec 10, 2040	DP	Y		
	RE48825	Mar 12, 2029	DS			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	>A> 11753419	Dec 10, 2040	DP	Y		
	RE48825	Mar 12, 2029	DS			
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001	>A> 12324806	May 29, 2040	U-4212			
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	10406240	Aug 15, 2028	DS DP U-4169		I-965	Mar 28, 2028
	11318121	Aug 15, 2028	DS DP U-4169			
	11951190	Nov 12, 2035	U-4169			
	12208102	Sep 18, 2041	U-4169			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001					M-187	Feb 28, 2028
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	12239659	Jun 14, 2044	U-4143			
	12290529	Aug 02, 2044	DP			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 001	12296050	Oct 05, 2043	DP U-4186		I-938	Mar 13, 2027
	12296050	Oct 05, 2043	DP U-4187		NCE	Sep 29, 2026
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 002	12296050	Oct 05, 2043	DP U-4186		I-938	Mar 13, 2027
	12296050	Oct 05, 2043	DP U-4187		NCE	Sep 29, 2026
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 003	12296050	Oct 05, 2043	DP U-4186		I-938	Mar 13, 2027
	12296050	Oct 05, 2043	DP U-4187		NCE	Sep 29, 2026
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 004	12296050	Oct 05, 2043	DP U-4186		I-938	Mar 13, 2027
	12296050	Oct 05, 2043	DP U-4187		NCE	Sep 29, 2026
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12213989	Nov 18, 2042	U-4137			
	12295940	Oct 11, 2043	DS DP			
<u>MELOXICAM - QAMZOVA</u>						
N 217593 001	12059423	Jul 19, 2040	DS DP			
<u>MELOXICAM - XIFYRM</u>						
N 218395 001	12263176	Jul 31, 2041	DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
	10058614	Apr 11, 2036	DP			
	10137131	Apr 11, 2036	DP U-1719			
	10195278	Apr 11, 2036	U-1719			
	10265324	Apr 11, 2036	U-1719			
	10363312	Apr 11, 2036	U-1719			
	10369224	Apr 11, 2036	U-4134			
	10426839	Apr 11, 2036	U-4135			
	10463736	Apr 11, 2036	DP			
	10471014	Apr 11, 2036	U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10471069	Apr 11, 2036	U-1719			
	10512692	Apr 11, 2036	U-1719			
	10512693	Apr 11, 2036	U-1719			
	10517950	Apr 11, 2036	U-1719			
	10532101	Apr 11, 2036	U-1719			
	10537642	Apr 11, 2036	U-1719			
	10561664	Apr 11, 2036	U-1719			
	10583144	Apr 11, 2036	U-1719			
	10653777	Apr 11, 2036	U-1719			
	10688102	Apr 11, 2036	U-1719			
	10688185	Apr 11, 2036	U-1719			
	10695429	Apr 11, 2036	U-1719			
	10695430	Apr 11, 2036	U-1719			
	10702535	Apr 11, 2036	U-4136			
	10702602	Apr 11, 2036	U-1719			
	10722583	Apr 11, 2036	U-1719			
	10729696	Apr 11, 2036	U-1719			
	10729697	Apr 11, 2036	U-1719			
	10729773	Apr 11, 2036	U-1719			
	10758617	Apr 11, 2036	U-1719			
	10758618	Apr 11, 2036	U-1719			
	10780165	Apr 11, 2036	U-1719			
	10780166	Apr 11, 2036	U-1719			
	10799588	Apr 11, 2036	U-1719			
	10821181	Apr 11, 2036	U-1719			
	10821182	Apr 11, 2036	U-1719			
	10894053	Apr 11, 2036	U-1719			
	10905693	Apr 11, 2036	U-1719			
	10918722	Apr 11, 2036	U-1719			
	10933136	Apr 11, 2036	U-1719			
	10933137	Apr 11, 2036	U-1719			
	10940153	Apr 11, 2036	U-1719			
	10987358	Apr 11, 2036	U-1719			
	11013805	Apr 11, 2036	U-1719			
	11013806	Apr 11, 2036	U-1719			
	11020483	Apr 11, 2036	U-1719			
	11045549	Apr 11, 2036	U-1719			
	11135295	Apr 11, 2036	U-1719			
	11207328	Apr 11, 2036	U-1719			
	11219626	Apr 11, 2036	U-1719			
	11285213	Apr 11, 2036	U-1719			
	11331323	Apr 11, 2036	U-1719			
	11369684	Apr 11, 2036	U-1719			
	11426414	Apr 11, 2036	U-1719			
	11471464	Apr 11, 2036	U-1719			
	11471465	Apr 11, 2036	U-1719			
	11504429	Apr 11, 2036	U-1719			
	11510927	Apr 11, 2036	U-1719			
	11571428	Apr 11, 2036	U-1719			
	11602563	Apr 11, 2036	U-1719			
	11607456	Apr 11, 2036	U-1719			
	11617755	Apr 11, 2036	U-1719			
	11617756	Apr 11, 2036	U-1719			
	11617791	Apr 11, 2036	U-1719			
	11628173	Apr 11, 2036	U-1719			
	11712441	Apr 11, 2036	U-1719			
	11738085	Apr 11, 2036	U-1719			
	11759522	Apr 11, 2036	U-1719			
	11801250	Apr 11, 2036	U-1719			
	11806354	Apr 11, 2036	U-1719			
	11826370	Apr 11, 2036	U-1719			
	11865117	Apr 11, 2036	U-1719			
	12128052	May 28, 2040	U-1719			
	9821075	Apr 11, 2036	DP U-1719			

MERCAPTOPYRINE - MERCAPTOPYRINE

A 216418 001

CGT

Aug 25, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MESNA - MESNA</u>						
A 218871 001					CGT	Jul 13, 2025
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	>A> 12303592	Aug 03, 2027	DP U-4197			
	>A> 12303592	Aug 03, 2027	DP U-4198			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	>A> 12303592	Aug 03, 2027	DP U-4197			
	>A> 12303592	Aug 03, 2027	DP U-4198			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	>A> 12303592	Aug 03, 2027	DP U-4197			
	>A> 12303592	Aug 03, 2027	DP U-4198			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	12194008	Dec 22, 2029	U-2843			
	12194009	Dec 22, 2029	U-2843			
<u>METRONIDAZOLE - LIKMEZ</u>						
N 216755 001	12257236	Jan 16, 2039	DP U-3169			
	12257236	Jan 16, 2039	DP U-4163			
	12257236	Jan 16, 2039	DP U-4164			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	12280042	May 30, 2038	DS U-2371			
<u>MIGLUSTAT - OPFOLDA</u>						
N 215211 001	12246062	Sep 16, 2038	U-3726			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	12059409	Sep 28, 2029	DP			
	12059409*PED	Mar 28, 2030				
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
	12097189*PED	Mar 28, 2030				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	12059409	Sep 28, 2029	DP			
	12059409*PED	Mar 28, 2030				
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
	12097189*PED	Mar 28, 2030				
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11571402	Feb 17, 2041	DP			
	11806321	Feb 17, 2041	U-4130			
	11806322	Mar 16, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12090128	Feb 17, 2041	DP U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12295925	Feb 17, 2041	U-4130			
	>A> 12324791	Mar 16, 2043	U-4130			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041		U-4130		
	11806321	Feb 17, 2041		U-4130		
	11806322	Mar 16, 2043		U-4130		
	11819487	Feb 17, 2041		U-4130		
	11839595	Mar 16, 2043		U-4130		
	11883375	Mar 16, 2043		U-4130		
	12011424	Feb 17, 2041		U-4130		
	12029711	Mar 15, 2044	DP	U-4130		
	12037306	Feb 17, 2041		U-4130		
	12220390	Mar 16, 2043		U-4130		
	12257215	Mar 16, 2043		U-4130		
	12263146	Feb 17, 2041		U-4130		
	12275688	Feb 17, 2041	DP	U-4130		
	12295925	Feb 17, 2041		U-4130		
>A>	12324791	Mar 16, 2043		U-4130		
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041		U-4130		
	11806321	Feb 17, 2041		U-4130		
	11806322	Mar 16, 2043		U-4130		
	11819487	Feb 17, 2041		U-4130		
	11839595	Mar 16, 2043		U-4130		
	11883375	Mar 16, 2043		U-4130		
	12029711	Mar 15, 2044	DP	U-4130		
	12037306	Feb 17, 2041		U-4130		
	12220390	Mar 16, 2043		U-4130		
	12257215	Mar 16, 2043		U-4130		
	12263146	Feb 17, 2041		U-4130		
	12275688	Feb 17, 2041	DP	U-4130		
	12295925	Feb 17, 2041		U-4130		
>A>	12324791	Mar 16, 2043		U-4130		
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	12268745	Jan 20, 2031		U-4172		
<u>MITOMYCIN - ZUSDURI</u>						
N 215793 001					>A> NP	Jun 12, 2028
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	>A> 12303635	Apr 08, 2039	DS DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Feb 27, 2035	DP	U-1384		
	10918616	Feb 27, 2035		U-1384		
	10918617	Feb 27, 2035		DP		
	10945985	Feb 27, 2035		DP		
	11590095	Feb 27, 2035		U-1384		
<u>MOTIXAFORTIDE ACETATE - APHEXDA</u>						
N 217159 001	12257285	Dec 29, 2041		DP		
	12268725	Dec 29, 2041		DP		
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NPP	Feb 07, 2028
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	12194143	Aug 16, 2039		DP	U-1752	
	12226526	Aug 16, 2039		DP	U-1752	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALMEFFENE HYDROCHLORIDE - OPVEE</u>						
N 217470 001	12290596	Aug 04, 2042	U-4182			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 001					NPP	Mar 27, 2028
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 002					NPP	Mar 27, 2028
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 003					NPP	Mar 27, 2028
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 001					PC	Nov 19, 2025
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 002					PC	Nov 19, 2025
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 003					PC	Nov 19, 2025
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	12186308	Apr 16, 2038	DP U-2804			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 003	11730725	Jan 25, 2039	DP			
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 001					D-195	Jan 31, 2028
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	7951958	Mar 11, 2026	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	7951958	Mar 11, 2026	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	12234210	Jul 08, 2042	DP			
	12247012	Jul 08, 2042	DP			
	12297177	Aug 09, 2039	DP			
	7951958	Mar 11, 2026	DS			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 001	12290494	Mar 08, 2041	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 002	12290494	Mar 08, 2041	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 001	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 002	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	10251848	Feb 26, 2035	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	12246054	Feb 03, 2036		U-2857		
	12251418	Feb 03, 2036		U-2857		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031		U-3186		
	10011633	Nov 08, 2031		U-3648		
	10093697	Nov 08, 2031		U-3186		
	10093697	Nov 08, 2031		U-3648		
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3648		
	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3648		
	11732006	Nov 08, 2031		U-3186		
	11732006	Nov 08, 2031		U-3648		
	12187812	Nov 08, 2031		U-3186		
	12187812	Nov 08, 2031		U-3648		
	9694018	Nov 08, 2031		U-3186		
	9694018	Nov 08, 2031		U-3648		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031		U-3186		
	10011633	Nov 08, 2031		U-3648		
	10093697	Nov 08, 2031		U-3186		
	10093697	Nov 08, 2031		U-3648		
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3648		
	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3648		
	11732006	Nov 08, 2031		U-3186		
	11732006	Nov 08, 2031		U-3648		
	12187812	Nov 08, 2031		U-3186		
	12187812	Nov 08, 2031		U-3648		
	9694018	Nov 08, 2031		U-3186		
	9694018	Nov 08, 2031		U-3648		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031		U-3186		
	10011633	Nov 08, 2031		U-3648		
	10093697	Nov 08, 2031		U-3186		
	10093697	Nov 08, 2031		U-3648		
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3648		
	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3648		
	11732006	Nov 08, 2031		U-3186		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	12194035	Aug 23, 2031	U-3141			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	12178816	Oct 07, 2029	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	12178816	Oct 07, 2029	DP			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	9127276	May 01, 2034	DS			
	9157082	Apr 27, 2032	U-4050			
	9163239	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9593333	Feb 14, 2034	U-4050			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	12275715	Sep 18, 2035	DS DP	U-3684		
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	9265740	Oct 24, 2030	DP	U-1569		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	9265740	Mar 05, 2029	DP			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001					M-270	Dec 20, 2027
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	>A> 12329752	Jul 16, 2039	DP			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10709691	Oct 12, 2035	U-2770			
	10709691	Oct 12, 2035	U-4177			
	8609862	Jan 13, 2031	U-2770			
	8609862	Jan 13, 2031	U-4177			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10709691	Oct 12, 2035	U-2770			
	10709691	Oct 12, 2035	U-4177			
	8609862	Jan 13, 2031	U-2770			
	8609862	Jan 13, 2031	U-4177			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	Mar 24, 2033	DS DP	U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	Mar 24, 2033	DS DP	U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	Mar 24, 2033	DS DP	U-2774		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12201614	Jun 08, 2037	U-4031			
<u>PATISIRAN SODIUM - ONPATTRO</u>						
N 210922 001	8168775	Aug 10, 2032	DS DP U-2378			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	12290566	Dec 14, 2038	DP U-4174			
	12290566	Dec 14, 2038	DP U-4175			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	11592396	Sep 01, 2030	DS			
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 001					>A> PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 002					>A> PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 003					>A> PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 004					>A> PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 005					>A> PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 006					>A> PC	Nov 25, 2025
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	12201615	Dec 25, 2039	U-3804			
	12201616	Oct 25, 2039	U-3804			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 004	12257342	Sep 26, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 005	12257342	Sep 26, 2036	DP			
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214966 001					CGT	Sep 06, 2025
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 001 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010 >A>	12336980	Dec 10, 2035			U-3103	
	RE43728	Nov 16, 2029	DS DP			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 212832 004	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 212832 005	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	12233166	Jun 18, 2038	DP			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	>A> 12325714	Sep 27, 2033	DS DP			
	>A> 12336990	Sep 29, 2037	U-3020			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
	>A> 12310968	Jul 20, 2036	U-3755			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
	>A> 12310968	Jul 20, 2036	U-3755			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12285417	Aug 29, 2039	U-2440			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001					ODE-504	Nov 15, 2031
					ODE-505	Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002					ODE-504	Nov 15, 2031
					ODE-505	Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003					ODE-504	Nov 15, 2031
					ODE-505	Nov 15, 2031
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	8309569	Jul 18, 2029	U-1707	Y		
	8309569	Jul 18, 2029	U-1708	Y		
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	12213967	Dec 30, 2040	DP			
	12213968	Dec 30, 2040	DP			
	12226406	Dec 30, 2040	DP			
	12295944	Aug 12, 2040	U-4183			
	12318373	Aug 12, 2040	U-4191			
	12318374	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 219285 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
	12122789	Apr 15, 2041	DS DP			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	>A> 12310956	Jun 07, 2037	U-3748			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	>A> 12310956	Jun 07, 2037	U-3970			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	>A> 11129818	Aug 25, 2037	U-3773			
	>A> 11129818	Aug 25, 2037	U-4203			
	>A> 11819496	Jun 07, 2037	U-3773			
	>A> 11819496	Jun 07, 2037	U-4203			
	>A> 11992480	Jun 07, 2037	U-3773			
	>A> 11992480	Jun 07, 2037	U-4203			
	>A> 12005051	Jun 07, 2037	U-3773			
	>A> 12005051	Jun 07, 2037	U-4203			
	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	>A> 12310956	Jun 07, 2037	U-3773			
	>A> 12310956	Jun 07, 2037	U-4203			
	>A> 9907788	Jun 07, 2037	U-3773			
	>A> 9907788	Jun 07, 2037	U-4203			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	12226419	May 20, 2031	DP			
	12233067	Jul 28, 2040	U-4151			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	12280037	Dec 11, 2041	U-3302			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001					M-311 M-312 ODE* ODE* ODE* ODE* ODE* ODE* ODE* ODE* ODE*	Sep 27, 2027 Sep 27, 2027 May 08, 2027 May 08, 2027 May 08, 2027 Sep 21, 2029 Sep 21, 2029 May 29, 2031 May 29, 2031 May 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002					M-311 M-312 ODE* ODE* ODE* ODE* ODE* ODE* ODE* ODE*	Sep 27, 2027 Sep 27, 2027 May 08, 2027 May 08, 2027 May 08, 2027 Sep 21, 2029 Sep 21, 2029 May 29, 2031 May 29, 2031 May 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003					M-311 M-312 ODE* ODE* ODE* ODE* ODE* ODE* ODE* ODE*	Sep 27, 2027 Sep 27, 2027 May 08, 2027 May 08, 2027 May 08, 2027 Sep 21, 2029 Sep 21, 2029 May 29, 2031 May 29, 2031 May 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004					M-311 M-312 ODE* ODE* ODE* ODE* ODE* ODE* ODE* ODE*	Sep 27, 2027 Sep 27, 2027 May 08, 2027 May 08, 2027 May 08, 2027 Sep 21, 2029 Sep 21, 2029 May 29, 2031 May 29, 2031 May 29, 2031
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	12220403	Mar 26, 2029	DP			
	>A> 12318367	Mar 26, 2029	DP			
	7425637	Mar 13, 2026	DS			
	8178693	Mar 13, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	12220403	Mar 26, 2029	DP			
	>A> 12318367	Mar 26, 2029	DP			
	7425637	Mar 13, 2026	DS			
	8178693	Mar 13, 2026	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 27, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	12295988	Oct 10, 2038	U-2628			
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 004	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 005	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 006	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DS DP U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12214017	Aug 24, 2038	DP U-3162			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	8039435	Aug 21, 2032	DS DP		NPP ODE-508 ODE-509	Dec 20, 2027 Dec 20, 2031 Dec 20, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12186321	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Apr 23, 2036	U-3889			
<u>SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN</u>						
N 219122 001	11944621	Oct 23, 2040	DP			
	12295953	Oct 23, 2040	DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	12304813	Feb 10, 2030	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	12304813	Feb 10, 2030	DP			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002					ODE*	Mar 19, 2027
<u>SOFPIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001	12156865	May 22, 2034	DP U-2398			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12263145	Dec 30, 2042	U-3693			
	12318362	Mar 19, 2040	U-3765			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	12290495	Apr 01, 2034	U-2096			
	12290495	Apr 01, 2034	U-2494			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
<u>SUCCINYLCHOLINE CHLORIDE - SUCCINYLCHOLINE CHLORIDE</u>						
N 215143 001	12295932	Nov 02, 2041	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP PED	Dec 12, 2027 Jun 12, 2028
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP PED	Dec 12, 2027 Jun 12, 2028
<u>SUZETRIGINE - JOURNAVX</u>						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
<u>TADALAFIL - TADLIO</u>						
N 214522 001	12186322	Dec 24, 2038	DP U-3397			
<u>TALETRECTINIB ADIPATE - IBTROZI</u>						
N 219713 001	>A> 9187489	Jun 03, 2033	DS DP U-4207		>A> NCE	Jun 11, 2030
	>A> 9751887	Jun 03, 2033	DS DP U-4207			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10426743	May 19, 2036	U-2625		I-956	Dec 12, 2027
	10426743	May 19, 2036	U-4048			
	11497718	Nov 13, 2039	U-4048			
	11612573	May 19, 2036	U-2625			
	11612573	May 19, 2036	U-4048			
	11938099	Nov 13, 2039	U-4048			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	12201604	Jan 25, 2033	U-3003			
	12201604	Jan 25, 2033	U-3865			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	12201604	Jan 25, 2033	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	12161645	Sep 12, 2031	U-2853			
	12162865	May 21, 2034	U-2736			
	12168014	May 03, 2038	U-2736			
	12168014	May 03, 2038	U-2852			
	12168014	May 03, 2038	U-2853			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	12168015	Sep 12, 2031	DS DP			
	12168016	Sep 12, 2031			U-2736	
	12168016	Sep 12, 2031			U-2853	
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001					NPP	Apr 04, 2028
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001					NPP	Apr 04, 2028
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	12310978	Feb 21, 2039			U-4194	
<u>TETRACAINE HYDROCHLORIDE - TETRACAINE HYDROCHLORIDE</u>						
A 217227 001					CGT	Jun 25, 2025
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 003	9931458	May 31, 2037	DP			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 002	11975013	Aug 16, 2041	DP			
<u>TICAGRELOR - TICAGRELOR</u>						
A 208390 001					PC	Oct 28, 2025
<u>TICAGRELOR - TICAGRELOR</u>						
A 208531 001					PC	Oct 28, 2025
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	7396341	Oct 10, 2026	DP		Y	
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP		Y	
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP		Y	
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP		Y	
	9027967*PED	Sep 30, 2027				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7396341	Oct 10, 2026	DP		Y	
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP		Y	
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP		Y	
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP		Y	
	9027967*PED	Sep 30, 2027				
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007					I-958	Dec 20, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012					I-958	Dec 20, 2027
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	7166722	Nov 16, 2028	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	7166722	Nov 16, 2028	DS DP			
<u>TIZANIDINE HYDROCHLORIDE - ONTRALFY</u>						
N 216190 001	12263158	May 07, 2042	DP U-2779			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034		U-3326		
	11253523	Mar 14, 2034		U-3327		
	11253523	Mar 14, 2034		U-3328		
	11253523	Mar 14, 2034		U-3329		
	11253523*PED	Sep 14, 2034				
	9937181	Mar 14, 2034	DP			
	9937181*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	10639309*PED	Sep 14, 2034				
	11253523	Mar 14, 2034		U-3326		
	11253523	Mar 14, 2034		U-3327		
	11253523	Mar 14, 2034		U-3328		
	11253523	Mar 14, 2034		U-3329		
	11253523*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 213082 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 001					PC	Nov 08, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063	002				PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063	003				PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063	004				PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063	005				PC	Nov 08, 2025
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679	001	12290503	Aug 21, 2040	DP U-3413		
		12290503	Aug 21, 2040	DP U-3414		
		12290503	Aug 21, 2040	DP U-3415		
<u>TRAVOPROST - IDOSE TR</u>						
N 218010	001	12201555	Feb 14, 2031	DS DP		
		12201557	Jun 18, 2030	DS DP U-4129		
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759	001	7199162	Mar 21, 2026	U-4142	NCE ODE-513 ODE-514	Jan 21, 2030 Jan 21, 2032 Jan 21, 2032
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759	002	7199162	Mar 21, 2026	U-4142	NCE ODE-513 ODE-514	Jan 21, 2030 Jan 21, 2032 Jan 21, 2032
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	001	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	002	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	003	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	004	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	005	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005	001	>A> 10898494	May 05, 2037	U-4200		
		>A> 11660304	May 05, 2037	U-4200		
		>A> 11712442	May 05, 2037	U-4199		
		>A> 11744835	May 05, 2037	DP		
		>A> 11744836	May 05, 2037	DP		
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005	002	>A> 10898494	May 05, 2037	U-4200		
		>A> 11660304	May 05, 2037	U-4200		
		>A> 11712442	May 05, 2037	U-4199		
		>A> 11744835	May 05, 2037	DP		
		>A> 11744836	May 05, 2037	DP		
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005	003	>A> 10898494	May 05, 2037	U-4200		
		>A> 11660304	May 05, 2037	U-4200		
		>A> 11712442	May 05, 2037	U-4199		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005 003	>A> 11744835	May 05, 2037	DP			
	>A> 11744836	May 05, 2037	DP			
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005 004	>A> 10898494	May 05, 2037	U-4200			
	>A> 11660304	May 05, 2037	U-4200			
	>A> 11712442	May 05, 2037	U-4199			
	>A> 11744835	May 05, 2037	DP			
	>A> 11744836	May 05, 2037	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12168666	Nov 13, 2040	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2025	DS DP U-2788			
	7452895	Nov 16, 2025	DS DP U-4153			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2025	DS DP U-2788			
	7452895	Nov 16, 2025	DS DP U-4153			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	12168004	Jan 30, 2035	DP			
	12194030	Dec 22, 2041	U-4121			
	12194030	Dec 22, 2041	U-4122			
	12220408	Jan 30, 2035	DP			
	>A> 12310953	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	12168004	Jan 30, 2035	DP			
	12220408	Jan 30, 2035	DP			
	>A> 12310953	Jan 30, 2035	DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001					I-966	Apr 28, 2028
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	12201639	Mar 17, 2040	DS DP U-3747			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	12161690	Nov 06, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	>A> 12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	>A> 12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006	>A> 12186362	Jan 30, 2035	DP			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12180219	Mar 12, 2034	DS DP		I-955	Dec 18, 2027
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12290499	Oct 17, 2042	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9662338	Apr 02, 2035	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	11103507	Feb 03, 2040		U-4145	NCE	Feb 14, 2030
	11679110	Feb 03, 2040		U-4145		
	12285430	Dec 23, 2039		U-4145		
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	11103507	Feb 03, 2040		U-4145	NCE	Feb 14, 2030
	11679110	Feb 03, 2040		U-4145		
	12285430	Dec 23, 2039		U-4145		
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	11103507	Feb 03, 2040		U-4145	NCE	Feb 14, 2030
	11679110	Feb 03, 2040		U-4145		
	12285430	Dec 23, 2039		U-4145		
	9181223	Mar 14, 2034	DS DP			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					NCE GAIN	May 03, 2027 May 03, 2032
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002					NCE GAIN	May 03, 2027 May 03, 2032
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12233106	Jul 11, 2042	U-3927			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515	001				I-964	Mar 20, 2028
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 218785	001	>A> 10570139	Apr 22, 2034	U-1745	>A> I-817	Jan 19, 2026
		>A> 10570139	Apr 22, 2034	U-2145	>A> I-936	Mar 07, 2027
		>A> 10570139	Apr 22, 2034	U-2537	>A> ODE*	Nov 14, 2026
		>A> 10570139	Apr 22, 2034	U-2666	>A> ODE*	Aug 31, 2028
		>A> 10570139	Apr 22, 2034	U-3063	>A> ODE*	Sep 14, 2028
		>A> 10570139	Apr 22, 2034	U-3486	>A> ODE*	Jan 19, 2030
		>A> 10570139	Apr 22, 2034	U-3860	>A> ODE*	Mar 07, 2031
		>A> 10927117	Aug 15, 2037	DS DP		
		>A> 11142528	Apr 22, 2034	DP U-1745		
		>A> 11142528	Apr 22, 2034	DP U-2145		
		>A> 11142528	Apr 22, 2034	DP U-2537		
		>A> 11142528	Apr 22, 2034	DP U-2666		
		>A> 11142528	Apr 22, 2034	DP U-3063		
		>A> 11142528	Apr 22, 2034	DP U-3486		
		>A> 11142528	Apr 22, 2034	DP U-3860		
		>A> 11591340	Aug 15, 2037	U-1745		
		>A> 11591340	Aug 15, 2037	U-2145		
		>A> 11591340	Aug 15, 2037	U-2537		
		>A> 11591340	Aug 15, 2037	U-2666		
		>A> 11591340	Aug 15, 2037	U-3063		
		>A> 11591340	Aug 15, 2037	U-3486		
		>A> 11591340	Aug 15, 2037	U-3727		
		>A> 11591340	Aug 15, 2037	U-3728		
		>A> 11591340	Aug 15, 2037	U-3729		
		>A> 11701357	Jun 24, 2039	U-3860		
		>A> 11786531	Jan 19, 2043	U-3715		
		>A> 11786531	Jan 19, 2043	U-3716		
		>A> 11786531	Jan 19, 2043	U-3717		
		>A> 11786531	Jan 19, 2043	U-3718		
		>A> 11786531	Jan 19, 2043	U-3719		
		>A> 11786531	Jan 19, 2043	U-3720		
		>A> 11786531	Jan 19, 2043	U-3875		
		>A> 11851437	Aug 15, 2037	DS DP		
		>A> 11884674	Aug 15, 2037	U-1745		
		>A> 11884674	Aug 15, 2037	U-2145		
		>A> 11884674	Aug 15, 2037	U-2537		
		>A> 11884674	Aug 15, 2037	U-2666		
		>A> 11884674	Aug 15, 2037	U-3063		
		>A> 11884674	Aug 15, 2037	U-3486		
		>A> 11884674	Aug 15, 2037	U-3860		
		>A> 11896596	Jan 19, 2043	U-3715		
		>A> 11896596	Jan 19, 2043	U-3716		
		>A> 11896596	Jan 19, 2043	U-3717		
		>A> 11896596	Jan 19, 2043	U-3718		
		>A> 11896596	Jan 19, 2043	U-3719		
		>A> 11896596	Jan 19, 2043	U-3720		
		>A> 11896596	Jan 19, 2043	U-3875		
		>A> 11911386	Jan 19, 2043	U-3715		
		>A> 11911386	Jan 19, 2043	U-3716		
		>A> 11911386	Jan 19, 2043	U-3717		
		>A> 11911386	Jan 19, 2043	U-3718		
		>A> 11911386	Jan 19, 2043	U-3719		
		>A> 11911386	Jan 19, 2043	U-3720		
		>A> 11911386	Jan 19, 2043	U-3875		
		>A> 11970500	Aug 15, 2037	U-1745		
		>A> 11970500	Aug 15, 2037	U-2145		
		>A> 11970500	Aug 15, 2037	U-2537		
		>A> 11970500	Aug 15, 2037	U-2666		
		>A> 11970500	Aug 15, 2037	U-3063		
		>A> 11970500	Aug 15, 2037	U-3486		
		>A> 11970500	Aug 15, 2037	U-3860		
		>A> 12233069	Jun 10, 2040	DP		
		>A> 9447106	Apr 22, 2034	DS DP U-1745		
		>A> 9447106	Apr 22, 2034	DS DP U-2145		
		>A> 9447106	Apr 22, 2034	DS DP U-2537		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 218785 001	>A> 9447106	Apr 22, 2034	DS DP U-2666			
	>A> 9447106	Apr 22, 2034	DS DP U-3063			
	>A> 9447106	Apr 22, 2034	DS DP U-3486			
	>A> 9447106	Apr 22, 2034	DS DP U-3860			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Aug 23, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 45TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm